0000310158-20-000009.txt : 20200506 0000310158-20-000009.hdr.sgml : 20200506 20200506163654 ACCESSION NUMBER: 0000310158-20-000009 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 20853161 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-Q 1 mrk0331202010q.htm 10-Q Document
false--12-31Q1202000003101581768600000017706000000860000008900000020000000.550.610.500.5065000000006500000000357710352235771035220.023500.02400.0387502580000003500000010380874961053090194 0000310158 2020-01-01 2020-03-31 0000310158 2020-04-30 0000310158 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000310158 mrk:A1.875Notesdue2026Member 2020-01-01 2020-03-31 0000310158 mrk:A1.375Notesdue2036Member 2020-01-01 2020-03-31 0000310158 mrk:A0.500Notesdue2024Member 2020-01-01 2020-03-31 0000310158 mrk:A2.500Notesdue2034Member 2020-01-01 2020-03-31 0000310158 mrk:A1.125Notesdue2021Member 2020-01-01 2020-03-31 0000310158 2019-01-01 2019-03-31 0000310158 2020-03-31 0000310158 2019-12-31 0000310158 2019-03-31 0000310158 2018-12-31 0000310158 mrk:ArQuleMember 2020-01-16 0000310158 mrk:ArQuleMember mrk:IPRDMK1026Member 2020-01-16 0000310158 mrk:ArQuleMember mrk:IPRDMK7075Member 2020-01-16 0000310158 mrk:ArQuleMember 2020-01-16 2020-01-16 0000310158 mrk:ArQuleMember us-gaap:MeasurementInputDiscountRateMember 2020-01-16 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:BayerAGMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember 2020-03-01 2020-03-31 0000310158 mrk:EisaiMember 2019-03-01 2019-03-31 0000310158 mrk:LenvimaMember us-gaap:OtherNoncurrentAssetsMember 2020-03-31 0000310158 mrk:EisaiMember 2018-03-01 2018-03-31 0000310158 mrk:EisaiMember srt:ScenarioForecastMember 2021-03-01 2021-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:AstraZenecaMember 2017-07-01 2017-07-31 0000310158 mrk:BayerAGMember mrk:SalesBasedMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:LynparzaMember us-gaap:OtherNoncurrentAssetsMember 2020-03-31 0000310158 mrk:AdempasMember us-gaap:OtherIntangibleAssetsMember 2020-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember srt:ScenarioForecastMember 2018-03-01 2021-03-31 0000310158 mrk:AstraZenecaMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:RegulatoryMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2017-08-01 2019-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-01-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2018-04-01 2019-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2019-01-01 2019-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-12-31 0000310158 mrk:EisaiMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember mrk:RegulatoryMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:BayerAGMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-12-31 0000310158 mrk:EisaiMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:EisaiMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-03-31 0000310158 us-gaap:OtherRestructuringMember 2019-01-01 2019-03-31 0000310158 mrk:AcceleratedDepreciationMember 2019-01-01 2019-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-03-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-03-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-03-31 0000310158 us-gaap:RestructuringChargesMember 2019-01-01 2019-03-31 0000310158 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-03-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-03-31 0000310158 us-gaap:RestructuringChargesMember 2020-01-01 2020-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0000310158 mrk:AcceleratedDepreciationMember 2020-01-01 2020-03-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-03-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-03-31 0000310158 us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-03-31 0000310158 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2019-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2020-03-31 0000310158 us-gaap:OtherRestructuringMember 2020-03-31 0000310158 us-gaap:OtherRestructuringMember 2019-12-31 0000310158 mrk:AcceleratedDepreciationMember 2020-03-31 0000310158 mrk:AcceleratedDepreciationMember 2019-12-31 0000310158 srt:ScenarioForecastMember 2020-12-31 0000310158 us-gaap:InterestRateSwapMember 2020-02-29 0000310158 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000310158 us-gaap:InterestRateSwapMember 2020-03-31 0000310158 srt:MaximumMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0000310158 mrk:A1.85NotesDue2020Member 2020-02-29 0000310158 us-gaap:FairValueInputsLevel2Member 2020-03-31 0000310158 mrk:SanofiPasteurMember 2019-12-31 0000310158 mrk:SanofiPasteurMember 2020-03-31 0000310158 srt:MaximumMember us-gaap:NondesignatedMember 2020-01-01 2020-03-31 0000310158 2019-10-01 2019-12-31 0000310158 mrk:SanofiPasteurMember us-gaap:MeasurementInputDiscountRateMember 2019-12-31 0000310158 us-gaap:AssetBackedSecuritiesMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000310158 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-03-31 0000310158 us-gaap:NondesignatedMember 2020-03-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:NondesignatedMember 2019-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-03-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember 2019-01-01 2019-03-31 0000310158 mrk:EurodominatedNotesMember 2019-01-01 2019-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-03-31 0000310158 mrk:EurodominatedNotesMember 2020-01-01 2020-03-31 0000310158 us-gaap:InterestRateSwapMember mrk:A2.40NotesDue2022Member 2020-03-31 0000310158 us-gaap:InterestRateSwapMember mrk:A3.875NotesDue2021Member 2020-03-31 0000310158 us-gaap:InterestRateSwapMember mrk:A2.35NotesDue2022Member 2020-03-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:CommercialPaperMember 2020-03-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2019-01-01 2019-03-31 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2020-01-01 2020-03-31 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-31 0000310158 us-gaap:InterestRateSwapMember 2019-01-01 2019-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-03-31 0000310158 us-gaap:InterestRateSwapMember 2020-01-01 2020-03-31 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2019-12-31 0000310158 mrk:LongTermDebtExcludingCurrentMaturitiesMember 2020-03-31 0000310158 mrk:LongTermDebtExcludingCurrentMaturitiesMember 2019-12-31 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2020-03-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2019-12-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2020-03-31 0000310158 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2020-03-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2019-12-31 0000310158 mrk:NewJerseyStateCourtMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-03-31 0000310158 mrk:FosamaxMember 2020-03-31 0000310158 mrk:OtherStateCourtMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-03-31 0000310158 mrk:FederalMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2014-03-01 2014-03-31 0000310158 mrk:LegalDefenseCostsMember 2019-12-31 0000310158 mrk:JanuviaMember mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember 2020-03-31 0000310158 mrk:CaliforniaStateCourtMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-03-31 0000310158 mrk:FederalMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-03-31 0000310158 mrk:LegalDefenseCostsMember 2020-03-31 0000310158 mrk:OtherStateCourtMember mrk:JanuviaMember 2020-03-31 0000310158 mrk:JanuviaMember 2020-03-31 0000310158 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000310158 us-gaap:TreasuryStockMember 2018-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000310158 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000310158 us-gaap:RetainedEarningsMember 2019-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000310158 us-gaap:CommonStockMember 2019-12-31 0000310158 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2019-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2020-03-31 0000310158 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000310158 us-gaap:CommonStockMember 2018-12-31 0000310158 us-gaap:TreasuryStockMember 2019-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000310158 us-gaap:RetainedEarningsMember 2020-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000310158 us-gaap:TreasuryStockMember 2020-03-31 0000310158 us-gaap:TreasuryStockMember 2019-03-31 0000310158 us-gaap:CommonStockMember 2020-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2019-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000310158 us-gaap:RetainedEarningsMember 2018-12-31 0000310158 us-gaap:CommonStockMember 2019-03-31 0000310158 us-gaap:RetainedEarningsMember 2019-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2018-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000310158 us-gaap:PerformanceSharesMember 2020-01-01 2020-03-31 0000310158 us-gaap:PerformanceSharesMember 2019-01-01 2019-03-31 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000310158 mrk:HealthcareServicesSegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000310158 srt:AsiaPacificMember 2020-01-01 2020-03-31 0000310158 country:US 2019-01-01 2019-03-31 0000310158 us-gaap:EMEAMember 2019-01-01 2019-03-31 0000310158 country:JP 2020-01-01 2020-03-31 0000310158 country:JP 2019-01-01 2019-03-31 0000310158 srt:LatinAmericaMember 2020-01-01 2020-03-31 0000310158 country:CN 2020-01-01 2020-03-31 0000310158 mrk:OtherCountriesMember 2020-01-01 2020-03-31 0000310158 mrk:OtherCountriesMember 2019-01-01 2019-03-31 0000310158 srt:AsiaPacificMember 2019-01-01 2019-03-31 0000310158 srt:LatinAmericaMember 2019-01-01 2019-03-31 0000310158 us-gaap:EMEAMember 2020-01-01 2020-03-31 0000310158 country:US 2020-01-01 2020-03-31 0000310158 country:CN 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-03-31 0000310158 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0000310158 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 mrk:InternationalMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 mrk:InternationalMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 iso4217:USD xbrli:pure iso4217:USD xbrli:shares xbrli:shares mrk:interest_rate_swap mrk:segment mrk:Claim mrk:Case



 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q
 
 
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2020
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 1-6571
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey
22-1918501
(State or other jurisdiction of incorporation)
(I.R.S Employer Identification No.)
 
 
2000 Galloping Hill Road
Kenilworth
New Jersey
07033
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) (908) 740-4000
 
Not Applicable
 
(Former name, former address and former fiscal year, if changed since last report.)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒   No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ☒   No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
☒
Accelerated filer
☐
 
 
 
 
Non-accelerated filer
☐
Smaller reporting company
☐
 
 
 
 
 
 
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒
Securities Registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock ($0.50 par value)
MRK
New York Stock Exchange
1.125% Notes due 2021
MRK/21
New York Stock Exchange
0.500% Notes due 2024
MRK 24
New York Stock Exchange
1.875% Notes due 2026
MRK/26
New York Stock Exchange
2.500% Notes due 2034
MRK/34
New York Stock Exchange
1.375% Notes due 2036
MRK 36A
New York Stock Exchange
The number of shares of common stock outstanding as of the close of business on April 30, 2020: 2,524,101,191
 





Table of Contents






Part I - Financial Information
Item 1. Financial Statements
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(Unaudited, $ in millions except per share amounts)
 
 
Three Months Ended 
 March 31,
 
2020
 
2019
Sales
$
12,057

 
$
10,816

Costs, Expenses and Other
 
 
 
Cost of sales
3,312

 
3,052

Selling, general and administrative
2,555

 
2,425

Research and development
2,209

 
1,931

Restructuring costs
72

 
153

Other (income) expense, net
71

 
188

 
8,219

 
7,749

Income Before Taxes
3,838

 
3,067

Taxes on Income
619

 
205

Net Income
3,219

 
2,862

Less: Net Loss Attributable to Noncontrolling Interests
—

 
(53
)
Net Income Attributable to Merck & Co., Inc.
$
3,219

 
$
2,915

Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
$
1.27

 
$
1.13

Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders
$
1.26

 
$
1.12

 
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited, $ in millions)
 
 
Three Months Ended 
 March 31,
 
2020
 
2019
Net Income Attributable to Merck & Co., Inc.
$
3,219

 
$
2,915

Other Comprehensive (Loss) Income Net of Taxes:
 
 
 
Net unrealized gain (loss) on derivatives, net of reclassifications
104

 
(48
)
Net unrealized (loss) gain on investments, net of reclassifications
(18
)
 
82

Benefit plan net gain and prior service credit, net of amortization
60

 
15

Cumulative translation adjustment
(344
)
 
150

 
(198
)
 
199

Comprehensive Income Attributable to Merck & Co., Inc.
$
3,021

 
$
3,114

 The accompanying notes are an integral part of these condensed consolidated financial statements.

- 3 -



MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, $ in millions except per share amounts)
 
 
March 31, 2020
 
December 31, 2019
Assets
 
 
 
Current Assets
 
 
 
Cash and cash equivalents
$
7,425

 
$
9,676

Short-term investments
7

 
774

Accounts receivable (net of allowance for doubtful accounts of $89 in 2020
and $86 in 2019)
8,182

 
6,778

Inventories (excludes inventories of $1,630 in 2020 and $1,480 in 2019
classified in Other assets - see Note 6)
5,846

 
5,978

Other current assets
4,714

 
4,277

Total current assets
26,174

 
27,483

Investments
555

 
1,469

Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,706
in 2020 and $17,686 in 2019
15,269

 
15,053

Goodwill
19,767

 
19,425

Other Intangibles, Net
16,096

 
14,196

Other Assets
7,052

 
6,771

 
$
84,913

 
$
84,397

Liabilities and Equity
 
 
 
Current Liabilities
 
 
 
Loans payable and current portion of long-term debt
$
6,361

 
$
3,610

Trade accounts payable
3,572

 
3,738

Accrued and other current liabilities
10,932

 
12,549

Income taxes payable
1,033

 
736

Dividends payable
1,585

 
1,587

Total current liabilities
23,483

 
22,220

Long-Term Debt
21,637

 
22,736

Deferred Income Taxes
1,943

 
1,470

Other Noncurrent Liabilities
11,550

 
11,970

Merck & Co., Inc. Stockholders’ Equity
 
 
 
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2020 and 2019
1,788

 
1,788

Other paid-in capital
39,697

 
39,660

Retained earnings
48,272

 
46,602

Accumulated other comprehensive loss
(6,391
)
 
(6,193
)
 
83,366

 
81,857

Less treasury stock, at cost:
1,053,090,194 shares in 2020 and 1,038,087,496 shares in 2019
57,161

 
55,950

Total Merck & Co., Inc. stockholders’ equity
26,205

 
25,907

Noncontrolling Interests
95

 
94

Total equity
26,300

 
26,001

 
$
84,913

 
$
84,397

The accompanying notes are an integral part of this condensed consolidated financial statement.

- 4 -



MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, $ in millions)
 
 
Three Months Ended 
 March 31,
 
2020
 
2019
Cash Flows from Operating Activities
 
 
 
Net income
$
3,219

 
$
2,862

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
821

 
898

Intangible asset impairment charges
—

 
104

Deferred income taxes
82

 
194

Share-based compensation
108

 
93

Other
143

 
120

Net changes in assets and liabilities
(3,666
)
 
(2,935
)
Net Cash Provided by Operating Activities
707

 
1,336

Cash Flows from Investing Activities
 
 
 
Capital expenditures
(986
)
 
(595
)
Purchases of securities and other investments
(49
)
 
(974
)
Proceeds from sales of securities and other investments
1,816

 
1,899

Acquisition of ArQule, Inc., net of cash acquired
(2,545
)
 
—

Other
136

 
38

Net Cash (Used in) Provided by Investing Activities
(1,628
)
 
368

Cash Flows from Financing Activities
 
 
 
Net change in short-term borrowings
3,583

 
(4,135
)
Payments on debt
(1,951
)
 
—

Proceeds from issuance of debt
—

 
4,958

Purchases of treasury stock
(1,281
)
 
(1,090
)
Dividends paid to stockholders
(1,551
)
 
(1,428
)
Proceeds from exercise of stock options
26

 
173

Other
(316
)
 
(92
)
Net Cash Used in Financing Activities
(1,490
)
 
(1,614
)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash
(63
)
 
20

Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash
(2,474
)
 
110

Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted
cash of $258 million at January 1, 2020 included in Other Assets)
9,934

 
7,967

Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash
of $35 million at March 31, 2020 included in Other Assets)
$
7,460

 
$
8,077

The accompanying notes are an integral part of this condensed consolidated financial statement.

- 5 -
Notes to Condensed Consolidated Financial Statements (unaudited)


1.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2020.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Planned Spin-Off of Women’s Health, Legacy Brands and Biosimilars into New Company
In February 2020, Merck announced its intention to spin-off products from its women’s health, trusted legacy brands and biosimilars businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The legacy brands included in the transaction consist of dermatology, non-opioid pain, respiratory, and select cardiovascular products including Zetia (ezetimibe) and Vytorin (ezetimibe and simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the first half of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women’s health, legacy brands and biosimilars businesses will be reflected as discontinued operations in the Company’s consolidated financial statements.
Recently Adopted Accounting Standards
In June 2016, the FASB issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.
Recently Issued Accounting Standards Not Yet Adopted
In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.


- 6 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

2.
Acquisitions, Research Collaborations and License Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138 million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95 million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in Selling, general and administrative expenses in the first quarter of 2020. ArQule’s lead investigational candidate, MK-1026 (formerly ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.
The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
 
 
($ in millions)
January 16, 2020
Cash and cash equivalents
$
145

IPR&D MK-1026 (formerly ARQ 531) (1)
2,280

IPR&D MK-7075 (formerly ARQ 092) (1)
170

Licensing arrangement for ARQ 087
80

Deferred income tax liabilities
(434
)
Other assets and liabilities, net
35

Total identifiable net assets
2,276

Goodwill (2)
414

Consideration transferred
$
2,690

(1) 
The fair values of the identifiable intangible assets related to in-process research and development (IPR&D) were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed.
(2) 
The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.
 

3.    Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca
In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor currently approved for certain types of advanced ovarian, breast and pancreatic cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda (pembrolizumab) and Imfinzi. The companies will also jointly develop and commercialize AstraZeneca’s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications. In April 2020, Koselugo was approved for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of Keytruda in combination with Lynparza or

- 7 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca of $1.6 billion in 2017 and made payments of $750 million over a multi-year period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
Prior to 2020, Merck accrued sales-based milestone payments aggregating $1.0 billion related to Lynparza, of which $200 million and $250 million was paid to AstraZeneca in 2019 and 2018, respectively, and $250 million was paid in the first quarter of 2020. Potential future sales-based milestone payments of $3.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of $60 million and $140 million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.7 billion remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $928 million at March 31, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Alliance revenue
$
145

 
$
79

 
 
 
 
Cost of sales (1)
28

 
19

Selling, general and administrative
33

 
27

Research and development
36

 
45

 
 
 
 
($ in millions)
March 31, 2020
 
December 31, 2019
Receivables from AstraZeneca included in Other current assets
$
142

 
$
128

Payables to AstraZeneca included in Accrued and other current liabilities (2)
326

 
577

(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone payments.
Eisai
In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with Keytruda for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in Research and development expenses.
Under the agreement, Merck made an upfront payment to Eisai of $750 million and agreed to make payments of up to $650 million for certain option rights through 2021 (of which $325 million was paid in March 2019, $200 million was paid in March 2020 and $125 million is expected to be paid in March 2021). In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
Prior to 2020, Merck accrued sales-based milestone payments aggregating $950 million related to Lenvima. Of these amounts, $50 million was paid to Eisai in 2019 and an additional $300 million was paid in the first quarter of 2020. Potential future sales-based milestone payments of $3.0 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.

- 8 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

In 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of $250 million in the aggregate from Merck to Eisai. Potential future regulatory milestone payments of $135 million remain under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $921 million at March 31, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Alliance revenue
$
128

 
$
74

 
 
 
 
Cost of sales (1)
35

 
51

Selling, general and administrative
11

 
19

Research and development
64

 
47

 
 
 
 
($ in millions)
March 31, 2020
 
December 31, 2019
Receivables from Eisai included in Other current assets
$
140

 
$
150

Payables to Eisai included in Accrued and other current liabilities (2)
425

 
700

Payables to Eisai included in Other Noncurrent Liabilities (3)
300

 
525

(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone and future option payments.
(3) Includes accrued milestone payments.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer’s vericiguat, which is in development for the potential treatment of worsening heart failure. Under the agreement, Bayer leads commercialization of Adempas in the Americas, while Merck leads commercialization in the rest of the world. For vericiguat, if approved, Bayer will lead commercialization in the rest of world and Merck will lead in the Americas. Both companies share in development costs and profits on sales and have the right to co-promote in territories where they are not the lead. Merck records sales of Adempas in its marketing territories, as well as alliance revenue, which is Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories. In addition, the agreement provides for additional contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.
Prior to 2020, Merck accrued $725 million of sales-based milestone payments for this collaboration, of which $350 million was paid to Bayer in 2018. There is an additional $400 million potential future sales-based milestone payment that has not yet been accrued as it is not deemed by the Company to be probable at this time.
The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was $844 million at March 31, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.

- 9 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Summarized financial information related to this collaboration is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Net sales of Adempas recorded by Merck
$
56

 
$
48

Alliance revenue
53

 
42

Total sales
109

 
90

 
 
 
 
Cost of sales (1)
28

 
29

Selling, general and administrative
15

 
8

Research and development
25

 
30

 
 
 
 
($ in millions)
March 31, 2020
 
December 31, 2019
Receivables from Bayer included in Other current assets
$
50

 
$
49

Payables to Bayer included in Other Noncurrent Liabilities (2)
375

 
375

(1) Includes amortization of intangible assets.
(2) Represents accrued milestone payment.
4.
Restructuring
In early 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $2.5 billion. The Company estimates that approximately 60% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 40% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately $800 million in 2020 related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.
The Company recorded total pretax costs of $168 million and $187 million in the first quarter of 2020 and 2019, respectively, related to restructuring program activities. Since inception of the Restructuring Program through March 31, 2020, Merck has recorded total pretax accumulated costs of approximately $1.1 billion. For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
 
Three Months Ended March 31, 2020
($ in millions)
Separation
Costs
 
Accelerated
Depreciation
 
Other
 
Total
Cost of sales
$
—

 
$
25

 
$
43

 
$
68

Selling, general and administrative
—

 
11

 
—

 
11

Research and development
—

 
17

 
—

 
17

Restructuring costs
47

 
—

 
25

 
72

 
$
47

 
$
53

 
$
68

 
$
168

 
Three Months Ended March 31, 2019
($ in millions)
Separation
Costs
 
Accelerated
Depreciation
 
Other
 
Total
Cost of sales
$
—

 
$
34

 
$
—

 
$
34

Restructuring costs
128

 
—

 
25

 
153

 
$
128

 
$
34

 
$
25

 
$
187


Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated.

- 10 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2020 and 2019 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 10) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2020:
($ in millions)
Separation
Costs
 
Accelerated
Depreciation
 
Other
 
Total
Restructuring reserves January 1, 2020
$
690

 
$
—

 
$
69

 
$
759

Expense
47

 
53

 
68

 
168

(Payments) receipts, net
(168
)
 
—

 
(122
)
 
(290
)
Non-cash activity
—

 
(53
)
 
42

 
(11
)
Restructuring reserves March 31, 2020 (1)
$
569

 
$
—

 
$
57

 
$
626

(1) 
The remaining cash outlays are expected to be substantially completed by the end of 2023.
5.
Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated other comprehensive income (AOCI) and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.

- 11 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI and remain in AOCI until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded component). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
 
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
 
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
 
Three Months Ended March 31,
 
Three Months Ended March 31,
($ in millions)
2020
 
2019
 
2020
 
2019
Net Investment Hedging Relationships
 
 
 
 
 
 
 
Foreign exchange contracts
$
(3
)
 
$
(11
)
 
$
(8
)
 
$
(8
)
Euro-denominated notes
(51
)
 
(30
)
 
—

 
—

(1) No amounts were reclassified from AOCI into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk.
In February 2020, five interest rate swaps with notional amounts of $250 million each matured. These swaps effectively converted the Company’s $1.25 billion, 1.85% fixed-rate notes due 2020 to variable rate debt. At March 31, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.
 
March 31, 2020
($ in millions)
Par Value of Debt
 
Number of Interest Rate Swaps Held
 
Total Swap Notional Amount
3.875% notes due 2021
$
1,150

 
5

 
$
1,150

2.40% notes due 2022
1,000

 
4

 
1,000

2.35% notes due 2022
1,250

 
5

 
1,250


- 12 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
 
Carrying Amount of Hedged Liabilities
 
Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount
($ in millions)
March 31, 2020
 
December 31, 2019
 
March 31, 2020
 
December 31, 2019
Balance Sheet Line Item in which Hedged Item is Included
 
 
 
 
 
 
 
Loans payable and current portion of long-term debt
$
1,160

 
$
1,249

 
$
11

 
$
(1
)
Long-Term Debt
2,315

 
3,409

 
69

 
14

Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
 
 
March 31, 2020
 
December 31, 2019
 
 
Fair Value of Derivative
 
U.S. Dollar
Notional
 
Fair Value of Derivative
 
U.S. Dollar
Notional
($ in millions)
Balance Sheet Caption
Asset
 
Liability
 
Asset
 
Liability
 
Derivatives Designated as Hedging Instruments
 
 
 
 
 
 
 
 
 
 
 
 
Interest rate swap contracts
Other current assets
$
11

 
$
—

 
$
1,150

 
$
—

 
$
—

 
$
—

Interest rate swap contracts
Other Assets
70

 
—

 
2,250

 
15

 
—

 
3,400

Interest rate swap contracts
Accrued and other current liabilities
—

 
—

 
—

 
—

 
1

 
1,250

Foreign exchange contracts
Other current assets
194

 
—

 
6,546

 
152

 
—

 
6,117

Foreign exchange contracts
Other Assets
88

 
—

 
2,064

 
55

 
—

 
2,160

Foreign exchange contracts
Accrued and other current liabilities
—

 
7

 
734

 
—

 
22

 
1,748

Foreign exchange contracts
Other Noncurrent Liabilities
—

 
1

 
5

 
—

 
1

 
53

 
 
$
363


$
8


$
12,749


$
222


$
24


$
14,728

Derivatives Not Designated as Hedging Instruments
 
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts
Other current assets
$
347

 
$
—

 
$
10,039

 
$
66

 
$
—

 
$
7,245

Foreign exchange contracts
Accrued and other current liabilities
—

 
85

 
4,665

 
—

 
73

 
8,693

 
 
$
347

 
$
85

 
$
14,704

 
$
66

 
$
73

 
$
15,938

 
 
$
710


$
93


$
27,453


$
288


$
97


$
30,666


As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 
March 31, 2020
 
December 31, 2019
($ in millions)
Asset
 
Liability
 
Asset
 
Liability
Gross amounts recognized in the condensed consolidated balance sheet
$
710

 
$
93

 
$
288

 
$
97

Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet
(89
)
 
(89
)
 
(84
)
 
(84
)
Cash collateral received
(216
)
 
—

 
(34
)
 
—

Net amounts
$
405

 
$
4

 
$
170

 
$
13



- 13 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:
 
Sales
 
Other (income) expense, net (1)
 
Other comprehensive income (loss)
 
Three Months Ended March 31,
 
Three Months Ended March 31,
 
Three Months Ended March 31,
($ in millions)
2020
 
2019
 
2020
 
2019
 
2020
 
2019
Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded
$
12,057

 
$
10,816

 
$
71

 
$
188

 
$
(198
)
 
$
199

(Gain) loss on fair value hedging relationships
 
 
 
 
 
 
 
 
 
 
 
Interest rate swap contracts
 
 
 
 
 
 
 
 
 
 
 
Hedged items
—

 
—

 
67

 
33

 
—

 
—

Derivatives designated as hedging instruments
—

 
—

 
(67
)
 
(23
)
 
—

 
—

Impact of cash flow hedging relationships
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts
 
 
 
 
 
 
 
 
 
 
 
Amount of gain (loss) recognized in OCI on derivatives
—

 
—

 
—

 
—

 
178

 
(13
)
Increase (decrease) in Sales as a result of AOCI reclassifications
46

 
44

 
—

 
—

 
(46
)
 
(44
)
Interest rate contracts
 
 
 
 
 
 
 
 
 
 
 
Amount of gain recognized in Other (income) expense, net on derivatives
—

 
—

 
(1
)
 
(1
)
 
—

 
—

Amount of loss recognized in OCI on derivatives
—

 
—

 
—

 
—

 
(1
)
 
(4
)
(1) Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
 
 
 
Amount of Derivative Pretax (Gain) Loss Recognized in Income
 
 
 
Three Months Ended March 31,
($ in millions)
Income Statement Caption
 
2020
 
2019
Derivatives Not Designated as Hedging Instruments
 
 
 
 
 
Foreign exchange contracts (1)
Other (income) expense, net
 
$
(180
)
 
$
118

Foreign exchange contracts (2)
Sales
 
(7
)
 
10

(1) These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2) These derivative contracts serve as economic hedges of forecasted transactions.
At March 31, 2020, the Company estimates $136 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCI to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.


- 14 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 
March 31, 2020
 
December 31, 2019
 
Amortized
Cost
 
Gross Unrealized
 
Fair
Value
 
Amortized
Cost
 
Gross Unrealized
 
Fair
Value
($ in millions)
Gains
 
Losses
 
Gains
 
Losses
 
U.S. government and agency securities
$
62

 
$
—

 
$
—

 
$
62

 
$
266

 
$
3

 
$
—

 
$
269

Foreign government bonds
2

 
—

 
—

 
2

 
—

 
—

 
—

 
—

Commercial paper
—

 
—

 
—

 
—

 
668

 
—

 
—

 
668

Corporate notes and bonds
—

 
—

 
—

 
—

 
608

 
13

 
—

 
621

Asset-backed securities
—

 
—

 
—

 
—

 
226

 
1

 
—

 
227

Total debt securities
$
64


$
—


$
—


$
64


$
1,768


$
17


$
—


$
1,785

Publicly traded equity securities (1)
 
 
 
 
 
 
779

 


 


 


 
838

Total debt and publicly traded equity securities








 
$
843

 








 
$
2,623


(1) Unrealized net losses recognized in Other (income) expense, net on equity securities still held at March 31, 2020 were $4 million in the first quarter of 2020. Unrealized net gains recognized in Other (income) expense, net on equity securities still held at March 31, 2019 were $114 million in the first quarter of 2019.
At March 31, 2020 and March 31, 2019, the Company also had $450 million and $542 million, respectively, of equity investments without readily determinable fair values included in Other Assets. During the first three months of 2019, the Company recognized unrealized losses of $9 million in Other (income) expense, net related to certain of these investments held at March 31, 2019 based on unfavorable observable price changes. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values still held at March 31, 2020 were $109 million and $21 million, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities, Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities, Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

- 15 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
 
Fair Value Measurements Using
 
Fair Value Measurements Using
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
($ in millions)
March 31, 2020
 
December 31, 2019
Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investments
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Foreign government bonds
$
—

 
$
2

 
$
—

 
$
2

 
$
—

 
$
—

 
$
—

 
$
—

Commercial paper
—

 
—

 
—

 
—

 
—

 
668

 
—

 
668

Corporate notes and bonds
—

 
—

 
—

 
—

 
—

 
621

 
—

 
621

Asset-backed securities (1)
—

 
—

 
—

 
—

 
—

 
227

 
—

 
227

U.S. government and agency securities
—

 
—

 
—

 
—

 
—

 
209

 
—

 
209

Publicly traded equity securities
560

 
—

 
—

 
560

 
518

 
—

 
—

 
518

 
560


2


—


562


518


1,725


—


2,243

Other assets (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
62

 
—

 
—

 
62

 
60

 
—

 
—

 
60

Publicly traded equity securities
219

 
—

 
—

 
219

 
320

 
—

 
—

 
320

 
281


—


—


281


380


—


—


380

Derivative assets (3)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Forward exchange contracts
—

 
455

 
—

 
455

 
—

 
169

 
—

 
169

Purchased currency options
—

 
174

 
—

 
174

 
—

 
104

 
—

 
104

Interest rate swaps
—

 
81

 
—

 
81

 
—

 
15

 
—

 
15

 
—


710


—


710


—


288


—


288

Total assets
$
841


$
712


$
—


$
1,553


$
898


$
2,013


$
—


$
2,911

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration
$
—

 
$
—

 
$
694

 
$
694

 
$
—

 
$
—

 
$
767

 
$
767

Derivative liabilities (3)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Forward exchange contracts
—

 
90

 
—

 
90

 
—

 
95

 
—

 
95

Written currency options
—

 
3

 
—

 
3

 
—

 
1

 
—

 
1

Interest rate swaps
—

 
—

 
—

 
—

 
—

 
1

 
—

 
1

 
—

 
93

 
—

 
93

 
—

 
97

 
—

 
97

Total liabilities
$
—


$
93


$
694


$
787


$
—


$
97


$
767


$
864

(1) 
Primarily all of the asset-backed securities were highly-rated (Standard & Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less.
(2) 
Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(3) 
The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of March 31, 2020 and December 31, 2019, Cash and cash equivalents included $6.8 billion and $8.9 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).

- 16 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Contingent Consideration
Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:
 
Three Months Ended March 31,
($ in millions)
2020
 
2019
Fair value January 1
$
767

 
$
788

Changes in estimated fair value (1)
33

 
(36
)
Payments
(106
)
 
(85
)
Fair value March 31 (2)(3)
$
694

 
$
667

(1) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2) Balance at March 31, 2020 includes $119 million recorded as a current liability for amounts expected to be paid within the next 12 months.
(3) At March 31, 2020 and December 31, 2019, $520 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.
The increase in the estimated fair value of liabilities for contingent consideration in the first quarter of 2020 primarily relates to MK-7264 (gefapixant), a program obtained in connection with the acquisition of Afferent Pharmaceuticals, following the conclusion of Phase 3 studies evaluating gefapixant for the treatment of chronic cough. The decline in the estimated fair value of liabilities for contingent consideration in the first quarter of 2019 primarily relates to a decision not to pursue an acute cough indication for gefapixant. The payments of contingent consideration in both periods relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at March 31, 2020, was $30.6 billion compared with a carrying value of $28.0 billion and at December 31, 2019, was $28.8 billion compared with a carrying value of $26.3 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the United States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $1.9 billion and $2.7 billion of accounts receivable in the first quarter of 2020 and the fourth quarter of 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $216 million and $34 million at March 31, 2020 and December 31, 2019, respectively. The

- 17 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

obligation to return such collateral is recorded in Accrued and other current liabilities. No cash collateral was advanced by the Company to counterparties as of March 31, 2020 or December 31, 2019.
6.
Inventories
Inventories consisted of:
($ in millions)
March 31, 2020
 
December 31, 2019
Finished goods
$
1,753

 
$
1,772

Raw materials and work in process
5,629

 
5,650

Supplies
232

 
207

Total (approximates current cost)
7,614

 
7,629

Decrease to LIFO cost
(138
)
 
(171
)
 
$
7,476

 
$
7,458

Recognized as:
 
 
 
Inventories
$
5,846

 
$
5,978

Other assets
1,630

 
1,480


Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At March 31, 2020 and December 31, 2019, these amounts included $1.4 billion and $1.3 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $258 million and $168 million at March 31, 2020 and December 31, 2019, respectively, of inventories produced in preparation for product launches.
7.
Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Fosamax
As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving Fosamax (Fosamax Litigation). As of March 31, 2020, approximately 3,590 cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.
All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, Glynn v. Merck, the jury returned a verdict in Merck’s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck’s

- 18 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

motion for judgment as a matter of law in the Glynn case and held that the plaintiff’s failure to warn claim was preempted by federal law.
In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court’s preemption decision in the Glynn case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Merck filed its initial brief on February 21, 2020, as required by the District Court.
Accordingly, as of March 31, 2020, approximately 970 cases were actively pending in the Femur Fracture MDL.
As of March 31, 2020, approximately 2,345 cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.
As of March 31, 2020, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California.
Additionally, there are four Femur Fracture cases pending in other state courts.
Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits.
Januvia/Janumet
As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving Januvia and/or Janumet. As of March 31, 2020, Merck is aware of approximately 1,410 product users alleging that Januvia and/or Janumet caused the development of pancreatic cancer and other injuries.
Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court).
In November 2015, the MDL and California State Court–in separate opinions–granted summary judgment to defendants on grounds of federal preemption.
Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceeding agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment and Daubert motions. Under the stipulated case management schedule, the hearings for Daubert and summary judgment motions are expected to take place in the second half of 2020.
As of March 31, 2020, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck’s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in Merck Sharp & Dohme Corp. v. Albrecht (relating to the Fosamax matter discussed above). Merck filed the opinion in Albrecht with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with Albrecht, that preemption presents a legal question to be resolved by the court.
In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against these lawsuits.

- 19 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Vioxx
As previously disclosed, Merck is a defendant in a lawsuit brought by the Attorney General of Utah alleging that Merck misrepresented the safety of Vioxx. The lawsuit is pending in Utah state court. Utah seeks damages and penalties under the Utah False Claims Act. A bench trial in this matter has been rescheduled for April 6, 2021.
Governmental Proceedings
As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General’s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck’s development of an insulin glargine product, and its subsequent termination, as well as Merck’s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. In February 2020, Merck received a subpoena for documents. Merck is cooperating with the California Attorney General’s investigation.
As previously disclosed, the Company’s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants’ motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants’ motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants’ motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. The Merck Defendants moved to dismiss the new allegations in both complaints. In October 2019, the magistrate judge issued a report and recommendation recommending that the district judge grant the motions in their entirety. In December 2019, the district court adopted this report and recommendation in part. The district court granted the Merck Defendants’ motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. Trial in this matter has been rescheduled to begin on February 23, 2021.
Bravecto Litigation
In January 2020, the Company was served with a complaint in the United States District Court for the District of New Jersey, seeking to certify a nationwide class action of purchasers or users of Bravecto (fluralaner) products in the United States or its territories between May 1, 2014 and December 27, 2019. The complaint contends Bravecto causes neurological events and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. A similar case was filed in Quebec, Canada in May 2019.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which,

- 20 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.
Bridion — Between January and March 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March and April 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier. No schedule for the cases has been set by the courts.
Januvia, Janumet, Janumet XR — In February 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of a patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of Januvia, Janumet, and Janumet XR following expiration of key patent protection in 2022, but prior to the expiration of the later-granted patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026, and a later granted patent owned by the Company covering the Janumet formulation which expires in 2028. Par Pharmaceutical dismissed its case in the U.S. District Court for the District of New Jersey against the Company and will litigate the action in the U.S. District Court for the District of Delaware. The Company filed a patent infringement lawsuit against Mylan Pharmaceuticals Inc. and Mylan Inc. (Mylan) in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. In February 2020, the Company amended its complaint against one defendant, Teva Pharmaceuticals USA, Inc., to add patent infringement claims related to a patent that expires in 2025 and covers certain processes for manufacturing sitagliptin. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single 3-day trial on invalidity issues in October 2021. The Court will schedule separate 1-day trials on infringement issues if necessary. In the Company’s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues.
The Company has settled with three generic companies such that these generic companies can bring their products to the market in November 2026 or earlier under certain circumstances.
In October 2019, Mylan filed a petition for Inter Partes Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of the 2026 patent. The Company filed a Patent Owner Preliminary Response in the IPR proceeding in February 2020. The Company expects the USPTO to determine whether it will institute the IPR proceeding in May 2020.
In Germany, a generic company has sought the revocation of the Supplementary Protection Certificate (SPC) for Janumet. If the generic company is successful, Janumet could lose market exclusivity in Germany as early as July 2022. It is possible that challenges to the Janumet SPC could occur in other European countries.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March 31, 2020 and December 31, 2019 of approximately $255 million and $240 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.


- 21 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

8.
Equity
 
Three Months Ended March 31,
 
  
Common Stock
Other
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests
Total
($ and shares in millions except per share amounts)
Shares
Par Value
Shares
Cost
Balance at January 1, 2019
3,577

$
1,788

$
38,808

$
42,579

$
(5,545
)
985

$
(50,929
)
$
181

$
26,882

Net income attributable to Merck & Co., Inc.
—

—

—

2,915

—

—

—

—

2,915

Other comprehensive income, net of taxes
—

—

—

—

199

—

—

—

199

Cash dividends declared on common stock ($0.55 per share)
—

—

—

(1,429
)
—

—

—

—

(1,429
)
Treasury stock shares purchased
—

—

—

—

—

14

(1,090
)
—

(1,090
)
Share-based compensation plans and other
—

—

(40
)
—

—

(5
)
283

—

243

Net loss attributable to noncontrolling interests
—

—

—

—

—

—

—

(53
)
(53
)
Other changes in noncontrolling ownership interests
—

—

—

—

—

—

—

3

3

Balance at March 31, 2019
3,577

$
1,788

$
38,768

$
44,065

$
(5,346
)
994

$
(51,736
)
$
131

$
27,670

Balance at January 1, 2020
3,577

$
1,788

$
39,660

$
46,602

$
(6,193
)
1,038

$
(55,950
)
$
94

$
26,001

Net income attributable to Merck & Co., Inc.
—

—

—

3,219

—

—

—

—

3,219

Other comprehensive loss, net of taxes
—

—

—

—

(198
)
—

—

—

(198
)
Cash dividends declared on common stock ($0.61 per share)
—

—

—

(1,549
)
—

—

—

—

(1,549
)
Treasury stock shares purchased
—

—

—

—

—

16

(1,281
)
—

(1,281
)
Share-based compensation plans and other
—

—

37

—

—

(1
)
70

—

107

Other changes in noncontrolling ownership interests
—

—

—

—

—

—

—

1

1

Balance at March 31, 2020
3,577

$
1,788

$
39,697

$
48,272

$
(6,391
)
1,053

$
(57,161
)
$
95

$
26,300

 

9.
Share-Based Compensation Plans
The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant.
The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Pretax share-based compensation expense
$
108

 
$
93

Income tax benefit
(15
)
 
(14
)
Total share-based compensation expense, net of taxes
$
93

 
$
79


During the first three months of 2020, the Company granted 58 thousand RSUs with a weighted-average grant date fair value of $85.66 per RSU and during the first three months of 2019 granted 70 thousand RSUs with a weighted-average grant date fair value of $77.39 per RSU. During the first three months of 2020, the Company granted 770 thousand PSUs with a weighted-average grant date fair value of $75.65 per PSU and during the first three months of 2019 granted 609 thousand PSUs with a weighted-average grant date fair value of $90.50 per PSU. The Company did not grant any stock options during the first three months of 2020 or 2019.
At March 31, 2020, there was $1.1 billion of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of 2.4 years. The Company typically communicates the value of annual share-based compensation awards to employees during the first quarter, but the related share amounts are not established and communicated until early May. Therefore, while the number of RSU, PSU and stock option grants disclosed above do not reflect any amounts relating to the annual grants, share-based compensation costs for the first quarter of 2020 and 2019 and unrecognized compensation expense at March 31, 2020 reflect an impact relating to the awards communicated to employees. For segment reporting, share-based compensation costs are unallocated expenses.
  



- 22 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

10.
Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components: 
  
Three Months Ended 
 March 31,
 
2020
 
2019
($ in millions)
U.S.
 
International
 
U.S.
 
International
Service cost
$
86

 
$
74

 
$
71

 
$
60

Interest cost
109

 
34

 
114

 
45

Expected return on plan assets
(194
)
 
(103
)
 
(206
)
 
(108
)
Amortization of unrecognized prior service credit
(12
)
 
(3
)
 
(12
)
 
(3
)
Net loss amortization
75

 
31

 
35

 
16

Termination benefits
3

 
1

 
2

 
—

Curtailments
2

 
(1
)
 
—

 
—

 
$
69


$
33


$
4


$
10

The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Service cost
$
13

 
$
12

Interest cost
14

 
17

Expected return on plan assets
(19
)
 
(18
)
Amortization of unrecognized prior service credit
(22
)
 
(21
)
 
$
(14
)
 
$
(10
)

In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring actions, curtailments were recorded on pension plans as reflected in the tables above.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 11), with the exception of certain amounts for termination benefits and curtailments, which are recorded in Restructuring costs if the event giving rise to the termination benefits or curtailment is related to restructuring actions as noted above.
11.
Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Interest income
$
(25
)
 
$
(89
)
Interest expense
212

 
209

Exchange losses
54

 
101

(Income) loss from investments in equity securities, net (1)
(52
)
 
25

Net periodic defined benefit plan (credit) cost other than service cost
(90
)
 
(141
)
Other, net
(28
)
 
83

 
$
71

 
$
188


(1) 
Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
The higher exchange losses in the first quarter of 2019 reflect losses on forward exchange contracts related to the acquisition of Antelliq Corporation.

- 23 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Other, net (as reflected in the table above) in the first quarter of 2019 includes $84 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment.
Interest paid for the three months ended March 31, 2020 and 2019 was $250 million and $195 million, respectively.
12.
Taxes on Income
The effective income tax rates of 16.1% and 6.7% for the first quarter of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. In addition, the effective income tax rate for the first quarter of 2019 reflects the favorable impact of a $360 million net tax benefit related to the settlement of certain federal income tax matters.
In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $360 million net tax benefit in the first quarter of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.
13.
Earnings Per Share
The calculations of earnings per share are as follows:
 
Three Months Ended 
 March 31,
($ and shares in millions except per share amounts)
2020
 
2019
Net income attributable to Merck & Co., Inc.
$
3,219

 
$
2,915

Average common shares outstanding
2,533

 
2,585

Common shares issuable (1)
14

 
18

Average common shares outstanding assuming dilution
2,547

 
2,603

Basic earnings per common share attributable to Merck & Co., Inc. common shareholders
$
1.27

 
$
1.13

Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders
$
1.26

 
$
1.12

(1) 
Issuable primarily under share-based compensation plans.
For both the first quarter of 2020 and 2019, 2 million of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.


- 24 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

14.
Other Comprehensive Income (Loss)
Changes in AOCI by component are as follows:
 
Three Months Ended March 31,
($ in millions)
Derivatives
 
Investments
 
Employee
Benefit
Plans
 
Cumulative
Translation
Adjustment
 
Accumulated Other
Comprehensive
Income (Loss)
Balance January 1, 2019, net of taxes
$
166

 
$
(78
)
 
$
(3,556
)
 
$
(2,077
)
 
$
(5,545
)
Other comprehensive income (loss) before reclassification adjustments, pretax
(13
)
 
76

 
(1
)
 
156

 
218

Tax
3

 
—

 
6

 
(6
)
 
3

Other comprehensive income (loss) before reclassification adjustments, net of taxes
(10
)
 
76

 
5

 
150

 
221

Reclassification adjustments, pretax
(48
)
(1) 
6

(2) 
14

(3) 
—

 
(28
)
Tax
10

 
—

 
(4
)
 
—

 
6

Reclassification adjustments, net of taxes
(38
)

6


10


—

 
(22
)
Other comprehensive income (loss), net of taxes
(48
)
 
82

 
15

 
150

 
199

Balance March 31, 2019, net of taxes
$
118

 
$
4

 
$
(3,541
)
 
$
(1,927
)
 
$
(5,346
)
Balance January 1, 2020, net of taxes
$
31

 
$
18

 
$
(4,261
)
 
$
(1,981
)
 
$
(6,193
)
Other comprehensive income (loss) before reclassification adjustments, pretax
178

 
3

 
—

 
(333
)
 
(152
)
Tax
(37
)
 
—

 
5

 
(11
)
 
(43
)
Other comprehensive income (loss) before reclassification adjustments, net of taxes
141

 
3

 
5

 
(344
)
 
(195
)
Reclassification adjustments, pretax
(47
)
(1) 
(21
)
(2) 
69

(3) 
—

 
1

Tax
10

 
—

 
(14
)
 
—

 
(4
)
Reclassification adjustments, net of taxes
(37
)

(21
)

55


—

 
(3
)
Other comprehensive income (loss), net of taxes
104

 
(18
)
 
60

 
(344
)
 
(198
)
Balance March 31, 2020, net of taxes
$
135


$
—


$
(4,201
)

$
(2,325
)

$
(6,391
)
(1) 
Relates to foreign currency cash flow hedges that were reclassified from AOCI to Sales.
(2) Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from AOCI to Other (income) expense, net.
(3) Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 10).
 

15.
Segment Reporting
The Company’s operations are principally managed on a products basis and include three operating segments, which are the Pharmaceutical, Animal Health and Healthcare Services segments. The Pharmaceutical and Animal Health segments are the only reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers.
The Healthcare Services segment provided services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company has been in the process of divesting the businesses in the Healthcare Services segment. The remaining businesses were divested during the first quarter of 2020.


- 25 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Sales of the Company’s products were as follows:
 
Three Months Ended March 31,
 
2020
 
2019
 ($ in millions)
U.S.
 
Int’l
 
Total
 
U.S.
 
Int’l
 
Total
Pharmaceutical:
 
 
 
 
 
 
 
 
 
 
 
Oncology
 
 
 
 
 
 
 
 
 
 
 
Keytruda
$
1,906

 
$
1,378

 
$
3,284

 
$
1,284

 
$
985

 
$
2,269

Alliance revenue - Lynparza (1)
85

 
60

 
145

 
50

 
29

 
79

Alliance revenue - Lenvima (1)
90

 
38

 
128

 
50

 
24

 
74

Emend
5

 
38

 
43

 
63

 
53

 
117

Vaccines
 
 
 
 
 
 
 
 
 
 
 
Gardasil/Gardasil 9
461

 
636

 
1,097

 
362

 
476

 
838

ProQuad/M-M-R II/Varivax
333

 
102

 
435

 
343

 
153

 
496

Pneumovax 23
182

 
75

 
256

 
125

 
59

 
185

RotaTeq
140

 
82

 
222

 
154

 
57

 
211

Vaqta
30

 
30

 
60

 
29

 
18

 
47

Hospital Acute Care
 
 
 
 
 
 
 
 
 
 
 
Bridion
143

 
157

 
299

 
119

 
136

 
255

Noxafil
8

 
87

 
94

 
91

 
99

 
190

Invanz
6

 
59

 
64

 
14

 
58

 
72

Prevymis
26

 
33

 
60

 
18

 
14

 
32

Cancidas
3

 
52

 
55

 
1

 
60

 
61

Primaxin
—

 
51

 
51

 
—

 
59

 
59

Cubicin
15

 
31

 
46

 
42

 
46

 
88

Zerbaxa
20

 
16

 
37

 
12

 
14

 
26

Immunology
 
 
 
 
 
 
 
 
 
 
 
Simponi
—

 
215

 
215

 
—

 
208

 
208

Remicade
—

 
88

 
88

 
—

 
123

 
123

Neuroscience
 
 
 
 
 
 
 
 
 
 
 
Belsomra
27

 
53

 
79

 
24

 
44

 
67

Virology
 
 
 
 
 
 
 
 
 
 
 
Isentress/Isentress HD
75

 
170

 
245

 
108

 
147

 
255

Zepatier
18

 
37

 
55

 
33

 
81

 
114

Cardiovascular
 
 
 
 
 
 
 
 
 
 
 
Zetia
(2
)
 
147

 
145

 
—

 
140

 
140

Vytorin
3

 
50

 
53

 
3

 
94

 
97

Atozet
—

 
122

 
122

 
—

 
94

 
94

Adempas
—

 
56

 
56

 
—

 
48

 
48

Alliance revenue - Adempas (2)
49

 
5

 
53

 
40

 
2

 
42

Diabetes
 
 
 
 
 
 
 
 
 
 
 
Januvia
355

 
419

 
774

 
384

 
440

 
824

Janumet
113

 
390

 
503

 
167

 
364

 
530

Women’s Health
 
 
 
 
 
 
 
 
 
 
 
Implanon/Nexplanon
149

 
45

 
195

 
149

 
50

 
199

NuvaRing
26

 
37

 
63

 
185

 
34

 
219

Diversified Brands
 
 
 
 
 
 
 
 
 
 
 
Singulair
5

 
151

 
155

 
5

 
186

 
191

Cozaar/Hyzaar
7

 
95

 
102

 
4

 
99

 
103

Nasonex
6

 
65

 
71

 
(1
)
 
97

 
96

Arcoxia
—

 
70

 
70

 
—

 
75

 
75

Follistim AQ
21

 
21

 
41

 
29

 
28

 
57

Other pharmaceutical (3)
409

 
780

 
1,194

 
328

 
754

 
1,082

Total Pharmaceutical segment sales
4,714


5,941


10,655


4,215


5,448


9,663

Animal Health:
 
 
 
 
 
 
 
 
 
 
 
Livestock
162

 
577

 
739

 
117

 
494

 
611

Companion Animals
222

 
253

 
475

 
177

 
237

 
414

Total Animal Health segment sales
384


830


1,214


294


731


1,025

Other segment sales (4)
23

 
—

 
23

 
39

 
—

 
39

Total segment sales
5,121


6,771


11,892


4,548


6,179


10,727

Other (5)
16

 
149

 
165

 
7

 
82

 
89

 
$
5,137

 
$
6,920

 
$
12,057

 
$
4,555

 
$
6,261

 
$
10,816

U.S. plus international may not equal total due to rounding.
(1) 
Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2) 
Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(3) 
Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(4) 
Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020.
(5) 
Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. Other in the first quarter of 2020 and 2019 also includes approximately $75 million and $15 million, respectively, related to the sale of the marketing rights for certain products.

- 26 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)

Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.2 billion and $2.6 billion for the three months ended March 31, 2020 and 2019, respectively.
Consolidated sales by geographic area where derived are as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
United States
$
5,137

 
$
4,555

Europe, Middle East and Africa
3,534

 
3,103

China
864

 
746

Japan
811

 
799

Asia Pacific (other than China and Japan)
728

 
745

Latin America
556

 
561

Other
427

 
307

 
$
12,057


$
10,816


A reconciliation of segment profits to Income before taxes is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Segment profits:
 
 
 
Pharmaceutical segment
$
7,477

 
$
6,574

Animal Health segment
478

 
415

Other segment
1

 
2

Total segment profits
7,956

 
6,991

Other profits
139

 
30

Unallocated:
 
 
 
Interest income
25

 
89

Interest expense
(212
)
 
(209
)
Depreciation and amortization
(381
)
 
(359
)
Research and development
(2,097
)
 
(1,843
)
Amortization of purchase accounting adjustments
(295
)
 
(397
)
Restructuring costs
(72
)
 
(153
)
Other unallocated, net
(1,225
)
 
(1,082
)
 
$
3,838

 
$
3,067


Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.

- 27 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Planned Spin-Off of Women’s Health, Legacy Brands and Biosimilars into New Company
In February 2020, Merck announced its intention to spin-off products from its women’s health, trusted legacy brands and biosimilars businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The legacy brands included in the transaction consist of dermatology, non-opioid pain, respiratory, and select cardiovascular products including Zetia (ezetimibe) and Vytorin (ezetimibe and simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the first half of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women’s health, legacy brands and biosimilars businesses will be reflected as discontinued operations in the Company’s consolidated financial statements.
Recent Developments
Business Developments
In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases, for $2.7 billion. ArQule’s lead investigational candidate, MK-1026 (formerly ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies (see Note 2 to the condensed consolidated financial statements).
Coronavirus Disease 2019 (COVID-19) Update
Overall, in response to the COVID-19 pandemic, Merck is focused on protecting the safety of its employees, ensuring that its supply of medicines and vaccines reaches its patients, contributing its scientific expertise to the development of antiviral and vaccine approaches, and supporting health care providers and Merck’s communities. Merck remains confident in the fundamental underlying demand for its products and its prospects for long-term growth, though COVID-19-related disruptions to patients’ ability to access health care providers will cause near-term challenges.

Business and Financial
In the first quarter of 2020, the estimated overall impact of COVID-19 to Merck’s revenue was immaterial. For the full-year 2020, Merck expects an unfavorable impact to revenue of approximately $2.1 billion (excluding the impact of foreign exchange) due to the COVID-19 pandemic, comprised of approximately $1.7 billion for Pharmaceutical revenue and approximately $400 million for Animal Health revenue.
In the first quarter of 2020, within the Company’s human health business, markets in Asia Pacific, including China, saw a negative impact from social distancing measures and reduced access to health care providers given the earlier prevalence of the virus; whereas other markets, particularly in Europe, saw customers build inventory due to concerns about supply and ability to access health care providers given social distancing measures.
Roughly two-thirds of Merck’s Pharmaceutical revenue is comprised of physician-administered products, which, despite strong underlying demand, are being affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the prioritization of COVID-19 patients at health care providers, are resulting in reduced administration of many of the Company’s human health products, in particular for its vaccines as well as for Keytruda (pembrolizumab) and Implanon/Nexplanon (etonogestrel implant). The Company anticipates reduced demand for its physician-administered products while pandemic-related access measures remain in place. In addition, declines in medical visits and elective surgeries also will have a negative impact on the demand for certain products, including Bridion (sugammadex) Injection.
In Merck’s Animal Health business, revenue was positively impacted by approximately $60 million in the first quarter of 2020 as customers made advance purchases to secure supply for livestock products and Bravecto (fluralaner), given the uncertainty related to expanding social distancing measures. The Company expects that reduced veterinary visits and decreased protein and milk consumption due to restaurant and school closures will negatively impact the business going forward. Merck also expects that the negative impacts on the economy will have an additional unfavorable effect on its Animal Health business.
While the Company expects to rely on governmental authorities to determine when operations can return to normal, and is cognizant that the duration, spread and severity of the outbreak will be critical determinants for the purposes of the full-year estimates provided above, Merck has assumed the majority of the negative impact will be in the second quarter of 2020, with a gradual return to normal operations beginning late in the second quarter and extending through the third quarter, with a full return to normal operations in the fourth quarter of 2020.

- 28 -



Operating expenses were positively impacted in the first quarter of 2020 by approximately $100 million, primarily driven by lower promotional and selling costs and delayed clinical program spending due to the COVID-19 pandemic. For the full-year 2020, Merck expects a favorable impact to operating expenses of approximately $400 million.
Merck’s financial strength and strong balance sheet is allowing it to continue with its capital allocation priorities, including investing in research and development and in growth drivers, investing in manufacturing capacity expansion, paying its dividend and continuing the search for value-enhancing business development. However, given these priorities and the current operating environment, Merck has temporarily suspended its share repurchase program.
Research
Building on its experience with antivirals and vaccines, Merck has teams of scientists researching COVID-19 and assessing internally available antiviral candidates and vaccine assets for potential to impact COVID-19. The Company also is engaged with a range of research organizations on collaborative efforts to accelerate the development of medicines and vaccines for COVID-19, including participation in the NIH-led ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines), a partnership that aims to develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials and regulatory processes and/or leveraging assets among all partners to rapidly respond to COVID-19 and future pandemics. 
Clinical Trials
The Company is making every effort to ensure that patients in affected areas who are enrolled in clinical trials are able to continue their treatment and receive appropriate care and monitoring. Conditions are fluid and evolving, but as local conditions allow, Merck is enrolling patients in ongoing studies and is starting new studies.
Manufacturing & Supply
Continuity of supply of the Company’s medicines and vaccines to its patients and customers is a critical priority for Merck. To date, the COVID-19 pandemic has not had a material impact on the production and supply of Merck’s medicines and vaccines. The Company continues to have normal supply levels for most of its products, including Keytruda and Gardasil [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] / Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), and doubled production capacity for Esmeron (rocuronium bromide), a muscle relaxant used for intubation in certain countries outside the United States, to address a surge in market demand due to the COVID-19 pandemic. In general, Merck’s total supply chains are 6 to 12 months in length. The Company currently believes supply of its medicines and vaccines will remain at normal levels through the pandemic.
Facilities and Employees
The majority of Merck’s manufacturing plants and clinical supply sites are fully operational and its laboratories are focused on essential operations. The Company is implementing steps to ensure business continuity. In many markets, including the United States, while the Company’s offices and laboratories remain open, Merck’s employees are primarily working from home. In China, most of the Company’s offices, laboratories and plants are now open, although some of Merck’s office- and laboratory-based employees continue to work from home. In many markets, the Company has paused in-person interactions with health care providers and its field-based employees are working from home, including in the United States.
Corporate Headquarters
In April 2020, Merck announced its intention to consolidate its New Jersey campuses into a single New Jersey headquarters location in Rahway by the end of 2023.
Pricing
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. In the United States, pricing pressure continues on many of the Company’s products. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s revenue performance in the first three months of 2020 was negatively affected by other cost-reduction measures taken by governments and other third-parties to lower health care costs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect revenue performance.


- 29 -



Operating Results
Sales
 
Three Months Ended 
 March 31,
 
 
 
% Change
Excluding
Foreign
Exchange
($ in millions)
2020
 
2019
 
% Change
 
United States
$
5,137

 
$
4,555

 
13
%
 
13
%
International
6,920

 
6,261

 
11
%
 
13
%
Total
$
12,057

 
$
10,816

 
11
%
 
13
%
U.S. plus international may not equal total due to rounding.

Worldwide sales were $12.1 billion for the first quarter of 2020, an increase of 11% compared with the first quarter of 2019. Sales growth was driven primarily by higher sales in the oncology franchise reflecting strong growth of Keytruda, as well as increased alliance revenue from Lynparza (olaparib) and Lenvima (lenvatinib). Also contributing to revenue growth in the first quarter of 2020 were higher sales of vaccines, including human papillomavirus (HPV) vaccine Gardasil/Gardasil 9 and Pneumovax 23 (pneumococcal vaccine polyvalent). Higher sales of certain hospital acute care products, including Bridion and Prevymis (letermovir), as well as higher sales of animal health products also drove revenue growth in the first quarter of 2020.
Sales growth was partially offset by the ongoing effects of generic competition for women’s health product NuvaRing (etonogestrel/ethinyl estradiol vaginal ring), hospital acute care products Noxafil (posaconazole) and Cubicin (daptomycin for injection), oncology product Emend (aprepitant), virology product Zepatier (elbasvir and grazoprevir) and cardiovascular product Vytorin. Lower sales of diabetes products Januvia (sitagliptin) and Janumet (sitagliptin/metformin HCl) also partially offset revenue growth in the quarter.
See Note 15 to the condensed consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select products in the franchises follows.
Pharmaceutical Segment
Oncology
 
Three Months Ended 
 March 31,
 
 
 
% Change
Excluding
Foreign
Exchange
($ in millions)
2020
 
2019
 
% Change
 
Keytruda
$
3,284

 
$
2,269

 
45
 %
 
46
 %
Alliance Revenue - Lynparza (1)
145

 
79

 
84
 %
 
86
 %
Alliance Revenue - Lenvima (1)
128

 
74

 
72
 %
 
73
 %
Emend
43

 
117

 
(63
)%
 
(63
)%
(1) Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).
Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma (cHL), esophageal cancer, gastric or gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient cancer, primary mediastinal large B-cell lymphoma (PMBCL), and urothelial carcinoma. Keytruda is also approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy for HNSCC, in combination with axitinib for renal cell carcinoma (RCC), and in combination with lenvatinib for endometrial carcinoma. The Keytruda clinical development program includes studies across a broad range of cancer types (see “Research and Development” below).
In January 2020, the U.S. Food and Drug Administration (FDA) approved Keytruda as monotherapy for the treatment of certain patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) based on the results of the KEYNOTE-057 trial.
In April 2020, the FDA granted accelerated approval for an additional recommended dosage of 400 mg every six weeks (Q6W) for Keytruda across all adult indications, including monotherapy and combination therapy. This new dosage option will be available in addition to the current dose of 200 mg every three weeks (Q3W).
Global sales of Keytruda grew 45% in the first quarter of 2020 driven by higher demand as the Company continues to launch Keytruda with multiple new indications globally. Sales in the United States continue to build across the multiple approved indications, in particular for the treatment of NSCLC as monotherapy, and in combination with chemotherapy for both nonsquamous

- 30 -



and squamous metastatic NSCLC, along with uptake in the RCC and adjuvant melanoma indications. Other indications contributing to U.S. sales growth include HNSCC, bladder cancer, melanoma, and MSI-H cancer. Keytruda sales growth in international markets was driven by continued uptake in approved indications, particularly in the European Union (EU).
Pursuant to a re-pricing rule, the Japanese government reduced the price of Keytruda by 17.5% effective February 2020. Additionally, Keytruda was subject to another price reduction of 20.9% in April 2020 under a provision of the Japanese pricing rules.
Lynparza, an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note 3 to the condensed consolidated financial statements), is approved for the treatment of certain types of advanced ovarian, breast and pancreatic cancers. Alliance revenue related to Lynparza increased 84% in the first quarter of 2020 largely driven by continued uptake across the multiple approved indications in the United States and in the EU.
Lenvima, an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note 3 to the condensed consolidated financial statements), is approved for the treatment of certain types of thyroid cancer, HCC, in combination with everolimus for certain patients with RCC, and in combination with Keytruda for the treatment of certain patients with endometrial carcinoma. Alliance revenue related to Lenvima grew 72% in the first quarter of 2020 primarily due to higher demand in the United States.
Global sales of Emend, for the prevention of chemotherapy-induced nausea and vomiting, declined 63% in the first quarter of 2020 primarily driven by lower demand and pricing in the United States due to generic competition, including recent generic competition for Emend for Injection following U.S. patent expiry in September 2019. The patent that provided U.S. market exclusivity for Emend expired in 2015 and the patent that provided market exclusivity in most major European markets expired in May 2019. Additionally, Emend for Injection will lose market exclusivity in major European markets in August 2020. The Company anticipates that sales of Emend for Injection in these markets will decline significantly thereafter.
In April 2020, the FDA approved Koselugo (selumetinib) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The FDA approval is based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored Phase 2 SPRINT Stratum 1 trial coordinated by the NCI’s Center for Cancer Research, Pediatric Oncology Branch. This is the first regulatory approval of a medicine for the treatment of NF1 PN, a rare and debilitating genetic condition. Koselugo is being jointly developed and commercialized with AstraZeneca globally (see Note 3 to the condensed consolidated financial statements).
Vaccines
 
Three Months Ended 
 March 31,
 
 
 
% Change
Excluding
Foreign
Exchange
($ in millions)
2020
 
2019
 
% Change
 
Gardasil/Gardasil 9
$
1,097

 
$
838

 
31
 %
 
33
 %
ProQuad
157

 
152

 
3
 %
 
3
 %
M-M-R II
100

 
123

 
(18
)%
 
(18
)%
Varivax
179

 
221

 
(19
)%
 
(19
)%
Pneumovax 23
256

 
185

 
39
 %
 
40
 %
Worldwide sales of Gardasil/Gardasil 9, vaccines to help prevent certain cancers and other diseases caused by certain types of HPV, grew 31% in the first quarter of 2020. Sales growth was partially driven by the timing of shipments in China, which contributed approximately $120 million of sales in the quarter, and public sector buying patterns in the United States, which benefited sales by approximately $70 million in the quarter. Higher demand in China and in the EU, as well as pricing in the United States also contributed to sales growth in the quarter. Growth was partially offset by the unfavorable effects of the COVID-19 pandemic in certain markets, particularly in Hong Kong and the United States.
Worldwide sales of M‑M‑R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help protect against measles, mumps and rubella, declined 18% in the first quarter of 2020 primarily driven by lower demand in Brazil and the United States. The Company anticipates that U.S. sales of M-M-R II will decline for the full year of 2020 compared with the full year of 2019 resulting from lower expected demand related to fewer measles outbreaks.
Global sales of Varivax (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), declined 19% in the first quarter of 2020 reflecting lower demand and the timing of government tenders in Latin America. Varivax sales are expected to decline for the full year of 2020 compared with the full year of 2019 due in part to the timing of government tenders in select Latin American markets.

- 31 -



Worldwide sales of Pneumovax 23, a vaccine to help prevent pneumococcal disease, grew 39% in the first quarter of 2020 due to higher demand in the United States and in the EU, driven largely by the COVID-19 pandemic.
Hospital Acute Care
 
Three Months Ended 
 March 31,
 
 
 
% Change
Excluding
Foreign
Exchange
($ in millions)
2020
 
2019
 
% Change
 
Bridion
$
299

 
$
255

 
17
 %
 
19
 %
Noxafil
94

 
190

 
(50
)%
 
(49
)%
Cubicin
46

 
88

 
(48
)%
 
(46
)%
Worldwide sales of Bridion, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 17% in the first quarter of 2020 driven by higher demand globally, particularly in the United States.
Worldwide sales of Noxafil, for the prevention of invasive fungal infections, declined 50% in the first quarter of 2020 primarily due to generic competition in the United States and in the EU. The patents that provided U.S. market exclusivity for certain forms of Noxafil representing the majority of U.S. Noxafil sales expired in July 2019. Additionally, the patent for Noxafil expired in a number of major European markets in December 2019. Accordingly, the Company is experiencing significant declines in Noxafil sales in these markets as a result of generic competition and expects the declines to continue.
Global sales of Cubicin, an I.V. antibiotic for complicated skin and skin structure infections or bacteremia when caused by designated susceptible organisms, declined 48% in the first quarter of 2020 primarily due to ongoing generic competition in the United States following expiration of the U.S. composition patent for Cubicin in 2016.
Immunology
 
Three Months Ended 
 March 31,
 
 
 
% Change
Excluding
Foreign
Exchange
($ in millions)
2020
 
2019
 
% Change
 
Simponi
$
215

 
$
208

 
3
 %
 
7
 %
Remicade
88

 
123

 
(28
)%
 
(27
)%
Sales of Simponi (golimumab), a once-monthly subcutaneous treatment for certain inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), grew 3% in the first quarter of 2020 driven by higher volumes in Russia.
Sales of Remicade (infliximab), a treatment for inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), declined 28% in the first quarter of 2020 driven by ongoing biosimilar competition in the Company’s marketing territories in Europe. The Company lost market exclusivity for Remicade in major European markets in 2015 and no longer has market exclusivity in any of its marketing territories. The Company is experiencing pricing and volume declines in these markets as a result of biosimilar competition and expects the declines to continue.
Virology
 
Three Months Ended 
 March 31,
 
 
 
% Change
Excluding
Foreign
Exchange
($ in millions)
2020
 
2019
 
% Change
 
Isentress/Isentress HD
$
245

 
$
255

 
(4
)%
 
(2
)%
Zepatier
55

 
114

 
(52
)%
 
(51
)%
Global combined sales of Isentress/Isentress HD (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 4% in the first quarter of 2020 primarily driven by lower demand and pricing in the United States due to competitive pressure, largely offset by higher volumes in Russia.
Global sales of Zepatier, a treatment for adult patients with chronic hepatitis C virus genotype (GT) 1 or GT4 infection, declined 52% in the first quarter of 2020 primarily driven by lower demand in the EU, the United States, and Taiwan due to competition and declining patient volumes.

- 32 -



Cardiovascular
 
Three Months Ended 
 March 31,
 
 
 
% Change
Excluding
Foreign
Exchange
($ in millions)
2020
 
2019
 
% Change
 
Zetia/Vytorin
$
198

 
$
238

 
(17
)%
 
(15
)%
Atozet
122

 
94

 
30
 %
 
34
 %
Rosuzet
32

 
14

 
126
 %
 
133
 %
Adempas
56

 
48

 
18
 %
 
20
 %
Alliance Revenue - Adempas (1)
53

 
42

 
26
 %
 
26
 %
(1) Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).
Combined global sales of Zetia (marketed in most countries outside the United States as Ezetrol) and Vytorin (marketed outside the United States as Inegy), medicines for lowering LDL cholesterol, declined 17% in the first quarter of 2020 primarily driven by generic competition for Inegy in the EU. The EU patents for Ezetrol and Inegy expired in April 2018 and April 2019, respectively. The Company expects the sales decline to continue. The sales decline was partially offset by higher demand for Ezetrol in China.
Sales of Atozet (ezetimibe and atorvastatin) (marketed outside of the United States), a medicine for lowering LDL cholesterol, grew 30% in the first quarter of 2020 primarily due to higher demand in the EU and in Japan.
Sales of Rosuzet (ezetimibe and rosuvastatin) (marketed outside of the United States), a medicine for lowering LDL cholesterol, more than doubled in the first quarter of 2020 primarily due to higher demand in Japan and Korea.
Adempas (riociguat), a cardiovascular drug for the treatment of pulmonary arterial hypertension, is part of a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Adempas (see Note 3 to the condensed consolidated financial statements). Revenue from Adempas includes sales in Merck’s marketing territories, which grew 18% in the first quarter of 2020, as well as Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories, which grew 26% in the first quarter of 2020.
Diabetes
 
Three Months Ended 
 March 31,
 
 
 
% Change
Excluding
Foreign
Exchange
($ in millions)
2020
 
2019
 
% Change
 
Januvia/Janumet
$
1,277

 
$
1,354

 
(6
)%
 
(4
)%
Worldwide combined sales of Januvia and Janumet, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 6% in the first quarter of 2020 as a result of continued pricing pressure in the United States. The Company expects U.S. pricing pressure to continue. The patents that provide market exclusivity for Januvia and Janumet in the United States expire in July 2022 (although six-month pediatric exclusivity may extend this date). The patent that provides market exclusivity for Januvia in the EU expires in July 2022 (although pediatric exclusivity may extend this date to September 2022). The supplementary patent certificate that provides market exclusivity for Janumet in the EU expires in April 2023. The Company anticipates sales of Januvia and Janumet in these markets will decline substantially after these patent expiries.
Women’s Health 
 
Three Months Ended 
 March 31,
 
 
 
% Change
Excluding
Foreign
Exchange
($ in millions)
2020
 
2019
 
% Change
 
Implanon/Nexplanon
$
195

 
$
199

 
(2
)%
 
(1
)%
NuvaRing
63

 
219

 
(71
)%
 
(71
)%
Worldwide sales of NuvaRing, a vaginal contraceptive product, declined 71% in the first quarter of 2020 driven by generic competition in the United States. The patent that provided U.S. market exclusivity for NuvaRing expired in April 2018 and generic competition began in December 2019. Accordingly, the Company is experiencing a rapid and substantial decline in U.S. NuvaRing sales and expects the decline to continue.

- 33 -



Biosimilars 
 
Three Months Ended 
 March 31,
 
 
 
% Change
Excluding
Foreign
Exchange
($ in millions)
2020
 
2019
 
% Change
 
Biosimilars
$
68

 
$
43

 
57
%
 
59
%
Biosimilar products are marketed by the Company pursuant to an agreement with Samsung Bioepis Co., Ltd. (Samsung) to develop and commercialize multiple pre-specified biosimilar candidates. Currently, the Company markets Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab) for the treatment of certain inflammatory diseases; Ontruzant (trastuzumab-dttb), a biosimilar to Herceptin (trastuzumab) for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and HER2 overexpressing gastric cancer; and Brenzys (etanercept biosimilar), a biosimilar to Enbrel for the treatment of certain inflammatory diseases. Merck’s commercialization territories under the agreement vary by product. Sale growth of biosimilars in the first quarter of 2020 was driven by continued uptake of Brenzys since launch in Brazil in 2019, Renflexis in United States since launch in 2017 and Ontruzant in the EU since launch in 2018.
In April 2020, Merck announced the U.S. launch of Ontruzant, which was approved by the FDA in January 2019.
Animal Health Segment
 
Three Months Ended 
 March 31,
 
 
 
% Change
Excluding
Foreign
Exchange
($ in millions)
2020
 
2019
 
% Change
 
Livestock
$
739

 
$
611

 
21
%
 
24
%
Companion Animal
475

 
414

 
15
%
 
17
%
Animal Health segment sales in the first quarter of 2020 reflect a benefit of approximately $60 million from the timing of customer purchases related to the COVID-19 pandemic. Sales of livestock products grew 21% in the first quarter of 2020 driven by the April 2019 acquisition of Antelliq Corporation (Antelliq) and COVID-19 related buy-in. Sales of companion animal products grew 15% in the first quarter of 2020 primarily driven by higher sales of the Bravecto line of products for parasitic control, due in part to COVID-19 related buy-in. The Company expects that reduced veterinary visits and decreased protein and milk consumption due to restaurant and school closures will negatively impact the business going forward. Merck also expects that the negative impacts on the economy will have an additional unfavorable effect on its Animal Health business.
Costs, Expenses and Other
 
Three Months Ended 
 March 31,
 
 
($ in millions)
2020
 
2019
 
% Change
Cost of sales
$
3,312

 
$
3,052

 
9
 %
Selling, general and administrative
2,555

 
2,425

 
5
 %
Research and development
2,209

 
1,931

 
14
 %
Restructuring costs
72

 
153

 
(53
)%
Other (income) expense, net
71

 
188

 
(62
)%
Cost of Sales
Cost of sales were $3.3 billion for the first quarter of 2020, an increase of 9% compared with the first quarter of 2019. Cost of sales includes the amortization of intangible assets recorded in connection with business acquisitions, which totaled $292 million and $397 million in the first quarter of 2020 and 2019, respectively. Cost of sales also includes the amortization of amounts capitalized in connection with collaborations of $90 million and $98 million in the first quarter of 2020 and 2019, respectively. Also included in cost of sales are expenses associated with restructuring activities which amounted to $68 million and $34 million in the first quarter of 2020 and 2019, respectively, including accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in Restructuring costs as discussed below.
Gross margin was 72.5% in the first quarter of 2020 compared with 71.8% in the first quarter of 2019. The gross margin improvement in 2020 was primarily driven by favorable product mix and lower amortization of intangible assets (noted above), partially offset by the unfavorable effects of royalties, manufacturing variances, pricing pressure, inventory write-offs, restructuring costs and foreign exchange.

- 34 -



Selling, General and Administrative
Selling, general and administrative (SG&A) expenses were $2.6 billion in the first quarter of 2020, an increase of 5% compared with the first quarter of 2019, primarily due to costs related to the planned spin-off of Organon and transaction costs related to the acquisition of ArQule (see Note 2 to the condensed consolidated financial statements). These increases were partially offset by lower promotional, selling, and administrative costs, due in part to the COVID-19 pandemic, and the favorable effect of foreign exchange.
Research and Development
Research and development (R&D) expenses increased 14% in the first quarter of 2020 to $2.2 billion driven primarily by higher expenses related to clinical development and increased investment in discovery research and early drug development, as well as higher licensing costs, partially offset by lower costs associated with program delays, reduced travel and fewer meetings due to the COVID-19 pandemic.
R&D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $1.5 billion and $1.4 billion in the first quarter of 2020 and 2019, respectively. Also included in R&D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $625 million and $545 million for the first quarter of 2020 and 2019, respectively. In addition, R&D expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration recorded in connection with business acquisitions. During the first quarter of 2020, the Company recorded net expenses of $33 million compared with a net reduction in expenses of $39 million in the first quarter of 2019 related to the changes in these estimates.
Restructuring Costs
In early 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $2.5 billion. The Company expects to record charges of approximately $800 million in 2020 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program to result in annual net cost savings of approximately $900 million by the end of 2023. Actions under previous global restructuring programs have been substantially completed.
Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $72 million and $153 million for the first quarter of 2020 and 2019, respectively. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses.
Additional costs associated with the Company’s restructuring activities are included in Cost of sales, Selling, general and administrative expenses and Research and development costs. The Company recorded aggregate pretax costs of $168 million and $187 million in the first quarter of 2020 and 2019, respectively, related to restructuring program activities (see Note 4 to the condensed consolidated financial statements).
Other (Income) Expense, Net
For details on the components of Other (income) expense, net see Note 11 to the condensed consolidated financial statements.

- 35 -



Segment Profits
 
 
 
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Pharmaceutical segment profits
$
7,477

 
$
6,574

Animal Health segment profits
478

 
415

Other non-reportable segment profits
1

 
2

Other
(4,118
)

(3,924
)
Income before taxes
$
3,838

 
$
3,067

Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&A expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-related costs, including the amortization of purchase accounting adjustments, intangible asset impairment charges, and changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above table. Also included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing sales.
Pharmaceutical segment profits grew 14% in the first quarter of 2020 driven primarily by higher sales, as well as lower selling and promotional costs driven in part by the COVID-19 pandemic, partially offset by the unfavorable effect of foreign exchange and higher administrative costs. Animal Health segment profits grew 15% in the first quarter of 2020 compared with the first quarter of 2019 reflecting higher sales driven by the Antelliq acquisition and COVID-19 related buy-in, partially offset by higher selling and administrative costs and the unfavorable effect of foreign exchange.
Taxes on Income
The effective income tax rates of 16.1% and 6.7% for the first quarter of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. In addition, the effective income tax rate for the first quarter of 2019 reflects the favorable impact of a $360 million net tax benefit related to the settlement of certain federal income tax matters.
In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $360 million net tax benefit in the first quarter of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.
Net Loss Attributable to Noncontrolling Interests
Net loss attributable to noncontrolling interests of $53 million for the first quarter of 2019 includes the portion of goodwill impairment charges related to certain businesses in the Healthcare Services segment that are attributable to noncontrolling interests.
Net Income and Earnings per Common Share
Net income attributable to Merck & Co., Inc. was $3.2 billion for the first quarter of 2020 compared with $2.9 billion for the first quarter of 2019. Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders (EPS) for the first quarter of 2020 were $1.26 compared with $1.12 in the first quarter of 2019.
Non-GAAP Income and Non-GAAP EPS
Non-GAAP income and non-GAAP EPS are alternative views of the Company’s performance that Merck is providing because management believes this information enhances investors’ understanding of the Company’s results as it permits investors to understand how management assesses performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs and certain other items. These excluded items are significant components in understanding and assessing financial performance. Non-

- 36 -



GAAP income and non-GAAP EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes non-GAAP EPS. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. Since non-GAAP income and non-GAAP EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the United States (GAAP).
A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:
 
Three Months Ended 
 March 31,
($ in millions except per share amounts)
2020
 
2019
Income before taxes as reported under GAAP
$
3,838

 
$
3,067

Increase (decrease) for excluded items:
 
 
 
Acquisition and divestiture-related costs
600

 
548

Restructuring costs
168

 
187

Non-GAAP income before taxes
4,606

 
3,802

Taxes on income as reported under GAAP
619

 
205

Estimated tax benefit on excluded items (1)
165

 
129

Net tax benefit from the settlement of certain federal income tax matters
—

 
360

Tax charge related to finalization of treasury regulations for the Tax Cuts and Job Act of 2017
—

 
(67
)
Non-GAAP taxes on income
784


627

Non-GAAP net income
3,822

 
3,175

Less: Net loss attributable to noncontrolling interests as reported under GAAP
—

 
(53
)
    Acquisition and divestiture-related costs attributable to noncontrolling interests
—

 
53

Non-GAAP net income attributable to noncontrolling interests
—


—

Non-GAAP net income attributable to Merck & Co., Inc.
$
3,822


$
3,175

EPS assuming dilution as reported under GAAP
$
1.26

 
$
1.12

EPS difference
0.24

 
0.10

Non-GAAP EPS assuming dilution
$
1.50


$
1.22

(1) 
The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.
Acquisition and Divestiture-Related Costs
Non-GAAP income and non-GAAP EPS exclude the impact of certain amounts recorded in connection with business acquisitions and divestitures. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with business acquisitions and divestitures.
Restructuring Costs
Non-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 4 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.
Certain Other Items
Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2019 is a net tax benefit related to the settlement of certain federal income tax matters (see Note

- 37 -



12 to the condensed consolidated financial statements) and a tax charge related to the finalization of U.S. treasury regulations related to the Tax Cuts and Jobs Act of 2017.
Research and Development Update
Keytruda is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently consists of more than 1,200 clinical trials, including more than 850 trials that combine Keytruda with other cancer treatments. These studies encompass more than 30 cancer types including: biliary tract, cervical, colorectal, cutaneous squamous cell, endometrial, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, melanoma, mesothelioma, nasopharyngeal, non-small-cell lung, ovarian, PMBCL, prostate, renal, small-cell lung, triple-negative breast and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.
Keytruda is under review in Japan as monotherapy and in combination with chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma based on results from the pivotal Phase 3 KEYNOTE-062 trial.
Keytruda is also under review in Japan as monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma based on the results of the Phase 3 KEYNOTE-181 trial.
In October 2019, the FDA accepted a supplemental Biologics License Application (BLA) seeking use of Keytruda for the treatment of patients with recurrent and/or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation based on the results of the KEYNOTE-629 trial. The FDA set a Prescription Drug User Fee Act (PDUFA) date of June 29, 2020.
In April 2020, the FDA accepted for Priority Review a supplemental BLA for Keytruda seeking accelerated approval as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high ≥10 mutations/megabase, as determined by an FDA-approved test, who have progressed following prior treatment and who have no satisfactory alternative treatment options based in part on results from the Phase 2 KEYNOTE-158 trial. The FDA set a PDUFA date of June 16, 2020.
Additionally, Keytruda received Breakthrough Therapy designation from the FDA in September 2019 for the combination of Keytruda with neoadjuvant chemotherapy for the treatment of high-risk, early-stage triple-negative breast cancer (TNBC) and in February 2020 for the combination of Keytruda with PADCEV (enfortumab vedotin-ejfv), in the first-line setting for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a candidate that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.
On April 30, 2020, the European Medicines Agency (EMA) announced that the Committee for Medicinal Products for Human Use (CHMP) did not recommend extending the use of Keytruda to the population of patients with NSCLC whose tumors express PD-L1 on fewer than 50% of cells. However, the CHMP did recommend that study data from the KEYNOTE-042 trial be included in the Keytruda product information, so that physicians would have access to the most contemporary information regarding use of this drug.
In March 2020, Merck announced that the Phase 3 KEYNOTE-204 trial evaluating Keytruda for the treatment of adult patients with relapsed or refractory cHL met one of its dual primary endpoints of progression-free survival (PFS). Based on an interim analysis conducted by an independent Data Monitoring Committee (DMC), Keytruda demonstrated a statistically significant and clinically meaningful improvement in PFS compared with brentuximab vedotin in this patient population. Per the pre-specified analysis plan, the other dual primary endpoint of overall survival (OS) was not formally tested at this interim analysis. The study will continue to evaluate OS. Results will be presented at an upcoming medical meeting and submitted to regulatory authorities. In March 2017, Keytruda was approved by the FDA for the treatment of adult and pediatric patients with refractory cHL, or who have relapsed after three or more prior lines of therapy. This accelerated approval was based on results of the Phase 2 KEYNOTE-087 trial; the Phase 3 KEYNOTE-204 trial is a confirmatory trial for Keytruda’s current indication in cHL.
In April 2020, Merck announced that the Phase 3 KEYNOTE-177 trial evaluating first-line treatment of Keytruda in patients with MSI-H or mismatch repair deficient unresectable or metastatic colorectal cancer met one of its dual primary endpoints of PFS. Based on an interim analysis conducted by an independent DMC, Keytruda monotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy (investigator’s choice of mFOLFOX6 or FOLFIRI, with or without bevacizumab or cetuximab). Based on the recommendation of the DMC, the study will continue without changes to evaluate OS, the other dual primary endpoint.

- 38 -



Lynparza is an oral PARP inhibitor currently approved for certain types of advanced ovarian, breast and pancreatic cancers being co-developed for multiple cancer types as part of a collaboration with AstraZeneca (see Note 3 to the condensed consolidated financial statements).
Lynparza is under review in the EU as a first-line maintenance monotherapy for patients with germline BRCA-mutated metastatic pancreatic cancer whose disease has not progressed following first-line platinum-based chemotherapy. Lynparza was approved for this indication by the FDA in December 2019 based on the results from the Phase 3 POLO trial. A decision from the EMA is expected in the second half of 2020.
In January 2020, the FDA accepted a supplemental New Drug Application (NDA) for Lynparza in combination with bevacizumab for the maintenance treatment of women with advanced ovarian cancer whose disease showed a complete or partial response to first-line treatment with platinum-based chemotherapy and bevacizumab based on the results from the pivotal Phase 3 PAOLA-1 trial. A PDUFA date is set for the second quarter of 2020. This indication is also under review in the EU.
Also in January 2020, the FDA accepted for Priority Review a supplemental NDA for Lynparza for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations, who have progressed following prior treatment with a new hormonal agent based on positive results from the Phase 3 PROfound trial. A PDUFA date is set for the second quarter of 2020. This indication is also under review in the EU and in other jurisdictions. In April 2020, Merck and AstraZeneca announced further positive results from the Phase 3 PROfound trial which showed a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS with Lynparza vs. enzalutamide or abiraterone in men with mCRPC selected for BRCA1/2 or ATM gene mutations, a subpopulation of HRR gene mutations. These data will be presented at a forthcoming medical meeting.
In March 2020, Merck and AstraZeneca announced high-level results from the Phase 3 GY004 trial, led by NRG Oncology and sponsored by the U.S. NCI, that examined primarily the efficacy and safety of investigational medicine cediranib in combination with Lynparza versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer. The trial did not meet the primary endpoint in the intent-to-treat population of a statistically significant improvement in PFS with cediranib in combination with Lynparza vs. platinum-based chemotherapy. The NCI and NRG Oncology will present the full data at a forthcoming medical meeting.
V503 is under review in Japan for an initial indication in females for the prevention of certain HPV-related diseases and precursors.
In February 2020, the FDA accepted for Priority Review a supplemental BLA for Gardasil 9 for the prevention of certain head and neck cancers caused by vaccine-type HPV in females and males 9 through 45 years of age. The FDA set a PDUFA date of June 2020.
In March 2020, Merck announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough. In these studies, the primary efficacy endpoints were met for the gefapixant 45 mg twice daily treatment arms - demonstrating a statistically significant decrease in 24-hour coughs per hour versus placebo. The gefapixant 15 mg twice daily treatment arms did not meet the primary efficacy endpoint in either Phase 3 study. The detailed findings will be shared at an upcoming medical meeting.
Also in March 2020, Merck announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating the efficacy and safety of its investigational drug vericiguat, an orally administered sGC stimulator being developed to treat patients with heart failure with reduced ejection fraction and following a worsening event. Vericiguat, when given in combination with available heart failure therapies, met the primary efficacy endpoint of reducing the risk for the composite endpoint of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction, compared to placebo. The results were presented at the virtual American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology and published in The New England Journal of Medicine. Vericiguat is being jointly developed with Bayer (see Note 3 to the condensed consolidated financial statements). Merck and Bayer plan to share VICTORIA data with regulatory authorities worldwide.
Merck and Pfizer Inc.’s Phase 3 VERTIS CV cardiovascular (CV) outcomes trial for Steglatro (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, achieved its primary endpoint of non-inferiority for major adverse CV events (MACE) compared to placebo in patients with type 2 diabetes mellitus and established atherosclerotic CV disease. MACE was defined as time to the first event of CV death, nonfatal myocardial infarction or nonfatal stroke. The key secondary endpoints of superiority for Steglatro versus placebo for time to composite of CV death or hospitalization for heart failure, CV death alone and the composite of renal death, dialysis/transplant or doubling of serum creatinine from baseline were not met. While not a pre-specified hypothesis for statistical testing, a reduction in hospitalization for heart failure was observed with Steglatro. The safety profile of Steglatro was consistent with that reported in previous studies. Detailed results of VERTIS CV are scheduled to be presented on June 16, 2020 at the virtual American Diabetes Association’s 80th Scientific Sessions.

- 39 -



The chart below reflects the Company’s research pipeline as of May 1, 2020. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.
Phase 2
Phase 3 (Phase 3 entry date)
Under Review
Cancer
MK-1026
     Hematological Malignancies
MK-1308(1)
Melanoma
Non-Small-Cell Lung
MK-1454(1)
Head and Neck
MK-3475 Keytruda
Advanced Solid Tumors
MK-4280(1) 
     Hematological Malignancies
     Non-Small-Cell Lung
MK-5890(1)
     Non-Small-Cell Lung
MK-7339 Lynparza(2)(3)
Advanced Solid Tumors
MK-7684(1)
     Non-Small-Cell Lung
MK-7902 Lenvima(1)(2)
Advanced Solid Tumors
V937
Melanoma
Cytomegalovirus
V160
HIV-1 Infection
MK-8591 (islatravir)
Overgrowth Syndrome
MK-7075
Respiratory Syncytial Virus
MK-1654
Schizophrenia
MK-8189

Cancer
MK-3475 Keytruda 
Biliary Tract (September 2019)
Breast (October 2015)
Cervical (October 2018) (EU)
Colorectal (November 2015)
Cutaneous Squamous Cell (August 2019) (EU)
Endometrial (August 2019) (EU)
Esophageal (December 2015) (EU)
Gastric (May 2015) (EU)
Hepatocellular (May 2016) (EU)
Mesothelioma (May 2018)
Nasopharyngeal (April 2016)
Ovarian (December 2018)
Prostate (May 2019)
Small-Cell Lung (May 2017) (EU)
MK-6482
Renal Cell (February 2020)
MK-7339 Lynparza(1)(2)
Non-Small-Cell Lung (June 2019)
MK-7902 Lenvima(1)(2)
Bladder (May 2019)
Endometrial (June 2018) (EU)
Head and Neck (February 2020)
Melanoma (March 2019)
Non-Small-Cell Lung (March 2019)
Cough
MK-7264 (gefapixant) (March 2018)
Heart Failure
MK-1242 (vericiguat) (September 2016)(2)
HIV-1 Infection
     MK-8591A (doravirine/islatravir) (February 2020)
Pneumoconjugate Vaccine
V114 (June 2018)
New Molecular Entities/Vaccines
Pediatric Neurofibromatosis Type 1
MK-5618 (selumetinib)(2) (EU)
HPV Vaccine
V503 Human Papillomavirus 9-valent Vaccine,
        Recombinant (JPN)

Certain Supplemental Filings
Cancer
MK-3475 Keytruda
• First-Line Metastatic Gastric Cancer
         (KEYNOTE-062) (JPN)
• Recurrent Locally Advanced or Metastatic Esophageal
         Cancer (KEYNOTE-180/KEYNOTE-181) (JPN)
• Recurrent and/or Metastatic Cutaneous Squamous Cell
         Carcinoma (KEYNOTE-629) (U.S.)
• Previously Treated Tumor Mutational Burden-High
         (KEYNOTE-158) (U.S.)
MK-7339 Lynparza(2)
• First-Line gBRCAm Metastatic Pancreatic Cancer
         (POLO) (EU)
• First-Line Maintenance Newly Diagnosed Advanced
         Ovarian Cancer (PAOLA) (U.S.) (EU)
• Metastatic Prostate Cancer (PROfound) (U.S.) (EU)
MK-7902 Lenvima(1)(2)
• First-Line Metastatic Hepatocellular Carcinoma
         (KEYNOTE-524) (U.S.)
Footnotes:
(1)  Being developed in combination with Keytruda.
(2)  Being developed in a collaboration.
(3)  Being developed as monotherapy and in combination with Keytruda.

Liquidity and Capital Resources
($ in millions)
March 31, 2020
 
December 31, 2019
Cash and investments
$
7,987

 
$
11,919

Working capital
2,691

 
5,263

Total debt to total liabilities and equity
33.0
%
 
31.2
%
Cash provided by operating activities was $707 million in the first three months of 2020 compared with $1.3 billion in the first three months of 2019. Cash provided by operating activities in the first three months of 2020 includes $750 million of payments related to collaborations with AstraZeneca and Eisai (see Note 3 to the condensed consolidated financial statements). Cash provided by operating activities continues to be the Company’s primary source of funds to finance operating needs, capital expenditures, treasury stock purchases and dividends paid to shareholders.
Cash used in investing activities was $1.6 billion in the first three months of 2020 compared with cash provided by investing activities of $368 million in the first three months of 2019. The change was driven primarily by the acquisition of ArQule in 2020 and higher capital expenditures, partially offset by lower purchases of securities and other investments.
Cash used in financing activities was $1.5 billion in the first three months of 2020 compared with $1.6 billion in the first three months of 2019. The lower use of cash in financing activities was driven primarily by a net increase in short-term borrowings in 2020 compared with a net decrease in short-term borrowing in 2019, partially offset by proceeds from the issuance of debt in 2019 (see below) and higher payments on debt (see below), higher purchases of treasury stock, lower proceeds from exercise of stock options and higher dividends paid to shareholders in 2020.

- 40 -



Capital expenditures totaled $986 million and $595 million for the first three months of 2020 and 2019, respectively. The increased capital expenditures reflect investment in new capital projects focused primarily on increasing manufacturing capacity for Merck’s key products.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $1.9 billion and $2.7 billion of accounts receivable in the first quarter of 2020 and the fourth quarter of 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows.
Dividends paid to stockholders were $1.6 billion and $1.4 billion for the first three months of 2020 and 2019, respectively. In January 2020, the Board of Directors declared a quarterly dividend of $0.61 per share on the Company’s common stock for the second quarter that was paid in April 2020.
In February 2020, the Company’s $1.25 billion, 1.85% notes and $700 million floating-rate notes matured in accordance with their terms and were repaid.
In March 2019, the Company issued $5.0 billion principal amount of senior unsecured notes consisting of $750 million of 2.90% notes due 2024, $1.75 billion of 3.40% notes due 2029, $1.0 billion of 3.90% notes due 2039, and $1.5 billion of 4.00% notes due 2049. The Company used the net proceeds from the offering of $5.0 billion for general corporate purposes, including the repayment of outstanding commercial paper borrowings.
In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. During the first three months of 2020, the Company purchased $1.3 billion (16 million shares) of its common stock for its treasury under this share repurchase program. As of March 31, 2020, the Company’s remaining share repurchase authorization was $5.9 billion. As noted above, the Company has temporarily suspended its share repurchase program.
The Company has a $6.0 billion credit facility that matures in June 2024. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Critical Accounting Policies
The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended December 31, 2019 included in Merck’s Form 10‑K filed on February 26, 2020. Certain of these accounting policies are considered critical as disclosed in the Critical Accounting Policies section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Merck’s Form 10-K because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates. There have been no significant changes in the Company’s critical accounting policies since December 31, 2019. See Note 1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during 2020.
Recently Issued Accounting Standards
For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.
Item 4. Controls and Procedures
Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that as of March 31, 2020, the Company’s disclosure controls and procedures are effective. For the first quarter of 2020, there were no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-

- 41 -



looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product development, product approvals, product potential and development programs. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including the impact of the recent global outbreak of COVID-19 and other risks and uncertainties some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.
The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10‑K for the year ended December 31, 2019, as filed on February 26, 2020, and in this Form 10-Q, the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.
PART II - Other Information
Item 1. Legal Proceedings
The information called for by this Item is incorporated herein by reference to Note 7 included in Part I, Item 1, Financial Statements (unaudited) — Notes to Condensed Consolidated Financial Statements.
Item 1A. Risk Factors
For a discussion of risks that affect the Company’s business, please refer to Part I, Item IA, “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. There have been no material changes to the risk factors as previously disclosed in the Company’s Annual Report on Form 10-K, except as follows:
The global COVID-19 pandemic is having an adverse impact on the Company’s business, operations and financial performance. The Company is unable to predict the extent to which the pandemic and related impacts will continue to adversely impact its business, operations, financial performance, results of operations, and financial condition.
The Company’s business and financial results will be negatively impacted by the recent outbreak of Coronavirus Disease 2019 (COVID-19). The severity, magnitude and duration of the COVID-19 pandemic is uncertain, rapidly changing and difficult to predict. The degree to which COVID-19 impacts the Company’s results will depend on future developments, including, but not limited to, the duration and spread of the outbreak, its severity, the actions taken to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.
Thus far in 2020, the COVID-19 pandemic has impacted the Company’s business and the Company continues to expect that it will impact the business in numerous ways, including but not limited to those outlined below:
Business and Financial:
In the first quarter of 2020, the estimated overall impact of COVID-19 to Merck’s revenue was immaterial. While difficult to predict the impact to the Company, using a set of assumptions, for the full-year 2020, Merck expects an unfavorable impact to revenue of approximately $2.1 billion (excluding the impact of foreign exchange) due to the COVID-19 pandemic, comprised of approximately $1.7 billion for Pharmaceutical revenue and approximately $400 million for Animal Health revenue.
In the first quarter of 2020, within the Company’s human health business, markets in Asia Pacific, including China, saw a negative impact from social distancing measures and reduced access to health care providers given the earlier prevalence of the virus; whereas other markets, particularly in Europe, saw customers build inventory due to concerns about supply and ability to access health care providers given social distancing measures.
Roughly two-thirds of Merck’s Pharmaceutical revenue is comprised of physician-administered products, which, despite strong underlying demand, are being affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the prioritization of COVID-19 patients at health care providers, are resulting in reduced administration of many of the Company’s human health products, in particular for its vaccines as well as for Keytruda and Implanon/Nexplanon. The Company anticipates reduced demand for its physician-administered products while pandemic-related access measures remain in place. In addition, declines in medical visits and elective surgeries also will have a negative impact on the demand for certain products, including Bridion.

- 42 -



In Merck’s Animal Health business, revenue was positively impacted by approximately $60 million in the first-quarter of 2020 as customers made advance purchases to secure supply for livestock products and Bravecto, given the uncertainty related to expanding social distancing measures. The Company expects that reduced veterinary visits and decreased protein and milk consumption due to restaurant and school closures will negatively impact the business going forward. Merck also expects that the negative impacts on the economy will have an additional unfavorable effect on its Animal Health business.
While the Company expects to rely on governmental authorities to determine when operations can return to normal, and is cognizant that the duration, spread and severity of the outbreak will be critical determinants for the purposes of the full-year estimates provided above, Merck has assumed the majority of the negative impact will be in the second quarter of 2020, with a gradual return to normal operations beginning late in the second quarter and extending through the third quarter, with a full return to normal operations in the fourth quarter of 2020. To the extent these assumptions prove to be incorrect, the Company’s results may differ materially from the estimates set forth herein.
Operating expenses were positively impacted in the first quarter of 2020 by approximately $100 million, primarily driven by lower promotional and selling costs and delayed clinical program spending due to the COVID-19 pandemic. While difficult to predict the impact to the Company, using a set of assumptions, for the full-year 2020, Merck expects a favorable impact to operating expenses of approximately $400 million.
Merck’s financial strength and strong balance sheet is allowing it to continue with its capital allocation priorities, including investing in research and development and in growth drivers, investing in manufacturing capacity expansion, paying its dividend and continuing the search for value-enhancing business development. However, given these priorities and the current operating environment, Merck has temporarily suspended its share repurchase program.
Clinical Trials:
The Company is making every effort to ensure that patients in affected areas who are enrolled in clinical trials are able to continue their treatment and receive appropriate care and monitoring. Conditions are fluid and evolving, but as local conditions allow, Merck is enrolling patients in ongoing studies and starting new studies. If the pandemic is prolonged, clinical trials could experience enrollment delays or new studies might experience delays in commencement which could cause delays in the Company’s ability to register products for new approvals or new indications.
Manufacturing & Supply:
Continuity of supply of the Company’s medicines and vaccines to its patients and customers is a critical priority for Merck. To date, the COVID-19 pandemic has not had a material impact on the production and supply of Merck’s medicines and vaccines. The Company continues to have normal supply levels for most of its products, including Keytruda and Gardasil/Gardasil 9. In general, Merck’s total supply chains are 6 to 12 months in length. The Company currently believes supply of its medicines and vaccines will remain at normal levels through the pandemic. However, if the pandemic is prolonged and the Company’s supply chains are disrupted, the Company’s business could be materially adversely affected.
Facilities and Employees:
The majority of Merck’s manufacturing plants and clinical supply sites are fully operational, and its laboratories are focused on essential operations. The Company is implementing steps to ensure business continuity. In many markets, including the United States, while the Company’s offices and laboratories remain open, Merck’s employees are primarily working from home. In China, most of the Company’s offices, laboratories and plants are now open; although some of Merck’s office- and laboratory-based employees continue to work from home. In many markets, the Company has paused in-person interactions with health care providers and its field-based employees are working from home, including in the United States. If the pandemic is prolonged, the Company’s operations could be adversely affected by these working conditions.
Despite the Company’s efforts to manage these impacts, their ultimate impact also depends on factors beyond the Company’s knowledge or control, including the duration and severity of the COVID-19 outbreak as well as third-party and government actions taken to contain its spread and mitigate its public health effects.

- 43 -




Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer purchases of equity securities for the three months ended March 31, 2020 were as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
 
 
 
 
 
($ in millions)
Period
Total Number
of Shares
Purchased (1)
 
Average Price
Paid Per
Share
 
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs (1)
January 1 - January 31
2,940,290

 
$89.35
 
$6,906
February 1 - February 29
4,170,086

 
$83.67
 
$6,557
March 1 - March 31
9,050,466

 
$74.00
 
$5,888
Total
16,160,842

 
$79.29
 
$5,888
(1) 
Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s common stock for its treasury.
Item 6. Exhibits
Number
  
Description
 
 
3.1

—
 
 
3.2

—
 
 
 
31.1

—
 
 
31.2

—
 
 
32.1

—
 
 
32.2

—
 
 
101.INS

—
XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
 
 
 
101.SCH

—
XBRL Taxonomy Extension Schema Document.
 
 
 
101.CAL

—
XBRL Taxonomy Extension Calculation Linkbase Document.
 
 
 
101.DEF

—
XBRL Taxonomy Extension Definition Linkbase Document.
 
 
 
101.LAB

—
XBRL Taxonomy Extension Label Linkbase Document.
 
 
 
101.PRE

—
XBRL Taxonomy Extension Presentation Linkbase Document.
 
 
 
104

—
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).


- 44 -





Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
MERCK & CO., INC.
 
 
 
Date: May 6, 2020
 
/s/ Jennifer Zachary
 
 
JENNIFER ZACHARY
 
 
Executive Vice President and General Counsel
 
 
 
Date: May 6, 2020
 
/s/ Rita A. Karachun
 
 
RITA A. KARACHUN
 
 
Senior Vice President Finance - Global Controller

- 45 -
 EX-31.1 2 exhibit311rule13a-14a1.htm EXHIBIT 31.1 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CEO 1Q20 Exhibit


Exhibit 31.1
CERTIFICATION
I, Kenneth C. Frazier, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 6, 2020
 
By:     
/s/ Kenneth C. Frazier
 
KENNETH C. FRAZIER
Chairman, President and Chief Executive Officer


 EX-31.2 3 exhibit312rule13a-14a1.htm EXHIBIT 31.2 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CFO 1Q20 Exhibit


Exhibit 31.2
CERTIFICATION
I, Robert M. Davis, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:   May 6, 2020
By:      
/s/ Robert M. Davis
 
ROBERT M. DAVIS
Executive Vice President, Global Services
and Chief Financial Officer


 EX-32.1 4 exhibit321section1350c.htm EXHIBIT 32.1 SECTION 1350 CERTIFICATION OF CEO 1Q20 Exhibit


Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
 
 
 
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated: May 6, 2020
/s/ Kenneth C. Frazier
 
Name:
Title:
KENNETH C. FRAZIER
Chairman, President and Chief Executive Officer




 EX-32.2 5 exhibit322section1350c.htm EXHIBIT 32.2 SECTION 1350 CERTIFICATION OF CFO 1Q20 Exhibit


Exhibit 32.2
Section 1350
Certification of Chief Financial Officer



Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
Dated: May 6, 2020
/s/ Robert M. Davis
 
Name:
Title:
ROBERT M. DAVIS
Executive Vice President, Global Services
and Chief Financial Officer





 EX-101.SCH 6 mrk-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - Acquisitions, Research Collaborations and License Agreements link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Collaborative Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Collaborative Arrangements - Schedule of Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1004001 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 2207201 - Disclosure - Contingencies Commitments and Contingencies (Policies) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Equity - Rollforward Reconciliations (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 2405405 - Disclosure - Financial Instruments - Fair Value Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 2405406 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2405411 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2405409 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2405412 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2405410 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2405410 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2405407 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2405408 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Inventories - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Inventories - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Other (Income) Expense, Net link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Other (Income) Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Other (Income) Expense, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Pension and Other Postretirement Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Pension and Other Postretirement Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Restructuring - Activities by Program (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Restructuring - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - Segment Reporting - Profits to Income Before Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - Segment Reporting - Revenues by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Segment Reporting - Sales of Company's Products (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Share-Based Compensation Plans link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Share-Based Compensation Plans - Expense Allocations (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Share-Based Compensation Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Share-Based Compensation Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Taxes on Income link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mrk-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 mrk-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 mrk-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Entities [Table] Entities [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock Common Stock [Member] 1.125% Notes due 2021 1.125% Notes due 2021 [Member] 1.125% Notes due 2021 [Member] 0.500% Notes due 2024 0.500% Notes due 2024 [Member] 0.500% Notes due 2024 [Member] 1.875% Notes due 2026 1.875% Notes due 2026 [Member] 1.875% Notes due 2026 [Member] 2.500% Notes due 2034 2.500% Notes due 2034 [Member] 2.500% Notes due 2034 [Member] 1.375% Notes due 2036 1.375% Notes due 2036 [Member] 1.375% Notes due 2036 [Member] Entity Information [Line Items] Entity Information [Line Items] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Derivative Instruments and Hedging Activities Disclosure [Abstract] Financial Instruments Financial Instruments Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Restructuring and Related Activities [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Separation Costs One-time Termination Benefits [Member] Accelerated Depreciation Accelerated Depreciation [Member] Accelerated Depreciation [Member] Other Other Restructuring [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Restructuring reserve, beginning balance Restructuring Reserve Expense Restructuring and Related Cost, Incurred Cost (Payments) receipts, net Payments for Restructuring Non-cash activity Restructuring Reserve Noncash Activity Noncash activity affecting the restructuring reserve, including accelerated depreciation. Restructuring reserve, ending balance Inventory Disclosure [Abstract] Inventory [Table] Inventory [Table] Inventory [Table] Inventory [Axis] Inventory [Axis] Inventory [Domain] Inventory [Domain] Inventories Not Expected to be Sold Within One Year Inventory Not Expected to be Sold Within One Year [Member] Inventory Not Expected to be Sold Within One Year [Member] Inventories Produced in Preparation for Product Launches Inventories Produced in Preparation for Product Launches [Member] Inventories Produced in Preparation for Product Launches [Member] Inventory [Line Items] Inventory [Line Items] Inventories classified in Other assets Inventory, Noncurrent Statement of Financial Position [Abstract] Assets Assets [Abstract] Current Assets Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Short-term investments Marketable Securities, Current Accounts receivable (net of allowance for doubtful accounts of $89 in 2020 and $86 in 2019) Accounts Receivable, after Allowance for Credit Loss, Current Inventories (excludes inventories of $1,630 in 2020 and $1,480 in 2019 classified in Other assets - see Note 6) Inventory, Net Other current assets Deferred Income Taxes and Other Assets, Current Total current assets Assets, Current Investments Marketable Securities, Noncurrent Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,706 in 2020 and $17,686 in 2019 Property, Plant and Equipment, Net Goodwill Goodwill Other Intangibles, Net Intangible Assets, Net (Excluding Goodwill) Other Assets Deferred Income Taxes and Other Assets, Noncurrent Total Assets Assets Liabilities and Equity Liabilities and Equity [Abstract] Current Liabilities Liabilities, Current [Abstract] Loans payable and current portion of long-term debt Debt, Current Trade accounts payable Accounts Payable, Current Accrued and other current liabilities Other Liabilities, Current Income taxes payable Accrued Income Taxes, Current Dividends payable Dividends Payable, Current Total current liabilities Liabilities, Current Long-Term Debt Long-term Debt, Excluding Current Maturities Deferred Income Taxes Deferred Income Tax Liabilities, Net Other Noncurrent Liabilities Other Liabilities, Noncurrent Merck & Co., Inc. Stockholders’ Equity Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019 Common Stock, Value, Issued Other paid-in capital Additional Paid in Capital, Common Stock Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Stockholders' equity before deduction for treasury stock Stockholders' Equity before Treasury Stock Less treasury stock, at cost: 1,053,090,194 shares in 2020 and 1,038,087,496 shares in 2019 Treasury Stock, Value Total Merck & Co., Inc. stockholders’ equity Stockholders' Equity Attributable to Parent Noncontrolling Interests Stockholders' Equity Attributable to Noncontrolling Interest Total equity Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Liabilities and Equity Statement of Cash Flows [Abstract] Restricted cash Restricted Cash and Cash Equivalents Equity [Abstract] Equity Schedule of Stockholders Equity [Table Text Block] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign exchange contracts Foreign Exchange Contract [Member] Euro-denominated notes Euro-dominated Notes [Member] Euro-dominated Notes [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Other (income) expense, net Other Nonoperating Income (Expense) [Member] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Revenue Sales [Member] Cost of sales Cost of Sales [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Research and development Research and Development Expense [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other current assets Other Current Assets [Member] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities [Member] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] AstraZeneca AstraZeneca [Member] AstraZeneca [Member] Eisai Eisai [Member] Eisai [Member] Bayer AG Bayer AG [Member] Bayer AG [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement Collaborative Arrangement [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Net sales of Adempas recorded by Merck Collaborative Arrangement, Sales, Net Collaborative Arrangement, Sales, Net Alliance revenue Collaborative Arrangement, Profit Sharing Collaborative Arrangement, Profit Sharing Sales Revenues Cost of sales Cost of Goods and Services Sold Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Receivables Receivables, Net, Current Payables, current Payables, Noncurrent Liabilities, Noncurrent Segment Reporting [Abstract] Number of operating segments Number of Operating Segments Sales discounts Sales Discounts Sales Discounts Derivative [Table] Derivative [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] 3.875% notes due 2021 3.875% Notes Due 2021 [Member] 3.875% Notes Due 2021 2.40% notes due 2022 2.40% Notes Due 2022 [Member] 2.40% Notes Due 2022 [Member] 2.35% notes due 2022 2.35% Notes Due 2022 [Member] 2.35% Notes Due 2022 [Member] Interest rate swap contracts Interest Rate Swap [Member] Derivative [Line Items] Derivative [Line Items] Stated interest rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Par Value of Debt Debt Instrument, Face Amount Number of Interest Rate Swaps Held (in interest rate swaps) Number of Interest Rate Derivatives Held Total swap notional amount Derivative, Notional Amount Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] ArQule ArQule [Member] ArQule [Member] Acquisitions Research Collaborations And License Agreements Transactions [Line Items] Business Acquisition [Line Items] Payment to acquire business Payments to Acquire Businesses, Gross Share-based compensation payments attributable to precombination service Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed Transaction costs Business Acquisition, Transaction Costs Changes in AOCI by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Other Income and Expenses [Abstract] Other (Income) Expense, Net Other Income and Other Expense Disclosure [Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Investments AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Employee Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Cumulative Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Equity, beginning balance Other comprehensive income (loss) before reclassification adjustments, pretax OCI, before Reclassifications, before Tax, Attributable to Parent Tax Other Comprehensive Income (Loss) before Reclassifications, Tax Other comprehensive income (loss) before reclassification adjustments, net of taxes OCI, before Reclassifications, Net of Tax, Attributable to Parent Reclassification adjustments, pretax Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Tax Reclassification from AOCI, Current Period, Tax Reclassification adjustments, net of taxes Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Equity, ending balance Other (Income) Expense, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Statement of Comprehensive Income [Abstract] Net Income Attributable to Merck & Co., Inc. Net Income (Loss) Attributable to Parent Other Comprehensive (Loss) Income Net of Taxes: Other Comprehensive Income (Loss), Net of Tax [Abstract] Net unrealized gain (loss) on derivatives, net of reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Net unrealized (loss) gain on investments, net of reclassifications Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Benefit plan net gain and prior service credit, net of amortization Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Comprehensive Income Attributable to Merck & Co., Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Sanofi Pasteur Sanofi Pasteur [Member] Sanofi Pasteur [Member] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair value, beginning balance Business Combination, Contingent Consideration, Liability Changes in estimated fair value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Fair value, ending balance Current liability Business Combination, Contingent Consideration, Liability, Current Contingent consideration Contingent consideration, measurement input, discount rate (as percent) Business Combination, Contingent Consideration, Liability, Measurement Input Fair Value of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Retirement Benefits [Abstract] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] U.S. UNITED STATES International Foreign Plan [Member] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Pension Plans Pension Plan [Member] Other Postretirement Benefit Plans Other Postretirement Benefits Plan [Member] Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Service cost Defined Benefit Plan, Service Cost Interest cost Defined Benefit Plan, Interest Cost Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Amortization of unrecognized prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Net loss amortization Defined Benefit Plan, Amortization of Gain (Loss) Termination benefits Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits Curtailments Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Commitments and Contingencies Disclosure [Abstract] Legal Costs, Policy Legal Costs, Policy [Policy Text Block] Equity Stockholders' Equity Note Disclosure [Text Block] Other Nonoperating Income (Expense) [Abstract] Component of Other Income / Expense of Nonoperating [Table] Component of Other Income / Expense of Nonoperating [Table] Component of Other Income / Expense of Nonoperating [Table] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Healthcare Services Segment Healthcare Services Segment [Member] Healthcare Services segment [Member] Component of Other Income / Expense of Nonoperating [Line Items] Component of Other Income / Expense of Nonoperating [Line Items] [Line Items] for Component of Other Income / Expense of Nonoperating [Table] Goodwill, Impairment Loss Goodwill, Impairment Loss Interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Share-based Payment Arrangement [Abstract] Share-Based Compensation Plans Share-based Payment Arrangement [Text Block] Pretax share-based compensation expense Share-based Payment Arrangement, Noncash Expense Income tax benefit Share-based Payment Arrangement, Expense, Tax Benefit Total share-based compensation expense, net of taxes Share-based Payment Arrangement, Expense, after Tax Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Financial Instrument Financial Instrument [Axis] Financial Instruments Financial Instruments [Domain] U.S. government and agency securities US Government Agencies Debt Securities [Member] Foreign government bonds Debt Security, Government, Non-US [Member] Commercial paper Commercial Paper [Member] Corporate notes and bonds Corporate Debt Securities [Member] Asset-backed securities Asset-backed Securities [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt securities, amortized cost Debt Securities, Available-for-sale, Amortized Cost Debt securities, unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Debt securities, unrealized losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Debt securities, fair value Debt Securities, Available-for-sale Publicly traded equity securities, fair value Equity Securities, FV-NI Total debt and publicly traded equity securities, fair value Debt Securities and Equity Securities, FV-NI Debt Securities and Equity Securities, FV-NI Unrealized net losses (gains) Equity Securities, FV-NI, Unrealized Gain (Loss) Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Loans payable and current portion of long-term debt Long Term Debt, Current Maturities [Member] Long Term Debt, Current Maturities [Member] Long-Term Debt Long Term Debt Excluding Current Maturities [Member] Long Term Debt Excluding Current Maturities [Member] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Carrying Amount of Hedged Liabilities Hedged Liability, Fair Value Hedge Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Recently Adopted and Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Publicly traded equity securities Equity Securities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Interest rate swap contracts Currency options Foreign Exchange Option [Member] Interest rate swap contracts Interest Rate Contract [Member] Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets Assets, Fair Value Disclosure [Abstract] Investments Publicly traded equity securities Investments Debt Securities, Trading, and Equity Securities, FV-NI Other assets Other Assets, Noncurrent Derivative assets Derivative Asset Total assets Assets, Fair Value Disclosure Liabilities Liabilities, Fair Value Disclosure [Abstract] Derivative liabilities Derivative Liability Total liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Primary weighted average life of collateral Investments, Primary Weighted Average Life of Collateral Investments, Primary Weighted Average Life of Collateral Loss Contingencies [Table] Loss Contingencies [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Fosamax Fosamax [Member] Fosamax [Member]. Januvia Januvia [Member] Januvia [Member] . Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Femur Fracture Litigation Femur Fracture Litigation [Member] Femur Fracture litigation. Cases Company Agreed To Toll Statute Of Limitations Cases Company Agreed ToToll Statute Of Limitations [Member] Cases Company Agreed To Toll Statute Of Limitations[Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Federal Federal [Member] Federal. New Jersey state court New Jersey State Court [Member] New Jersey state court member. California state court California State Court [Member] California state court. Other state courts Other State Court [Member] Other state court. SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Legal Defense Costs Legal Defense Costs [Member] Legal Defense Costs [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Loss contingency, pending claims, number (in legal matters) Loss Contingency, Pending Claims, Number Loss contingency, claims dismissed, number (in legal matters) Loss Contingency, Claims Dismissed, Number Loss contingency, claims on appeal, number (in legal matters) Loss Contingency, Claims on Appeal, Number Loss Contingency, Claims on Appeal, Number Legal defense costs reserve Estimated Litigation Liability Segment Reporting Segment Reporting Disclosure [Text Block] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Other (income) expense, net Other Nonoperating Income (Expense) Other comprehensive income (loss) Hedged items Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Derivatives designated as hedging instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Amount of gain (loss) recognized in OCI on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Increase (decrease) in Sales as a result of AOCI reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Amount of gain recognized in Other (income) expense, net on derivatives Derivative, Gain (Loss) on Derivative, Net Income Statement [Abstract] Costs, Expenses and Other Costs and Expenses [Abstract] Restructuring costs Restructuring Charges Total Costs, Expenses and Other Costs Expenses And Other Total of cost of sales, operating expenses and nonoperating income or expense. Income Before Taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Taxes on Income Income Tax Expense (Benefit) Net Income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Less: Net Loss Attributable to Noncontrolling Interests Net Income (Loss) Attributable to Noncontrolling Interest Net Income Attributable to Merck & Co., Inc. Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) Earnings Per Share, Basic Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) Earnings Per Share, Diluted Income Tax Disclosure [Abstract] Income Tax Examination [Table] Income Tax Examination [Table] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Domestic Tax Authority Domestic Tax Authority [Member] Income Tax Examination [Line Items] Income Tax Examination [Line Items] Effective income tax rate (as percent) Effective Income Tax Rate Reconciliation, Percent Tax benefit recognized related to settlement Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Income taxes paid Income Taxes Paid Gross amounts recognized in the consolidated balance sheet, asset Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset Derivative Asset, Not Offset, Policy Election Deduction Cash collateral received, asset Derivative, Collateral, Obligation to Return Cash Net amounts, asset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Gross amounts recognized in the consolidated balance sheet, liability Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability Derivative Liability, Not Offset, Policy Election Deduction Cash collateral received, liability Derivative, Collateral, Right to Reclaim Cash Net amounts, liability Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Cost of sales Selling, general and administrative Research and development Restructuring costs Restructuring Charges [Member] Total pretax restructuring costs Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Performance Share Units (PSUs) Performance Shares [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Shares granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Weighted-average fair value per share granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Forecast Forecast [Member] Cumulative costs since program inception Restructuring and Related Cost, Cost Incurred to Date Estimate of cumulative pre tax costs that will result in cash outlays Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense). Estimate of cumulative pre tax costs that will be noncash Estimate Of Cumulative Pre Tax Costs That Will Be Noncash Estimate of cumulative pre tax costs that will be noncash. Expected restructuring and related cost Restructuring and Related Cost, Expected Cost Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] IPR&D MK-1026 IPR&D MK-1026 [Member] IPR&D MK-1026 [Member] IPR&D MK-7075 IPR&D MK-7075 [Member] IPR&D MK-7075 [Member] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Licensing arrangement Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Deferred income tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Present value discount rate Intangible Asset, Measurement Input Intangible Asset, Measurement Input Earnings Per Share [Abstract] Net income attributable to Merck & Co., Inc. Average common shares outstanding Weighted Average Number of Shares Outstanding, Basic Common shares issuable (1) Weighted Average Number Diluted Shares Outstanding Adjustment Average common shares outstanding assuming dilution Weighted Average Number of Shares Outstanding, Diluted Basic earnings per common share attributable to Merck & Co., Inc. common shareholders Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Stockholders Equity [Table] Stockholders Equity [Table] Stockholders Equity [Table] Other Paid-In Capital Additional Paid-in Capital [Member] Retained Earnings Retained Earnings [Member] Accumulated Other Comprehensive Loss Treasury Stock Treasury Stock [Member] Non- controlling Interests Noncontrolling Interest [Member] Stockholders Equity [Line Items] Stockholders Equity [Line Items] [Line Items] for Stockholders Equity [Table] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Shares, beginning balance (in shares) Common Stock, Shares, Issued Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax Cash dividends declared on common stock Dividends, Common Stock, Cash Treasury stock shares purchased (in shares) Treasury Stock, Shares, Acquired Treasury stock shares purchased Treasury Stock, Value, Acquired, Cost Method Share-based compensation plans and other (in shares) Stockholders' Equity, Other Shares Share-based compensation plans and other Stockholders' Equity, Other Net income (loss) attributable to noncontrolling interests Noncontrolling interest, changes in ownership interest, other Noncontrolling interest, changes in ownership interest, other Noncontrolling interest, changes in ownership interest, other Shares, ending balance (in shares) Cash dividends declared on common stock (in dollars per share) Common Stock, Dividends, Per Share, Declared Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Total segment profits Operating Segments [Member] Other profits Corporate, Non-Segment [Member] Unallocated Segment Reconciling Items [Member] Pharmaceutical segment Pharmaceutical segment [Member] Pharmaceutical segment. Animal Health segment Animal Health segment [Member] Animal Health segment [Member] Other segment Other Segments [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Profits Interest income Investment Income, Interest Interest expense Interest Expense Depreciation and amortization Depreciation, Depletion and Amortization Research and development Amortization of purchase accounting adjustments Amortization Of Purchase Accounting Adjustments Amortization of purchase accounting adjustments. Restructuring costs Other unallocated, net Segment Reporting Unallocated Other Expenses Net Other net expenses not allocated to segments. Components of net cost of defined benefit plans Schedule of Net Benefit Costs [Table Text Block] Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefits Disclosure [Text Block] Collaboration Arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Derivatives Designated as Hedging Instruments Designated as Hedging Instrument [Member] Derivatives Not Designated as Hedging Instruments Not Designated as Hedging Instrument [Member] Other Assets Other Assets [Member] Accrued and other current liabilities Accrued Liabilities [Member] Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Fair Value of Derivative, Asset Fair Value of Derivative, Liability U.S Dollar Notional Amount Finished goods Inventory, Finished Goods, Gross Raw materials and work in process Inventory, Work in Process and Raw Materials Supplies Other Inventory, Supplies, Gross Total (approximates current cost) Inventory, Gross Decrease to LIFO cost Inventory, LIFO Reserve Total current and noncurrent inventories Inventory Net And Inventory Noncurrent Total of current and noncurrent inventories. Recognized as: Recognized As [Abstract] Recognized as. Inventories Other assets Inventories Inventory Disclosure [Text Block] Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Charges Related to Restructuring Program Activities by Type of Cost Restructuring and Related Costs [Table Text Block] Charges and Spending Relating to Restructuring Activities by Program Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Summary of Interest Rate Swaps Held Schedule of Interest Rate Derivatives [Table Text Block] Amounts Recorded on Balance Sheet Related to Fair Value Hedges Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis Offsetting Assets And Liabilities [Table Text Block] Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis. Location and Amount of Pretax (Gains) Losses of Derivatives Derivative Instruments, Gain (Loss) [Table Text Block] Income Statement Effects of Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Information on Investments in Debt and Equity Securities Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Information About the Changes in Liabilities for Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Taxes on Income Income Tax Disclosure [Text Block] Interest income Interest expense Exchange losses Foreign Currency Transaction Gain (Loss), before Tax (Income) loss from investments in equity securities, net (1) Equity Securities, FV-NI, Gain (Loss) Net periodic defined benefit plan (credit) cost other than service cost Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Other, net Other Nonoperating Income Expense, Other Other nonoperating income and expense items not separately disclosed. Other (income) expense, net Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States Europe, Middle East and Africa EMEA [Member] China CHINA Japan JAPAN Asia Pacific (other than China and Japan) Asia Pacific [Member] Latin America Latin America [Member] Other Other Countries [Member] Other Countries [Member] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Earnings Per Share Earnings Per Share [Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 1.85% Notes Due 2020 1.85% Notes Due 2020 [Member] 1.85% Notes Due 2020 [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum Maximum [Member] Maximum average period of maturities of contracts in years (less than) Derivative, Average Remaining Maturity Number of interest rate swaps held (in interest rate swaps) Pretax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Unrealized losses recognized on investments in equity securities without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount Cumulative unrealized gains on investments Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Cumulative unrealized losses on investments Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Cash equivalents Cash Equivalents, at Carrying Value Payments of contingent consideration Fair value of loans payable and long-term debt, including current portion Debt Instrument, Fair Value Disclosure Debt, carrying amount Debt, Long-term and Short-term, Combined Amount Accounts Receivable, Sale Accounts Receivable, Sale Cash collateral received from counterparties Cash collateral advanced to counterparties Face amount of debt Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Treasury stock, shares (shares) Treasury Stock, Shares Calculations of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Amounts of Share-Based Compensation Cost Recorded in Consolidated Statement of Income Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Assumptions Used to Determine Weighted-Average Fair Value of Options Granted Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Sales-Based Milestones Sales-Based Milestones [Member] Sales-Based Milestones [Member] Regulatory Milestones Regulatory Milestones [Member] Regulatory Milestones [Member] Lynparza Lynparza [Member] Lynparza [Member] Lenvima Lenvima [Member] Lenvima [Member] Adempas Adempas [Member] Adempas Other Assets Other Noncurrent Assets [Member] Other intangible assets Other Intangible Assets [Member] Upfront and milestone payments Upfront And Milestone Payments Made To Collaborative Partner Upfront and milestone payments made to partner as part of collaborative arrangement. License option payment related to collaborative arrangement License option payment related to collaborative arrangement License option payment related to collaborative arrangement Probable contingent payments collaborative arrangement Probable Contingent Payments Collaborative Arrangement Probable Contingent Payments Collaborative Arrangement Milestone payments made to collaborative partner Milestone Payments Made to Collaborative Partner Milestone Payments Made to Collaborative Partner Contingent milestone payments collaborative arrangement Contingent Payments Collaborative Arrangement Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement. Finite-lived intangible assets Finite-Lived Intangible Assets, Net Other liabilities, noncurrent Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Restructuring Restructuring and Related Activities Disclosure [Text Block] Total Pharmaceutical segment sales Total Animal Health segment sales Other segment sales (4) International International [Member] International [Member] Operating Segments Other Keytruda Keytruda [Member] Keytruda [Member] Alliance revenue - Lynparza (1) Alliance revenue - Lynparza [Member] Alliance revenue - Lynparza [Member] Alliance revenue - Lenvima (1) Emend Emend [Member] Emend [Member]. Gardasil/Gardasil 9 Gardasil/Gardasil 9 [Member] Gardasil/Gardasil 9 [Member]. ProQuad/M-M-R II/Varivax ProQuad MMR II Varivax [Member] ProQuad/M-M-R II/Varivax [Member]. Pneumovax 23 Pneumovax 23 [Member] Pneumovax 23[Member]. RotaTeq Rotateq [Member] RotaTeq [Member] Vaqta Vaqta [Member] Vaqta [Member] Bridion Bridion [Member] Bridion [Member]. Noxafil Noxafil [Member] Noxafil [Member]. Invanz Invanz [Member] Invanz [Member]. Prevymis Prevymis [Member] Prevymis [Member] Cancidas Cancidas [Member] Cancidas [Member]. Primaxin Primaxin [Member] Primaxin [Member]. Cubicin Cubicin [Member] Cubicin [Member] Zerbaxa Zerbaxa [Member] Zerbaxa [Member] Simponi Simponi [Member] Simponi [Member]. Remicade Remicade [Member] Remicade [Member]. Belsomra Belsomra [Member] Belsomra [Member] Isentress/Isentress HD Isentress/Isentress HD [Member] Isentress/Isentress HD [Member]. Zepatier Zepatier [Member] Zepatier [Member] Zetia Zetia [Member] Zetia [Member] . Vytorin Vytorin [Member] Vytorin [Member] . Atozet Atozet [Member] Atozet [Member] Alliance revenue - Adempas (2) Alliance Revenue - Adempas [Member] Alliance Revenue - Adempas [Member] Janumet Janumet [Member] Janumet [Member]. Implanon/Nexplanon Implanon/Nexplanon [Member] Implanon/Nexplanon [Member]. NuvaRing Nuvaring [Member] NuvaRing [Member]. Singulair Singulair [Member] Singulair [Member]. Cozaar/Hyzaar Nasonex [Member] Nasonex [Member]. Nasonex Cozaar Hyzaar [Member] Cozaar/Hyzaar [Member]. Arcoxia Arcoxia [Member] Arcoxia [Member]. Follistim AQ Follistim Aq [Member] Follistim AQ [Member]. Other pharmaceutical (3) Other Pharmaceutical [Member] Other pharmaceutical. Livestock Livestock [Member] Livestock [Member] Companion Animals Companion Animals [Member] Companion Animals [Member] Proceeds from Sale of Intangible Assets Proceeds from Sale of Intangible Assets Acquisitions, Divestitures, Research Collaborations and License Agreements Acquisitions Divestitures Research Collaborations And License Agreements [Text Block] Information related to acquisitions, divestitures, research collaborations and license agreements. Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Intangible asset impairment charges Goodwill and Intangible Asset Impairment Deferred income taxes Deferred Income Tax Expense (Benefit) Share-based compensation Other Other Noncash Income (Expense) Net changes in assets and liabilities Increase (Decrease) in Operating Capital Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Payments to Acquire Productive Assets Purchases of securities and other investments Payments to Acquire Marketable Securities Proceeds from sales of securities and other investments Proceeds from Sale, Maturity and Collection of Investments Acquisition of ArQule, Inc., net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Other Payments for (Proceeds from) Other Investing Activities Net Cash (Used in) Provided by Investing Activities Net Cash Provided by (Used in) Investing Activities Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Net change in short-term borrowings Proceeds from (Repayments of) Short-term Debt Payments on debt Repayments of Long-term Debt Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt Purchases of treasury stock Payments for Repurchase of Common Stock Dividends paid to stockholders Payments of Ordinary Dividends, Common Stock Proceeds from exercise of stock options Proceeds from Stock Options Exercised Other Proceeds from (Payments for) Other Financing Activities Net Cash Used in Financing Activities Net Cash Provided by (Used in) Financing Activities Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 million at January 1, 2020 included in Other Assets) Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $35 million at March 31, 2020 included in Other Assets) Foreign currency Currency Swap [Member] Forecasted transactions Foreign Exchange Future [Member] Sales Amount of Derivative Pretax (Gain) Loss Recognized in Income Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Sales of Company's products Revenue from External Customers by Products and Services [Table Text Block] Consolidated revenues by geographic area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Reconciliation of segment profits to income before taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] EX-101.PRE 10 mrk-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Equity
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Equity
Equity
 
Three Months Ended March 31,
 
  
Common Stock
Other
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests
Total
($ and shares in millions except per share amounts)
Shares
Par Value
Shares
Cost
Balance at January 1, 2019
3,577

$
1,788

$
38,808

$
42,579

$
(5,545
)
985

$
(50,929
)
$
181

$
26,882

Net income attributable to Merck & Co., Inc.
—

—

—

2,915

—

—

—

—

2,915

Other comprehensive income, net of taxes
—

—

—

—

199

—

—

—

199

Cash dividends declared on common stock ($0.55 per share)
—

—

—

(1,429
)
—

—

—

—

(1,429
)
Treasury stock shares purchased
—

—

—

—

—

14

(1,090
)
—

(1,090
)
Share-based compensation plans and other
—

—

(40
)
—

—

(5
)
283

—

243

Net loss attributable to noncontrolling interests
—

—

—

—

—

—

—

(53
)
(53
)
Other changes in noncontrolling ownership interests
—

—

—

—

—

—

—

3

3

Balance at March 31, 2019
3,577

$
1,788

$
38,768

$
44,065

$
(5,346
)
994

$
(51,736
)
$
131

$
27,670

Balance at January 1, 2020
3,577

$
1,788

$
39,660

$
46,602

$
(6,193
)
1,038

$
(55,950
)
$
94

$
26,001

Net income attributable to Merck & Co., Inc.
—

—

—

3,219

—

—

—

—

3,219

Other comprehensive loss, net of taxes
—

—

—

—

(198
)
—

—

—

(198
)
Cash dividends declared on common stock ($0.61 per share)
—

—

—

(1,549
)
—

—

—

—

(1,549
)
Treasury stock shares purchased
—

—

—

—

—

16

(1,281
)
—

(1,281
)
Share-based compensation plans and other
—

—

37

—

—

(1
)
70

—

107

Other changes in noncontrolling ownership interests
—

—

—

—

—

—

—

1

1

Balance at March 31, 2020
3,577

$
1,788

$
39,697

$
48,272

$
(6,391
)
1,053

$
(57,161
)
$
95

$
26,300

 
XML 12 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Restructuring
 3 Months Ended
Mar. 31, 2020
Restructuring and Related Activities [Abstract]  
Restructuring
Restructuring
In early 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $2.5 billion. The Company estimates that approximately 60% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 40% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately $800 million in 2020 related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.
The Company recorded total pretax costs of $168 million and $187 million in the first quarter of 2020 and 2019, respectively, related to restructuring program activities. Since inception of the Restructuring Program through March 31, 2020, Merck has recorded total pretax accumulated costs of approximately $1.1 billion. For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
 
Three Months Ended March 31, 2020
($ in millions)
Separation
Costs
 
Accelerated
Depreciation
 
Other
 
Total
Cost of sales
$
—

 
$
25

 
$
43

 
$
68

Selling, general and administrative
—

 
11

 
—

 
11

Research and development
—

 
17

 
—

 
17

Restructuring costs
47

 
—

 
25

 
72

 
$
47

 
$
53

 
$
68

 
$
168

 
Three Months Ended March 31, 2019
($ in millions)
Separation
Costs
 
Accelerated
Depreciation
 
Other
 
Total
Cost of sales
$
—

 
$
34

 
$
—

 
$
34

Restructuring costs
128

 
—

 
25

 
153

 
$
128

 
$
34

 
$
25

 
$
187


Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2020 and 2019 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 10) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2020:
($ in millions)
Separation
Costs
 
Accelerated
Depreciation
 
Other
 
Total
Restructuring reserves January 1, 2020
$
690

 
$
—

 
$
69

 
$
759

Expense
47

 
53

 
68

 
168

(Payments) receipts, net
(168
)
 
—

 
(122
)
 
(290
)
Non-cash activity
—

 
(53
)
 
42

 
(11
)
Restructuring reserves March 31, 2020 (1)
$
569

 
$
—

 
$
57

 
$
626

(1) 
The remaining cash outlays are expected to be substantially completed by the end of 2023.
XML 13 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Taxes on Income
 3 Months Ended
Mar. 31, 2020
Income Tax Disclosure [Abstract]  
Taxes on Income
Taxes on Income
The effective income tax rates of 16.1% and 6.7% for the first quarter of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. In addition, the effective income tax rate for the first quarter of 2019 reflects the favorable impact of a $360 million net tax benefit related to the settlement of certain federal income tax matters.
In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $360 million net tax benefit in the first quarter of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.
XML 14 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Pension and Other Postretirement Benefit Plans (Tables)
 3 Months Ended
Mar. 31, 2020
Pension Plans  
Defined Benefit Plan Disclosure [Line Items]  
Components of net cost of defined benefit plans
The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components: 
  
Three Months Ended 
 March 31,
 
2020
 
2019
($ in millions)
U.S.
 
International
 
U.S.
 
International
Service cost
$
86

 
$
74

 
$
71

 
$
60

Interest cost
109

 
34

 
114

 
45

Expected return on plan assets
(194
)
 
(103
)
 
(206
)
 
(108
)
Amortization of unrecognized prior service credit
(12
)
 
(3
)
 
(12
)
 
(3
)
Net loss amortization
75

 
31

 
35

 
16

Termination benefits
3

 
1

 
2

 
—

Curtailments
2

 
(1
)
 
—

 
—

 
$
69


$
33


$
4


$
10
Other Postretirement Benefit Plans  
Defined Benefit Plan Disclosure [Line Items]  
Components of net cost of defined benefit plans
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Service cost
$
13

 
$
12

Interest cost
14

 
17

Expected return on plan assets
(19
)
 
(18
)
Amortization of unrecognized prior service credit
(22
)
 
(21
)
 
$
(14
)
 
$
(10
)
XML 15 R36.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Reporting (Tables)
 3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Sales of Company's products
Sales of the Company’s products were as follows:
 
Three Months Ended March 31,
 
2020
 
2019
 ($ in millions)
U.S.
 
Int’l
 
Total
 
U.S.
 
Int’l
 
Total
Pharmaceutical:
 
 
 
 
 
 
 
 
 
 
 
Oncology
 
 
 
 
 
 
 
 
 
 
 
Keytruda
$
1,906

 
$
1,378

 
$
3,284

 
$
1,284

 
$
985

 
$
2,269

Alliance revenue - Lynparza (1)
85

 
60

 
145

 
50

 
29

 
79

Alliance revenue - Lenvima (1)
90

 
38

 
128

 
50

 
24

 
74

Emend
5

 
38

 
43

 
63

 
53

 
117

Vaccines
 
 
 
 
 
 
 
 
 
 
 
Gardasil/Gardasil 9
461

 
636

 
1,097

 
362

 
476

 
838

ProQuad/M-M-R II/Varivax
333

 
102

 
435

 
343

 
153

 
496

Pneumovax 23
182

 
75

 
256

 
125

 
59

 
185

RotaTeq
140

 
82

 
222

 
154

 
57

 
211

Vaqta
30

 
30

 
60

 
29

 
18

 
47

Hospital Acute Care
 
 
 
 
 
 
 
 
 
 
 
Bridion
143

 
157

 
299

 
119

 
136

 
255

Noxafil
8

 
87

 
94

 
91

 
99

 
190

Invanz
6

 
59

 
64

 
14

 
58

 
72

Prevymis
26

 
33

 
60

 
18

 
14

 
32

Cancidas
3

 
52

 
55

 
1

 
60

 
61

Primaxin
—

 
51

 
51

 
—

 
59

 
59

Cubicin
15

 
31

 
46

 
42

 
46

 
88

Zerbaxa
20

 
16

 
37

 
12

 
14

 
26

Immunology
 
 
 
 
 
 
 
 
 
 
 
Simponi
—

 
215

 
215

 
—

 
208

 
208

Remicade
—

 
88

 
88

 
—

 
123

 
123

Neuroscience
 
 
 
 
 
 
 
 
 
 
 
Belsomra
27

 
53

 
79

 
24

 
44

 
67

Virology
 
 
 
 
 
 
 
 
 
 
 
Isentress/Isentress HD
75

 
170

 
245

 
108

 
147

 
255

Zepatier
18

 
37

 
55

 
33

 
81

 
114

Cardiovascular
 
 
 
 
 
 
 
 
 
 
 
Zetia
(2
)
 
147

 
145

 
—

 
140

 
140

Vytorin
3

 
50

 
53

 
3

 
94

 
97

Atozet
—

 
122

 
122

 
—

 
94

 
94

Adempas
—

 
56

 
56

 
—

 
48

 
48

Alliance revenue - Adempas (2)
49

 
5

 
53

 
40

 
2

 
42

Diabetes
 
 
 
 
 
 
 
 
 
 
 
Januvia
355

 
419

 
774

 
384

 
440

 
824

Janumet
113

 
390

 
503

 
167

 
364

 
530

Women’s Health
 
 
 
 
 
 
 
 
 
 
 
Implanon/Nexplanon
149

 
45

 
195

 
149

 
50

 
199

NuvaRing
26

 
37

 
63

 
185

 
34

 
219

Diversified Brands
 
 
 
 
 
 
 
 
 
 
 
Singulair
5

 
151

 
155

 
5

 
186

 
191

Cozaar/Hyzaar
7

 
95

 
102

 
4

 
99

 
103

Nasonex
6

 
65

 
71

 
(1
)
 
97

 
96

Arcoxia
—

 
70

 
70

 
—

 
75

 
75

Follistim AQ
21

 
21

 
41

 
29

 
28

 
57

Other pharmaceutical (3)
409

 
780

 
1,194

 
328

 
754

 
1,082

Total Pharmaceutical segment sales
4,714


5,941


10,655


4,215


5,448


9,663

Animal Health:
 
 
 
 
 
 
 
 
 
 
 
Livestock
162

 
577

 
739

 
117

 
494

 
611

Companion Animals
222

 
253

 
475

 
177

 
237

 
414

Total Animal Health segment sales
384


830


1,214


294


731


1,025

Other segment sales (4)
23

 
—

 
23

 
39

 
—

 
39

Total segment sales
5,121


6,771


11,892


4,548


6,179


10,727

Other (5)
16

 
149

 
165

 
7

 
82

 
89

 
$
5,137

 
$
6,920

 
$
12,057

 
$
4,555

 
$
6,261

 
$
10,816

U.S. plus international may not equal total due to rounding.
(1) 
Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2) 
Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(3) 
Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(4) 
Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020.
(5) 
Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.
Consolidated revenues by geographic area
Consolidated sales by geographic area where derived are as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
United States
$
5,137

 
$
4,555

Europe, Middle East and Africa
3,534

 
3,103

China
864

 
746

Japan
811

 
799

Asia Pacific (other than China and Japan)
728

 
745

Latin America
556

 
561

Other
427

 
307

 
$
12,057


$
10,816
Reconciliation of segment profits to income before taxes
A reconciliation of segment profits to Income before taxes is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Segment profits:
 
 
 
Pharmaceutical segment
$
7,477

 
$
6,574

Animal Health segment
478

 
415

Other segment
1

 
2

Total segment profits
7,956

 
6,991

Other profits
139

 
30

Unallocated:
 
 
 
Interest income
25

 
89

Interest expense
(212
)
 
(209
)
Depreciation and amortization
(381
)
 
(359
)
Research and development
(2,097
)
 
(1,843
)
Amortization of purchase accounting adjustments
(295
)
 
(397
)
Restructuring costs
(72
)
 
(153
)
Other unallocated, net
(1,225
)
 
(1,082
)
 
$
3,838

 
$
3,067
XML 16 R57.htm IDEA: XBRL DOCUMENT v3.20.1
Contingencies - Narrative (Details)
$ in Millions
 1 Months Ended
Mar. 31, 2014
Case
Mar. 31, 2020
USD ($)
Claim
Case
Dec. 31, 2019
USD ($)
Legal Defense Costs      
Loss Contingencies [Line Items]      
Legal defense costs reserve | $   $ 255 $ 240
Fosamax      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters)   3,590  
Fosamax | Femur Fracture Litigation | Federal      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters)   970  
Loss contingency, claims dismissed, number (in legal matters) 650    
Loss contingency, claims on appeal, number (in legal matters) 515    
Fosamax | Femur Fracture Litigation | New Jersey state court      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters)   2,345  
Fosamax | Femur Fracture Litigation | California state court      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters)   275  
Fosamax | Femur Fracture Litigation | Other state courts      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters)   4  
Januvia      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters) | Claim   1,410  
Januvia | Other state courts      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters) | Claim   6  
Januvia | Cases Company Agreed To Toll Statute Of Limitations      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters) | Claim   50  
XML 17 R53.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Mar. 31, 2019
Dec. 31, 2018
Assets        
Investments $ 64 $ 1,785    
Publicly traded equity securities 779 838    
Derivative assets 710 288    
Liabilities        
Contingent consideration 694 767 $ 667 $ 788
Derivative liabilities 93 97    
Foreign government bonds        
Assets        
Investments 2 0    
Corporate notes and bonds        
Assets        
Investments 0 621    
Commercial paper        
Assets        
Investments 0 668    
Asset-backed securities        
Assets        
Investments $ 0 227    
Liabilities        
Primary weighted average life of collateral 5 years      
U.S. government and agency securities        
Assets        
Investments $ 62 269    
Fair Value, Measurements, Recurring        
Assets        
Investments 562 2,243    
Other assets 281 380    
Derivative assets 710 288    
Total assets 1,553 2,911    
Liabilities        
Contingent consideration 694 767    
Derivative liabilities 93 97    
Total liabilities 787 864    
Fair Value, Measurements, Recurring | Foreign exchange contracts        
Assets        
Derivative assets 455 169    
Liabilities        
Derivative liabilities 90 95    
Fair Value, Measurements, Recurring | Interest rate swap contracts        
Assets        
Derivative assets 81 15    
Fair Value, Measurements, Recurring | Currency options        
Assets        
Derivative assets 174 104    
Liabilities        
Derivative liabilities 3 1    
Fair Value, Measurements, Recurring | Interest rate swap contracts        
Liabilities        
Derivative liabilities 0 1    
Fair Value, Measurements, Recurring | Level 1        
Assets        
Investments 560 518    
Other assets 281 380    
Derivative assets 0 0    
Total assets 841 898    
Liabilities        
Contingent consideration 0 0    
Derivative liabilities 0 0    
Total liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts        
Assets        
Derivative assets 0 0    
Fair Value, Measurements, Recurring | Level 1 | Currency options        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts        
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 2        
Assets        
Investments 2 1,725    
Other assets 0 0    
Derivative assets 710 288    
Total assets 712 2,013    
Liabilities        
Contingent consideration 0 0    
Derivative liabilities 93 97    
Total liabilities 93 97    
Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts        
Assets        
Derivative assets 455 169    
Liabilities        
Derivative liabilities 90 95    
Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts        
Assets        
Derivative assets 81 15    
Fair Value, Measurements, Recurring | Level 2 | Currency options        
Assets        
Derivative assets 174 104    
Liabilities        
Derivative liabilities 3 1    
Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts        
Liabilities        
Derivative liabilities 0 1    
Fair Value, Measurements, Recurring | Level 3        
Assets        
Investments 0 0    
Other assets 0 0    
Derivative assets 0 0    
Total assets 0 0    
Liabilities        
Contingent consideration 694 767    
Derivative liabilities 0 0    
Total liabilities 694 767    
Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts        
Assets        
Derivative assets 0 0    
Fair Value, Measurements, Recurring | Level 3 | Currency options        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts        
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Foreign government bonds        
Assets        
Investments 2 0    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 2        
Assets        
Investments 2 0    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Corporate notes and bonds        
Assets        
Investments 0 621    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 2        
Assets        
Investments 0 621    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Commercial paper        
Assets        
Investments 0 668    
Fair Value, Measurements, Recurring | Commercial paper | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Commercial paper | Level 2        
Assets        
Investments 0 668    
Fair Value, Measurements, Recurring | Commercial paper | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Asset-backed securities        
Assets        
Investments 0 227    
Fair Value, Measurements, Recurring | Asset-backed securities | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Asset-backed securities | Level 2        
Assets        
Investments 0 227    
Fair Value, Measurements, Recurring | Asset-backed securities | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | U.S. government and agency securities        
Assets        
Investments 0 209    
Other assets 62 60    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 1        
Assets        
Investments 0 0    
Other assets 62 60    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 2        
Assets        
Investments 0 209    
Other assets 0 0    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 3        
Assets        
Investments 0 0    
Other assets 0 0    
Fair Value, Measurements, Recurring | Publicly traded equity securities        
Assets        
Publicly traded equity securities 560 518    
Other assets 219 320    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 1        
Assets        
Publicly traded equity securities 560 518    
Other assets 219 320    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 2        
Assets        
Publicly traded equity securities 0 0    
Other assets 0 0    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 3        
Assets        
Publicly traded equity securities 0 0    
Other assets $ 0 $ 0    
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.20.1
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash Flows from Operating Activities    
Net income $ 3,219 $ 2,862
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 821 898
Intangible asset impairment charges 0 104
Deferred income taxes 82 194
Share-based compensation 108 93
Other 143 120
Net changes in assets and liabilities (3,666) (2,935)
Net Cash Provided by Operating Activities 707 1,336
Cash Flows from Investing Activities    
Capital expenditures (986) (595)
Purchases of securities and other investments (49) (974)
Proceeds from sales of securities and other investments 1,816 1,899
Acquisition of ArQule, Inc., net of cash acquired (2,545) 0
Other 136 38
Net Cash (Used in) Provided by Investing Activities (1,628) 368
Cash Flows from Financing Activities    
Net change in short-term borrowings 3,583 (4,135)
Payments on debt (1,951) 0
Proceeds from issuance of debt 0 4,958
Purchases of treasury stock (1,281) (1,090)
Dividends paid to stockholders (1,551) (1,428)
Proceeds from exercise of stock options 26 173
Other (316) (92)
Net Cash Used in Financing Activities (1,490) (1,614)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash (63) 20
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash (2,474) 110
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 million at January 1, 2020 included in Other Assets) 9,934 7,967
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $35 million at March 31, 2020 included in Other Assets) $ 7,460 $ 8,077
XML 19 R2.htm IDEA: XBRL DOCUMENT v3.20.1
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]    
Sales $ 12,057 $ 10,816
Costs, Expenses and Other    
Cost of sales 3,312 3,052
Selling, general and administrative 2,555 2,425
Research and development 2,209 1,931
Restructuring costs 72 153
Other (income) expense, net 71 188
Total Costs, Expenses and Other 8,219 7,749
Income Before Taxes 3,838 3,067
Taxes on Income 619 205
Net Income 3,219 2,862
Less: Net Loss Attributable to Noncontrolling Interests 0 (53)
Net Income Attributable to Merck & Co., Inc. $ 3,219 $ 2,915
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.27 $ 1.13
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.26 $ 1.12
XML 20 R70.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Reporting - Profits to Income Before Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Segment Reporting Information [Line Items]    
Profits $ 3,838 $ 3,067
Interest income 25 89
Interest expense (212) (209)
Depreciation and amortization (821) (898)
Research and development (2,209) (1,931)
Restructuring costs (72) (153)
Total segment profits    
Segment Reporting Information [Line Items]    
Profits 7,956 6,991
Total segment profits | Pharmaceutical segment    
Segment Reporting Information [Line Items]    
Profits 7,477 6,574
Total segment profits | Animal Health segment    
Segment Reporting Information [Line Items]    
Profits 478 415
Total segment profits | Other segment    
Segment Reporting Information [Line Items]    
Profits 1 2
Other profits    
Segment Reporting Information [Line Items]    
Profits 139 30
Unallocated    
Segment Reporting Information [Line Items]    
Interest income 25 89
Interest expense (212) (209)
Depreciation and amortization (381) (359)
Research and development (2,097) (1,843)
Amortization of purchase accounting adjustments (295) (397)
Restructuring costs (72) (153)
Other unallocated, net $ (1,225) $ (1,082)
XML 21 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 22 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Restructuring - Charges Activities by Type of Cost (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs $ 168 $ 187
Separation Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 47 128
Accelerated Depreciation    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 53 34
Other    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 68 25
Cost of sales    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 68 34
Cost of sales | Separation Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0 0
Cost of sales | Accelerated Depreciation    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 25 34
Cost of sales | Other    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 43 0
Selling, general and administrative    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 11  
Selling, general and administrative | Separation Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0  
Selling, general and administrative | Accelerated Depreciation    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 11  
Selling, general and administrative | Other    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0  
Research and development    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 17  
Research and development | Separation Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0  
Research and development | Accelerated Depreciation    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 17  
Research and development | Other    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0  
Restructuring costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 72 153
Restructuring costs | Separation Costs    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 47 128
Restructuring costs | Accelerated Depreciation    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs 0 0
Restructuring costs | Other    
Restructuring Cost and Reserve [Line Items]    
Total pretax restructuring costs $ 25 $ 25
XML 23 R46.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Summary of Interest Rate Swaps Held (Details)
Mar. 31, 2020
USD ($)
interest_rate_swap
Feb. 29, 2020
USD ($)
Dec. 31, 2019
USD ($)
Derivative [Line Items]      
Total swap notional amount $ 27,453,000,000   $ 30,666,000,000
Interest rate swap contracts      
Derivative [Line Items]      
Number of Interest Rate Swaps Held (in interest rate swaps) 14 5  
Total swap notional amount   $ 250,000,000  
3.875% notes due 2021 | Interest rate swap contracts      
Derivative [Line Items]      
Stated interest rate (as percent) 3.875%    
Par Value of Debt $ 1,150,000,000    
Number of Interest Rate Swaps Held (in interest rate swaps) | interest_rate_swap 5    
Total swap notional amount $ 1,150,000,000    
2.40% notes due 2022 | Interest rate swap contracts      
Derivative [Line Items]      
Stated interest rate (as percent) 2.40%    
Par Value of Debt $ 1,000,000,000    
Number of Interest Rate Swaps Held (in interest rate swaps) | interest_rate_swap 4    
Total swap notional amount $ 1,000,000,000    
2.35% notes due 2022 | Interest rate swap contracts      
Derivative [Line Items]      
Stated interest rate (as percent) 2.35%    
Par Value of Debt $ 1,250,000,000    
Number of Interest Rate Swaps Held (in interest rate swaps) | interest_rate_swap 5    
Total swap notional amount $ 1,250,000,000    
XML 24 R65.htm IDEA: XBRL DOCUMENT v3.20.1
Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Earnings Per Share [Abstract]    
Net income attributable to Merck & Co., Inc. $ 3,219 $ 2,915
Average common shares outstanding 2,533 2,585
Common shares issuable (1) 14 18
Average common shares outstanding assuming dilution 2,547 2,603
Basic earnings per common share attributable to Merck & Co., Inc. common shareholders $ 1.27 $ 1.13
Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders $ 1.26 $ 1.12
Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive (in shares) 2 2
XML 25 R61.htm IDEA: XBRL DOCUMENT v3.20.1
Pension and Other Postretirement Benefit Plans (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Other Postretirement Benefit Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost $ 13 $ 12
Interest cost 14 17
Expected return on plan assets (19) (18)
Amortization of unrecognized prior service credit (22) (21)
Net periodic benefit cost (14) (10)
U.S. | Pension Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost 86 71
Interest cost 109 114
Expected return on plan assets (194) (206)
Amortization of unrecognized prior service credit (12) (12)
Net loss amortization 75 35
Termination benefits 3 2
Curtailments 2 0
Net periodic benefit cost 69 4
International | Pension Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost 74 60
Interest cost 34 45
Expected return on plan assets (103) (108)
Amortization of unrecognized prior service credit (3) (3)
Net loss amortization 31 16
Termination benefits 1 0
Curtailments (1) 0
Net periodic benefit cost $ 33 $ 10
XML 26 R69.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Reporting - Revenues by Geographic Area (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Revenue from External Customer [Line Items]    
Sales $ 12,057 $ 10,816
United States    
Revenue from External Customer [Line Items]    
Sales 5,137 4,555
Europe, Middle East and Africa    
Revenue from External Customer [Line Items]    
Sales 3,534 3,103
China    
Revenue from External Customer [Line Items]    
Sales 864 746
Japan    
Revenue from External Customer [Line Items]    
Sales 811 799
Asia Pacific (other than China and Japan)    
Revenue from External Customer [Line Items]    
Sales 728 745
Latin America    
Revenue from External Customer [Line Items]    
Sales 556 561
Other    
Revenue from External Customer [Line Items]    
Sales $ 427 $ 307
XML 27 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Restructuring (Tables)
 3 Months Ended
Mar. 31, 2020
Restructuring and Related Activities [Abstract]  
Charges Related to Restructuring Program Activities by Type of Cost
The following tables summarize the charges related to restructuring program activities by type of cost:
 
Three Months Ended March 31, 2020
($ in millions)
Separation
Costs
 
Accelerated
Depreciation
 
Other
 
Total
Cost of sales
$
—

 
$
25

 
$
43

 
$
68

Selling, general and administrative
—

 
11

 
—

 
11

Research and development
—

 
17

 
—

 
17

Restructuring costs
47

 
—

 
25

 
72

 
$
47

 
$
53

 
$
68

 
$
168

 
Three Months Ended March 31, 2019
($ in millions)
Separation
Costs
 
Accelerated
Depreciation
 
Other
 
Total
Cost of sales
$
—

 
$
34

 
$
—

 
$
34

Restructuring costs
128

 
—

 
25

 
153

 
$
128

 
$
34

 
$
25

 
$
187
Charges and Spending Relating to Restructuring Activities by Program
The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March 31, 2020:
($ in millions)
Separation
Costs
 
Accelerated
Depreciation
 
Other
 
Total
Restructuring reserves January 1, 2020
$
690

 
$
—

 
$
69

 
$
759

Expense
47

 
53

 
68

 
168

(Payments) receipts, net
(168
)
 
—

 
(122
)
 
(290
)
Non-cash activity
—

 
(53
)
 
42

 
(11
)
Restructuring reserves March 31, 2020 (1)
$
569

 
$
—

 
$
57

 
$
626

(1) 
The remaining cash outlays are expected to be substantially completed by the end of 2023.
XML 28 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Basis of Presentation (Policies)
 3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2020.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Recently Adopted and Issued Accounting Standards
Recently Adopted Accounting Standards
In June 2016, the FASB issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.
Recently Issued Accounting Standards Not Yet Adopted
In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
XML 29 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 643 357 1 false 145 0 false 8 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.merck.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME Sheet http://www.merck.com/role/CondensedConsolidatedStatementOfIncome CONDENSED CONSOLIDATED STATEMENT OF INCOME Statements 2 false false R3.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Sheet http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET Sheet http://www.merck.com/role/CondensedConsolidatedBalanceSheet CONDENSED CONSOLIDATED BALANCE SHEET Statements 4 false false R5.htm 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://www.merck.com/role/CondensedConsolidatedBalanceSheetParenthetical CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Sheet http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Statements 6 false false R7.htm 1004001 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) Sheet http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlowsParenthetical CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) Statements 7 false false R8.htm 2101100 - Disclosure - Basis of Presentation Sheet http://www.merck.com/role/BasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 2102100 - Disclosure - Acquisitions, Research Collaborations and License Agreements Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreements Acquisitions, Research Collaborations and License Agreements Notes 9 false false R10.htm 2103100 - Disclosure - Collaborative Arrangements Sheet http://www.merck.com/role/CollaborativeArrangements Collaborative Arrangements Notes 10 false false R11.htm 2104100 - Disclosure - Restructuring Sheet http://www.merck.com/role/Restructuring Restructuring Notes 11 false false R12.htm 2105100 - Disclosure - Financial Instruments Sheet http://www.merck.com/role/FinancialInstruments Financial Instruments Notes 12 false false R13.htm 2106100 - Disclosure - Inventories Sheet http://www.merck.com/role/Inventories Inventories Notes 13 false false R14.htm 2107100 - Disclosure - Contingencies Sheet http://www.merck.com/role/Contingencies Contingencies Notes 14 false false R15.htm 2108100 - Disclosure - Equity Sheet http://www.merck.com/role/Equity Equity Notes 15 false false R16.htm 2109100 - Disclosure - Share-Based Compensation Plans Sheet http://www.merck.com/role/ShareBasedCompensationPlans Share-Based Compensation Plans Notes 16 false false R17.htm 2110100 - Disclosure - Pension and Other Postretirement Benefit Plans Sheet http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlans Pension and Other Postretirement Benefit Plans Notes 17 false false R18.htm 2111100 - Disclosure - Other (Income) Expense, Net Sheet http://www.merck.com/role/OtherIncomeExpenseNet Other (Income) Expense, Net Notes 18 false false R19.htm 2112100 - Disclosure - Taxes on Income Sheet http://www.merck.com/role/TaxesOnIncome Taxes on Income Notes 19 false false R20.htm 2113100 - Disclosure - Earnings Per Share Sheet http://www.merck.com/role/EarningsPerShare Earnings Per Share Notes 20 false false R21.htm 2114100 - Disclosure - Other Comprehensive Income (Loss) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLoss Other Comprehensive Income (Loss) Notes 21 false false R22.htm 2115100 - Disclosure - Segment Reporting Sheet http://www.merck.com/role/SegmentReporting Segment Reporting Notes 22 false false R23.htm 2201201 - Disclosure - Basis of Presentation (Policies) Sheet http://www.merck.com/role/BasisOfPresentationPolicies Basis of Presentation (Policies) Policies 23 false false R24.htm 2207201 - Disclosure - Contingencies Commitments and Contingencies (Policies) Sheet http://www.merck.com/role/ContingenciesCommitmentsAndContingenciesPolicies Contingencies Commitments and Contingencies (Policies) Policies 24 false false R25.htm 2302301 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables) Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsTables Acquisitions, Research Collaborations and License Agreements (Tables) Tables http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreements 25 false false R26.htm 2303301 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.merck.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.merck.com/role/CollaborativeArrangements 26 false false R27.htm 2304301 - Disclosure - Restructuring (Tables) Sheet http://www.merck.com/role/RestructuringTables Restructuring (Tables) Tables http://www.merck.com/role/Restructuring 27 false false R28.htm 2305301 - Disclosure - Financial Instruments (Tables) Sheet http://www.merck.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.merck.com/role/FinancialInstruments 28 false false R29.htm 2306301 - Disclosure - Inventories (Tables) Sheet http://www.merck.com/role/InventoriesTables Inventories (Tables) Tables http://www.merck.com/role/Inventories 29 false false R30.htm 2308301 - Disclosure - Equity (Tables) Sheet http://www.merck.com/role/EquityTables Equity (Tables) Tables http://www.merck.com/role/Equity 30 false false R31.htm 2309301 - Disclosure - Share-Based Compensation Plans (Tables) Sheet http://www.merck.com/role/ShareBasedCompensationPlansTables Share-Based Compensation Plans (Tables) Tables http://www.merck.com/role/ShareBasedCompensationPlans 31 false false R32.htm 2310301 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) Sheet http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansTables Pension and Other Postretirement Benefit Plans (Tables) Tables http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlans 32 false false R33.htm 2311301 - Disclosure - Other (Income) Expense, Net (Tables) Sheet http://www.merck.com/role/OtherIncomeExpenseNetTables Other (Income) Expense, Net (Tables) Tables http://www.merck.com/role/OtherIncomeExpenseNet 33 false false R34.htm 2313301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.merck.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.merck.com/role/EarningsPerShare 34 false false R35.htm 2314301 - Disclosure - Other Comprehensive Income (Loss) (Tables) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossTables Other Comprehensive Income (Loss) (Tables) Tables http://www.merck.com/role/OtherComprehensiveIncomeLoss 35 false false R36.htm 2315301 - Disclosure - Segment Reporting (Tables) Sheet http://www.merck.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.merck.com/role/SegmentReporting 36 false false R37.htm 2402402 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details) Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsAcquisitionsDetails Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details) Details http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsTables 37 false false R38.htm 2402403 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details) Details 38 false false R39.htm 2403402 - Disclosure - Collaborative Arrangements - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails Collaborative Arrangements - Narrative (Details) Details 39 false false R40.htm 2403403 - Disclosure - Collaborative Arrangements - Schedule of Transactions (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails Collaborative Arrangements - Schedule of Transactions (Details) Details 40 false false R41.htm 2404402 - Disclosure - Restructuring - Narrative (Details) Sheet http://www.merck.com/role/RestructuringNarrativeDetails Restructuring - Narrative (Details) Details 41 false false R42.htm 2404403 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) Sheet http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails Restructuring - Charges Activities by Type of Cost (Details) Details 42 false false R43.htm 2404404 - Disclosure - Restructuring - Activities by Program (Details) Sheet http://www.merck.com/role/RestructuringActivitiesByProgramDetails Restructuring - Activities by Program (Details) Details 43 false false R44.htm 2405402 - Disclosure - Financial Instruments - Narrative (Details) Sheet http://www.merck.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments - Narrative (Details) Details 44 false false R45.htm 2405403 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails Financial Instruments - Effect of Net Investment Hedges (Details) Details 45 false false R46.htm 2405404 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details) Sheet http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails Financial Instruments - Summary of Interest Rate Swaps Held (Details) Details 46 false false R47.htm 2405405 - Disclosure - Financial Instruments - Fair Value Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails Financial Instruments - Fair Value Hedges (Details) Details 47 false false R48.htm 2405406 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Details 48 false false R49.htm 2405407 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Details 49 false false R50.htm 2405408 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) Sheet http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) Details 50 false false R51.htm 2405409 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Details 51 false false R52.htm 2405410 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails Financial Instruments - Information on Available-for-sale Investments (Details) Details 52 false false R53.htm 2405411 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 53 false false R54.htm 2405412 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Details 54 false false R55.htm 2406402 - Disclosure - Inventories - Inventories (Details) Sheet http://www.merck.com/role/InventoriesInventoriesDetails Inventories - Inventories (Details) Details 55 false false R56.htm 2406403 - Disclosure - Inventories - Narrative (Details) Sheet http://www.merck.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 56 false false R57.htm 2407402 - Disclosure - Contingencies - Narrative (Details) Sheet http://www.merck.com/role/ContingenciesNarrativeDetails Contingencies - Narrative (Details) Details 57 false false R58.htm 2408402 - Disclosure - Equity - Rollforward Reconciliations (Details) Sheet http://www.merck.com/role/EquityRollforwardReconciliationsDetails Equity - Rollforward Reconciliations (Details) Details 58 false false R59.htm 2409402 - Disclosure - Share-Based Compensation Plans - Expense Allocations (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails Share-Based Compensation Plans - Expense Allocations (Details) Details 59 false false R60.htm 2409403 - Disclosure - Share-Based Compensation Plans - Narrative (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails Share-Based Compensation Plans - Narrative (Details) Details 60 false false R61.htm 2410402 - Disclosure - Pension and Other Postretirement Benefit Plans (Details) Sheet http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails Pension and Other Postretirement Benefit Plans (Details) Details http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansTables 61 false false R62.htm 2411402 - Disclosure - Other (Income) Expense, Net (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetDetails Other (Income) Expense, Net (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 62 false false R63.htm 2411403 - Disclosure - Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 63 false false R64.htm 2412401 - Disclosure - Taxes on Income (Details) Sheet http://www.merck.com/role/TaxesOnIncomeDetails Taxes on Income (Details) Details http://www.merck.com/role/TaxesOnIncome 64 false false R65.htm 2413402 - Disclosure - Earnings Per Share (Details) Sheet http://www.merck.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.merck.com/role/EarningsPerShareTables 65 false false R66.htm 2414402 - Disclosure - Other Comprehensive Income (Loss) (Details) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossDetails Other Comprehensive Income (Loss) (Details) Details http://www.merck.com/role/OtherComprehensiveIncomeLossTables 66 false false R67.htm 2415402 - Disclosure - Segment Reporting - Narrative (Details) Sheet http://www.merck.com/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 67 false false R68.htm 2415403 - Disclosure - Segment Reporting - Sales of Company's Products (Details) Sheet http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails Segment Reporting - Sales of Company's Products (Details) Details 68 false false R69.htm 2415404 - Disclosure - Segment Reporting - Revenues by Geographic Area (Details) Sheet http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails Segment Reporting - Revenues by Geographic Area (Details) Details 69 false false R70.htm 2415405 - Disclosure - Segment Reporting - Profits to Income Before Taxes (Details) Sheet http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails Segment Reporting - Profits to Income Before Taxes (Details) Details 70 false false All Reports Book All Reports mrk0331202010q.htm exhibit311rule13a-14a1.htm exhibit312rule13a-14a1.htm exhibit321section1350c.htm exhibit322section1350c.htm mrk-20200331.xsd mrk-20200331_cal.xml mrk-20200331_def.xml mrk-20200331_lab.xml mrk-20200331_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 true true XML 30 R43.htm IDEA: XBRL DOCUMENT v3.20.1
Restructuring - Activities by Program (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance $ 759  
Expense 168 $ 187
(Payments) receipts, net (290)  
Non-cash activity (11)  
Restructuring reserve, ending balance 626  
Separation Costs    
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 690  
Expense 47 128
(Payments) receipts, net (168)  
Non-cash activity 0  
Restructuring reserve, ending balance 569  
Accelerated Depreciation    
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 0  
Expense 53 34
(Payments) receipts, net 0  
Non-cash activity (53)  
Restructuring reserve, ending balance 0  
Other    
Restructuring Reserve [Roll Forward]    
Restructuring reserve, beginning balance 69  
Expense 68 $ 25
(Payments) receipts, net (122)  
Non-cash activity 42  
Restructuring reserve, ending balance $ 57  
XML 31 R47.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Fair Value Hedges (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Loans payable and current portion of long-term debt    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Carrying Amount of Hedged Liabilities $ 1,160 $ 1,249
Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount 11 (1)
Long-Term Debt    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Carrying Amount of Hedged Liabilities 2,315 3,409
Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount $ 69 $ 14
XML 32 R68.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Reporting - Sales of Company's Products (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Segment Reporting Information [Line Items]    
Sales $ 12,057 $ 10,816
Proceeds from Sale of Intangible Assets 75 15
Operating Segments    
Segment Reporting Information [Line Items]    
Sales 11,892 10,727
Other    
Segment Reporting Information [Line Items]    
Sales 165 89
United States    
Segment Reporting Information [Line Items]    
Sales 5,137 4,555
United States | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 5,121 4,548
United States | Other    
Segment Reporting Information [Line Items]    
Sales 16 7
International    
Segment Reporting Information [Line Items]    
Sales 6,920 6,261
International | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 6,771 6,179
International | Other    
Segment Reporting Information [Line Items]    
Sales 149 82
Total Pharmaceutical segment sales | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 10,655 9,663
Total Pharmaceutical segment sales | Operating Segments | Keytruda    
Segment Reporting Information [Line Items]    
Sales 3,284 2,269
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lynparza (1)    
Segment Reporting Information [Line Items]    
Sales 145 79
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lenvima (1)    
Segment Reporting Information [Line Items]    
Sales 128 74
Total Pharmaceutical segment sales | Operating Segments | Emend    
Segment Reporting Information [Line Items]    
Sales 43 117
Total Pharmaceutical segment sales | Operating Segments | Gardasil/Gardasil 9    
Segment Reporting Information [Line Items]    
Sales 1,097 838
Total Pharmaceutical segment sales | Operating Segments | ProQuad/M-M-R II/Varivax    
Segment Reporting Information [Line Items]    
Sales 435 496
Total Pharmaceutical segment sales | Operating Segments | Pneumovax 23    
Segment Reporting Information [Line Items]    
Sales 256 185
Total Pharmaceutical segment sales | Operating Segments | RotaTeq    
Segment Reporting Information [Line Items]    
Sales 222 211
Total Pharmaceutical segment sales | Operating Segments | Vaqta    
Segment Reporting Information [Line Items]    
Sales 60 47
Total Pharmaceutical segment sales | Operating Segments | Bridion    
Segment Reporting Information [Line Items]    
Sales 299 255
Total Pharmaceutical segment sales | Operating Segments | Noxafil    
Segment Reporting Information [Line Items]    
Sales 94 190
Total Pharmaceutical segment sales | Operating Segments | Invanz    
Segment Reporting Information [Line Items]    
Sales 64 72
Total Pharmaceutical segment sales | Operating Segments | Prevymis    
Segment Reporting Information [Line Items]    
Sales 60 32
Total Pharmaceutical segment sales | Operating Segments | Cancidas    
Segment Reporting Information [Line Items]    
Sales 55 61
Total Pharmaceutical segment sales | Operating Segments | Primaxin    
Segment Reporting Information [Line Items]    
Sales 51 59
Total Pharmaceutical segment sales | Operating Segments | Cubicin    
Segment Reporting Information [Line Items]    
Sales 46 88
Total Pharmaceutical segment sales | Operating Segments | Zerbaxa    
Segment Reporting Information [Line Items]    
Sales 37 26
Total Pharmaceutical segment sales | Operating Segments | Simponi    
Segment Reporting Information [Line Items]    
Sales 215 208
Total Pharmaceutical segment sales | Operating Segments | Remicade    
Segment Reporting Information [Line Items]    
Sales 88 123
Total Pharmaceutical segment sales | Operating Segments | Belsomra    
Segment Reporting Information [Line Items]    
Sales 79 67
Total Pharmaceutical segment sales | Operating Segments | Isentress/Isentress HD    
Segment Reporting Information [Line Items]    
Sales 245 255
Total Pharmaceutical segment sales | Operating Segments | Zepatier    
Segment Reporting Information [Line Items]    
Sales 55 114
Total Pharmaceutical segment sales | Operating Segments | Zetia    
Segment Reporting Information [Line Items]    
Sales 145 140
Total Pharmaceutical segment sales | Operating Segments | Vytorin    
Segment Reporting Information [Line Items]    
Sales 53 97
Total Pharmaceutical segment sales | Operating Segments | Atozet    
Segment Reporting Information [Line Items]    
Sales 122 94
Total Pharmaceutical segment sales | Operating Segments | Adempas    
Segment Reporting Information [Line Items]    
Sales 56 48
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Adempas (2)    
Segment Reporting Information [Line Items]    
Sales 53 42
Total Pharmaceutical segment sales | Operating Segments | Januvia    
Segment Reporting Information [Line Items]    
Sales 774 824
Total Pharmaceutical segment sales | Operating Segments | Janumet    
Segment Reporting Information [Line Items]    
Sales 503 530
Total Pharmaceutical segment sales | Operating Segments | Implanon/Nexplanon    
Segment Reporting Information [Line Items]    
Sales 195 199
Total Pharmaceutical segment sales | Operating Segments | NuvaRing    
Segment Reporting Information [Line Items]    
Sales 63 219
Total Pharmaceutical segment sales | Operating Segments | Singulair    
Segment Reporting Information [Line Items]    
Sales 155 191
Total Pharmaceutical segment sales | Operating Segments | Cozaar/Hyzaar    
Segment Reporting Information [Line Items]    
Sales 102 103
Total Pharmaceutical segment sales | Operating Segments | Nasonex    
Segment Reporting Information [Line Items]    
Sales 71 96
Total Pharmaceutical segment sales | Operating Segments | Arcoxia    
Segment Reporting Information [Line Items]    
Sales 70 75
Total Pharmaceutical segment sales | Operating Segments | Follistim AQ    
Segment Reporting Information [Line Items]    
Sales 41 57
Total Pharmaceutical segment sales | Operating Segments | Other pharmaceutical (3)    
Segment Reporting Information [Line Items]    
Sales 1,194 1,082
Total Pharmaceutical segment sales | United States | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 4,714 4,215
Total Pharmaceutical segment sales | United States | Operating Segments | Keytruda    
Segment Reporting Information [Line Items]    
Sales 1,906 1,284
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lynparza (1)    
Segment Reporting Information [Line Items]    
Sales 85 50
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lenvima (1)    
Segment Reporting Information [Line Items]    
Sales 90 50
Total Pharmaceutical segment sales | United States | Operating Segments | Emend    
Segment Reporting Information [Line Items]    
Sales 5 63
Total Pharmaceutical segment sales | United States | Operating Segments | Gardasil/Gardasil 9    
Segment Reporting Information [Line Items]    
Sales 461 362
Total Pharmaceutical segment sales | United States | Operating Segments | ProQuad/M-M-R II/Varivax    
Segment Reporting Information [Line Items]    
Sales 333 343
Total Pharmaceutical segment sales | United States | Operating Segments | Pneumovax 23    
Segment Reporting Information [Line Items]    
Sales 182 125
Total Pharmaceutical segment sales | United States | Operating Segments | RotaTeq    
Segment Reporting Information [Line Items]    
Sales 140 154
Total Pharmaceutical segment sales | United States | Operating Segments | Vaqta    
Segment Reporting Information [Line Items]    
Sales 30 29
Total Pharmaceutical segment sales | United States | Operating Segments | Bridion    
Segment Reporting Information [Line Items]    
Sales 143 119
Total Pharmaceutical segment sales | United States | Operating Segments | Noxafil    
Segment Reporting Information [Line Items]    
Sales 8 91
Total Pharmaceutical segment sales | United States | Operating Segments | Invanz    
Segment Reporting Information [Line Items]    
Sales 6 14
Total Pharmaceutical segment sales | United States | Operating Segments | Prevymis    
Segment Reporting Information [Line Items]    
Sales 26 18
Total Pharmaceutical segment sales | United States | Operating Segments | Cancidas    
Segment Reporting Information [Line Items]    
Sales 3 1
Total Pharmaceutical segment sales | United States | Operating Segments | Primaxin    
Segment Reporting Information [Line Items]    
Sales 0 0
Total Pharmaceutical segment sales | United States | Operating Segments | Cubicin    
Segment Reporting Information [Line Items]    
Sales 15 42
Total Pharmaceutical segment sales | United States | Operating Segments | Zerbaxa    
Segment Reporting Information [Line Items]    
Sales 20 12
Total Pharmaceutical segment sales | United States | Operating Segments | Simponi    
Segment Reporting Information [Line Items]    
Sales 0 0
Total Pharmaceutical segment sales | United States | Operating Segments | Remicade    
Segment Reporting Information [Line Items]    
Sales 0 0
Total Pharmaceutical segment sales | United States | Operating Segments | Belsomra    
Segment Reporting Information [Line Items]    
Sales 27 24
Total Pharmaceutical segment sales | United States | Operating Segments | Isentress/Isentress HD    
Segment Reporting Information [Line Items]    
Sales 75 108
Total Pharmaceutical segment sales | United States | Operating Segments | Zepatier    
Segment Reporting Information [Line Items]    
Sales 18 33
Total Pharmaceutical segment sales | United States | Operating Segments | Zetia    
Segment Reporting Information [Line Items]    
Sales (2) 0
Total Pharmaceutical segment sales | United States | Operating Segments | Vytorin    
Segment Reporting Information [Line Items]    
Sales 3 3
Total Pharmaceutical segment sales | United States | Operating Segments | Atozet    
Segment Reporting Information [Line Items]    
Sales 0 0
Total Pharmaceutical segment sales | United States | Operating Segments | Adempas    
Segment Reporting Information [Line Items]    
Sales 0 0
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Adempas (2)    
Segment Reporting Information [Line Items]    
Sales 49 40
Total Pharmaceutical segment sales | United States | Operating Segments | Januvia    
Segment Reporting Information [Line Items]    
Sales 355 384
Total Pharmaceutical segment sales | United States | Operating Segments | Janumet    
Segment Reporting Information [Line Items]    
Sales 113 167
Total Pharmaceutical segment sales | United States | Operating Segments | Implanon/Nexplanon    
Segment Reporting Information [Line Items]    
Sales 149 149
Total Pharmaceutical segment sales | United States | Operating Segments | NuvaRing    
Segment Reporting Information [Line Items]    
Sales 26 185
Total Pharmaceutical segment sales | United States | Operating Segments | Singulair    
Segment Reporting Information [Line Items]    
Sales 5 5
Total Pharmaceutical segment sales | United States | Operating Segments | Cozaar/Hyzaar    
Segment Reporting Information [Line Items]    
Sales 7 4
Total Pharmaceutical segment sales | United States | Operating Segments | Nasonex    
Segment Reporting Information [Line Items]    
Sales 6 (1)
Total Pharmaceutical segment sales | United States | Operating Segments | Arcoxia    
Segment Reporting Information [Line Items]    
Sales 0 0
Total Pharmaceutical segment sales | United States | Operating Segments | Follistim AQ    
Segment Reporting Information [Line Items]    
Sales 21 29
Total Pharmaceutical segment sales | United States | Operating Segments | Other pharmaceutical (3)    
Segment Reporting Information [Line Items]    
Sales 409 328
Total Pharmaceutical segment sales | International | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 5,941 5,448
Total Pharmaceutical segment sales | International | Operating Segments | Keytruda    
Segment Reporting Information [Line Items]    
Sales 1,378 985
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lynparza (1)    
Segment Reporting Information [Line Items]    
Sales 60 29
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lenvima (1)    
Segment Reporting Information [Line Items]    
Sales 38 24
Total Pharmaceutical segment sales | International | Operating Segments | Emend    
Segment Reporting Information [Line Items]    
Sales 38 53
Total Pharmaceutical segment sales | International | Operating Segments | Gardasil/Gardasil 9    
Segment Reporting Information [Line Items]    
Sales 636 476
Total Pharmaceutical segment sales | International | Operating Segments | ProQuad/M-M-R II/Varivax    
Segment Reporting Information [Line Items]    
Sales 102 153
Total Pharmaceutical segment sales | International | Operating Segments | Pneumovax 23    
Segment Reporting Information [Line Items]    
Sales 75 59
Total Pharmaceutical segment sales | International | Operating Segments | RotaTeq    
Segment Reporting Information [Line Items]    
Sales 82 57
Total Pharmaceutical segment sales | International | Operating Segments | Vaqta    
Segment Reporting Information [Line Items]    
Sales 30 18
Total Pharmaceutical segment sales | International | Operating Segments | Bridion    
Segment Reporting Information [Line Items]    
Sales 157 136
Total Pharmaceutical segment sales | International | Operating Segments | Noxafil    
Segment Reporting Information [Line Items]    
Sales 87 99
Total Pharmaceutical segment sales | International | Operating Segments | Invanz    
Segment Reporting Information [Line Items]    
Sales 59 58
Total Pharmaceutical segment sales | International | Operating Segments | Prevymis    
Segment Reporting Information [Line Items]    
Sales 33 14
Total Pharmaceutical segment sales | International | Operating Segments | Cancidas    
Segment Reporting Information [Line Items]    
Sales 52 60
Total Pharmaceutical segment sales | International | Operating Segments | Primaxin    
Segment Reporting Information [Line Items]    
Sales 51 59
Total Pharmaceutical segment sales | International | Operating Segments | Cubicin    
Segment Reporting Information [Line Items]    
Sales 31 46
Total Pharmaceutical segment sales | International | Operating Segments | Zerbaxa    
Segment Reporting Information [Line Items]    
Sales 16 14
Total Pharmaceutical segment sales | International | Operating Segments | Simponi    
Segment Reporting Information [Line Items]    
Sales 215 208
Total Pharmaceutical segment sales | International | Operating Segments | Remicade    
Segment Reporting Information [Line Items]    
Sales 88 123
Total Pharmaceutical segment sales | International | Operating Segments | Belsomra    
Segment Reporting Information [Line Items]    
Sales 53 44
Total Pharmaceutical segment sales | International | Operating Segments | Isentress/Isentress HD    
Segment Reporting Information [Line Items]    
Sales 170 147
Total Pharmaceutical segment sales | International | Operating Segments | Zepatier    
Segment Reporting Information [Line Items]    
Sales 37 81
Total Pharmaceutical segment sales | International | Operating Segments | Zetia    
Segment Reporting Information [Line Items]    
Sales 147 140
Total Pharmaceutical segment sales | International | Operating Segments | Vytorin    
Segment Reporting Information [Line Items]    
Sales 50 94
Total Pharmaceutical segment sales | International | Operating Segments | Atozet    
Segment Reporting Information [Line Items]    
Sales 122 94
Total Pharmaceutical segment sales | International | Operating Segments | Adempas    
Segment Reporting Information [Line Items]    
Sales 56 48
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Adempas (2)    
Segment Reporting Information [Line Items]    
Sales 5 2
Total Pharmaceutical segment sales | International | Operating Segments | Januvia    
Segment Reporting Information [Line Items]    
Sales 419 440
Total Pharmaceutical segment sales | International | Operating Segments | Janumet    
Segment Reporting Information [Line Items]    
Sales 390 364
Total Pharmaceutical segment sales | International | Operating Segments | Implanon/Nexplanon    
Segment Reporting Information [Line Items]    
Sales 45 50
Total Pharmaceutical segment sales | International | Operating Segments | NuvaRing    
Segment Reporting Information [Line Items]    
Sales 37 34
Total Pharmaceutical segment sales | International | Operating Segments | Singulair    
Segment Reporting Information [Line Items]    
Sales 151 186
Total Pharmaceutical segment sales | International | Operating Segments | Cozaar/Hyzaar    
Segment Reporting Information [Line Items]    
Sales 95 99
Total Pharmaceutical segment sales | International | Operating Segments | Nasonex    
Segment Reporting Information [Line Items]    
Sales 65 97
Total Pharmaceutical segment sales | International | Operating Segments | Arcoxia    
Segment Reporting Information [Line Items]    
Sales 70 75
Total Pharmaceutical segment sales | International | Operating Segments | Follistim AQ    
Segment Reporting Information [Line Items]    
Sales 21 28
Total Pharmaceutical segment sales | International | Operating Segments | Other pharmaceutical (3)    
Segment Reporting Information [Line Items]    
Sales 780 754
Total Animal Health segment sales | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 1,214 1,025
Total Animal Health segment sales | Operating Segments | Livestock    
Segment Reporting Information [Line Items]    
Sales 739 611
Total Animal Health segment sales | Operating Segments | Companion Animals    
Segment Reporting Information [Line Items]    
Sales 475 414
Total Animal Health segment sales | United States | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 384 294
Total Animal Health segment sales | United States | Operating Segments | Livestock    
Segment Reporting Information [Line Items]    
Sales 162 117
Total Animal Health segment sales | United States | Operating Segments | Companion Animals    
Segment Reporting Information [Line Items]    
Sales 222 177
Total Animal Health segment sales | International | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 830 731
Total Animal Health segment sales | International | Operating Segments | Livestock    
Segment Reporting Information [Line Items]    
Sales 577 494
Total Animal Health segment sales | International | Operating Segments | Companion Animals    
Segment Reporting Information [Line Items]    
Sales 253 237
Other segment sales (4) | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 23 39
Other segment sales (4) | United States | Operating Segments    
Segment Reporting Information [Line Items]    
Sales 23 39
Other segment sales (4) | International | Operating Segments    
Segment Reporting Information [Line Items]    
Sales $ 0 $ 0
XML 33 R64.htm IDEA: XBRL DOCUMENT v3.20.1
Taxes on Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Tax Examination [Line Items]    
Effective income tax rate (as percent) 16.10% 6.70%
Internal Revenue Service (IRS) | Domestic Tax Authority    
Income Tax Examination [Line Items]    
Tax benefit recognized related to settlement   $ 360
Income taxes paid   $ 107
XML 34 R60.htm IDEA: XBRL DOCUMENT v3.20.1
Share-Based Compensation Plans - Narrative (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Billions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards $ 1.1  
Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards 2 years 4 months 24 days  
Restricted Stock Units (RSUs)    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted (in shares) 58 70
Weighted-average fair value per share granted (in dollars per share) $ 85.66 $ 77.39
Performance Share Units (PSUs)    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted (in shares) 770 609
Weighted-average fair value per share granted (in dollars per share) $ 75.65 $ 90.50
EXCEL 35 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 36 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborative Arrangements (Tables)
 3 Months Ended
Mar. 31, 2020
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Alliance revenue
$
145

 
$
79

 
 
 
 
Cost of sales (1)
28

 
19

Selling, general and administrative
33

 
27

Research and development
36

 
45

 
 
 
 
($ in millions)
March 31, 2020
 
December 31, 2019
Receivables from AstraZeneca included in Other current assets
$
142

 
$
128

Payables to AstraZeneca included in Accrued and other current liabilities (2)
326

 
577

(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Alliance revenue
$
128

 
$
74

 
 
 
 
Cost of sales (1)
35

 
51

Selling, general and administrative
11

 
19

Research and development
64

 
47

 
 
 
 
($ in millions)
March 31, 2020
 
December 31, 2019
Receivables from Eisai included in Other current assets
$
140

 
$
150

Payables to Eisai included in Accrued and other current liabilities (2)
425

 
700

Payables to Eisai included in Other Noncurrent Liabilities (3)
300

 
525

(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone and future option payments.
(3) Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Net sales of Adempas recorded by Merck
$
56

 
$
48

Alliance revenue
53

 
42

Total sales
109

 
90

 
 
 
 
Cost of sales (1)
28

 
29

Selling, general and administrative
15

 
8

Research and development
25

 
30

 
 
 
 
($ in millions)
March 31, 2020
 
December 31, 2019
Receivables from Bayer included in Other current assets
$
50

 
$
49

Payables to Bayer included in Other Noncurrent Liabilities (2)
375

 
375

(1) Includes amortization of intangible assets.
(2) Represents accrued milestone payment.

XML 38 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Reporting
 3 Months Ended
Mar. 31, 2020
Segment Reporting [Abstract]  
Segment Reporting
Segment Reporting
The Company’s operations are principally managed on a products basis and include three operating segments, which are the Pharmaceutical, Animal Health and Healthcare Services segments. The Pharmaceutical and Animal Health segments are the only reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers.
The Healthcare Services segment provided services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company has been in the process of divesting the businesses in the Healthcare Services segment. The remaining businesses were divested during the first quarter of 2020.

Sales of the Company’s products were as follows:
 
Three Months Ended March 31,
 
2020
 
2019
 ($ in millions)
U.S.
 
Int’l
 
Total
 
U.S.
 
Int’l
 
Total
Pharmaceutical:
 
 
 
 
 
 
 
 
 
 
 
Oncology
 
 
 
 
 
 
 
 
 
 
 
Keytruda
$
1,906

 
$
1,378

 
$
3,284

 
$
1,284

 
$
985

 
$
2,269

Alliance revenue - Lynparza (1)
85

 
60

 
145

 
50

 
29

 
79

Alliance revenue - Lenvima (1)
90

 
38

 
128

 
50

 
24

 
74

Emend
5

 
38

 
43

 
63

 
53

 
117

Vaccines
 
 
 
 
 
 
 
 
 
 
 
Gardasil/Gardasil 9
461

 
636

 
1,097

 
362

 
476

 
838

ProQuad/M-M-R II/Varivax
333

 
102

 
435

 
343

 
153

 
496

Pneumovax 23
182

 
75

 
256

 
125

 
59

 
185

RotaTeq
140

 
82

 
222

 
154

 
57

 
211

Vaqta
30

 
30

 
60

 
29

 
18

 
47

Hospital Acute Care
 
 
 
 
 
 
 
 
 
 
 
Bridion
143

 
157

 
299

 
119

 
136

 
255

Noxafil
8

 
87

 
94

 
91

 
99

 
190

Invanz
6

 
59

 
64

 
14

 
58

 
72

Prevymis
26

 
33

 
60

 
18

 
14

 
32

Cancidas
3

 
52

 
55

 
1

 
60

 
61

Primaxin
—

 
51

 
51

 
—

 
59

 
59

Cubicin
15

 
31

 
46

 
42

 
46

 
88

Zerbaxa
20

 
16

 
37

 
12

 
14

 
26

Immunology
 
 
 
 
 
 
 
 
 
 
 
Simponi
—

 
215

 
215

 
—

 
208

 
208

Remicade
—

 
88

 
88

 
—

 
123

 
123

Neuroscience
 
 
 
 
 
 
 
 
 
 
 
Belsomra
27

 
53

 
79

 
24

 
44

 
67

Virology
 
 
 
 
 
 
 
 
 
 
 
Isentress/Isentress HD
75

 
170

 
245

 
108

 
147

 
255

Zepatier
18

 
37

 
55

 
33

 
81

 
114

Cardiovascular
 
 
 
 
 
 
 
 
 
 
 
Zetia
(2
)
 
147

 
145

 
—

 
140

 
140

Vytorin
3

 
50

 
53

 
3

 
94

 
97

Atozet
—

 
122

 
122

 
—

 
94

 
94

Adempas
—

 
56

 
56

 
—

 
48

 
48

Alliance revenue - Adempas (2)
49

 
5

 
53

 
40

 
2

 
42

Diabetes
 
 
 
 
 
 
 
 
 
 
 
Januvia
355

 
419

 
774

 
384

 
440

 
824

Janumet
113

 
390

 
503

 
167

 
364

 
530

Women’s Health
 
 
 
 
 
 
 
 
 
 
 
Implanon/Nexplanon
149

 
45

 
195

 
149

 
50

 
199

NuvaRing
26

 
37

 
63

 
185

 
34

 
219

Diversified Brands
 
 
 
 
 
 
 
 
 
 
 
Singulair
5

 
151

 
155

 
5

 
186

 
191

Cozaar/Hyzaar
7

 
95

 
102

 
4

 
99

 
103

Nasonex
6

 
65

 
71

 
(1
)
 
97

 
96

Arcoxia
—

 
70

 
70

 
—

 
75

 
75

Follistim AQ
21

 
21

 
41

 
29

 
28

 
57

Other pharmaceutical (3)
409

 
780

 
1,194

 
328

 
754

 
1,082

Total Pharmaceutical segment sales
4,714


5,941


10,655


4,215


5,448


9,663

Animal Health:
 
 
 
 
 
 
 
 
 
 
 
Livestock
162

 
577

 
739

 
117

 
494

 
611

Companion Animals
222

 
253

 
475

 
177

 
237

 
414

Total Animal Health segment sales
384


830


1,214


294


731


1,025

Other segment sales (4)
23

 
—

 
23

 
39

 
—

 
39

Total segment sales
5,121


6,771


11,892


4,548


6,179


10,727

Other (5)
16

 
149

 
165

 
7

 
82

 
89

 
$
5,137

 
$
6,920

 
$
12,057

 
$
4,555

 
$
6,261

 
$
10,816

U.S. plus international may not equal total due to rounding.
(1) 
Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2) 
Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(3) 
Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(4) 
Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020.
(5) 
Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. Other in the first quarter of 2020 and 2019 also includes approximately $75 million and $15 million, respectively, related to the sale of the marketing rights for certain products.
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.2 billion and $2.6 billion for the three months ended March 31, 2020 and 2019, respectively.
Consolidated sales by geographic area where derived are as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
United States
$
5,137

 
$
4,555

Europe, Middle East and Africa
3,534

 
3,103

China
864

 
746

Japan
811

 
799

Asia Pacific (other than China and Japan)
728

 
745

Latin America
556

 
561

Other
427

 
307

 
$
12,057


$
10,816


A reconciliation of segment profits to Income before taxes is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Segment profits:
 
 
 
Pharmaceutical segment
$
7,477

 
$
6,574

Animal Health segment
478

 
415

Other segment
1

 
2

Total segment profits
7,956

 
6,991

Other profits
139

 
30

Unallocated:
 
 
 
Interest income
25

 
89

Interest expense
(212
)
 
(209
)
Depreciation and amortization
(381
)
 
(359
)
Research and development
(2,097
)
 
(1,843
)
Amortization of purchase accounting adjustments
(295
)
 
(397
)
Restructuring costs
(72
)
 
(153
)
Other unallocated, net
(1,225
)
 
(1,082
)
 
$
3,838

 
$
3,067


Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.
XML 39 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Other (Income) Expense, Net
 3 Months Ended
Mar. 31, 2020
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net
Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Interest income
$
(25
)
 
$
(89
)
Interest expense
212

 
209

Exchange losses
54

 
101

(Income) loss from investments in equity securities, net (1)
(52
)
 
25

Net periodic defined benefit plan (credit) cost other than service cost
(90
)
 
(141
)
Other, net
(28
)
 
83

 
$
71

 
$
188


(1) 
Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
The higher exchange losses in the first quarter of 2019 reflect losses on forward exchange contracts related to the acquisition of Antelliq Corporation.
Other, net (as reflected in the table above) in the first quarter of 2019 includes $84 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment.
Interest paid for the three months ended March 31, 2020 and 2019 was $250 million and $195 million, respectively.
XML 40 R14.htm IDEA: XBRL DOCUMENT v3.20.1
Contingencies
 3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Contingencies
Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Fosamax
As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving Fosamax (Fosamax Litigation). As of March 31, 2020, approximately 3,590 cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.
All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, Glynn v. Merck, the jury returned a verdict in Merck’s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck’s
motion for judgment as a matter of law in the Glynn case and held that the plaintiff’s failure to warn claim was preempted by federal law.
In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court’s preemption decision in the Glynn case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Merck filed its initial brief on February 21, 2020, as required by the District Court.
Accordingly, as of March 31, 2020, approximately 970 cases were actively pending in the Femur Fracture MDL.
As of March 31, 2020, approximately 2,345 cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.
As of March 31, 2020, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California.
Additionally, there are four Femur Fracture cases pending in other state courts.
Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits.
Januvia/Janumet
As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving Januvia and/or Janumet. As of March 31, 2020, Merck is aware of approximately 1,410 product users alleging that Januvia and/or Janumet caused the development of pancreatic cancer and other injuries.
Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court).
In November 2015, the MDL and California State Court–in separate opinions–granted summary judgment to defendants on grounds of federal preemption.
Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceeding agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment and Daubert motions. Under the stipulated case management schedule, the hearings for Daubert and summary judgment motions are expected to take place in the second half of 2020.
As of March 31, 2020, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck’s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in Merck Sharp & Dohme Corp. v. Albrecht (relating to the Fosamax matter discussed above). Merck filed the opinion in Albrecht with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with Albrecht, that preemption presents a legal question to be resolved by the court.
In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against these lawsuits.
Vioxx
As previously disclosed, Merck is a defendant in a lawsuit brought by the Attorney General of Utah alleging that Merck misrepresented the safety of Vioxx. The lawsuit is pending in Utah state court. Utah seeks damages and penalties under the Utah False Claims Act. A bench trial in this matter has been rescheduled for April 6, 2021.
Governmental Proceedings
As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General’s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck’s development of an insulin glargine product, and its subsequent termination, as well as Merck’s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. In February 2020, Merck received a subpoena for documents. Merck is cooperating with the California Attorney General’s investigation.
As previously disclosed, the Company’s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants’ motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants’ motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants’ motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. The Merck Defendants moved to dismiss the new allegations in both complaints. In October 2019, the magistrate judge issued a report and recommendation recommending that the district judge grant the motions in their entirety. In December 2019, the district court adopted this report and recommendation in part. The district court granted the Merck Defendants’ motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. Trial in this matter has been rescheduled to begin on February 23, 2021.
Bravecto Litigation
In January 2020, the Company was served with a complaint in the United States District Court for the District of New Jersey, seeking to certify a nationwide class action of purchasers or users of Bravecto (fluralaner) products in the United States or its territories between May 1, 2014 and December 27, 2019. The complaint contends Bravecto causes neurological events and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. A similar case was filed in Quebec, Canada in May 2019.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which,
if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.
Bridion — Between January and March 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March and April 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier. No schedule for the cases has been set by the courts.
Januvia, Janumet, Janumet XR — In February 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of a patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of Januvia, Janumet, and Janumet XR following expiration of key patent protection in 2022, but prior to the expiration of the later-granted patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026, and a later granted patent owned by the Company covering the Janumet formulation which expires in 2028. Par Pharmaceutical dismissed its case in the U.S. District Court for the District of New Jersey against the Company and will litigate the action in the U.S. District Court for the District of Delaware. The Company filed a patent infringement lawsuit against Mylan Pharmaceuticals Inc. and Mylan Inc. (Mylan) in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. In February 2020, the Company amended its complaint against one defendant, Teva Pharmaceuticals USA, Inc., to add patent infringement claims related to a patent that expires in 2025 and covers certain processes for manufacturing sitagliptin. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single 3-day trial on invalidity issues in October 2021. The Court will schedule separate 1-day trials on infringement issues if necessary. In the Company’s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues.
The Company has settled with three generic companies such that these generic companies can bring their products to the market in November 2026 or earlier under certain circumstances.
In October 2019, Mylan filed a petition for Inter Partes Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of the 2026 patent. The Company filed a Patent Owner Preliminary Response in the IPR proceeding in February 2020. The Company expects the USPTO to determine whether it will institute the IPR proceeding in May 2020.
In Germany, a generic company has sought the revocation of the Supplementary Protection Certificate (SPC) for Janumet. If the generic company is successful, Janumet could lose market exclusivity in Germany as early as July 2022. It is possible that challenges to the Janumet SPC could occur in other European countries.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March 31, 2020 and December 31, 2019 of approximately $255 million and $240 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
XML 41 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborative Arrangements
 3 Months Ended
Mar. 31, 2020
Collaborative Arrangements [Abstract]  
Collaborative Arrangements Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca
In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor currently approved for certain types of advanced ovarian, breast and pancreatic cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda (pembrolizumab) and Imfinzi. The companies will also jointly develop and commercialize AstraZeneca’s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications. In April 2020, Koselugo was approved for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of Keytruda in combination with Lynparza or
Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca of $1.6 billion in 2017 and made payments of $750 million over a multi-year period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
Prior to 2020, Merck accrued sales-based milestone payments aggregating $1.0 billion related to Lynparza, of which $200 million and $250 million was paid to AstraZeneca in 2019 and 2018, respectively, and $250 million was paid in the first quarter of 2020. Potential future sales-based milestone payments of $3.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of $60 million and $140 million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.7 billion remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $928 million at March 31, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Alliance revenue
$
145

 
$
79

 
 
 
 
Cost of sales (1)
28

 
19

Selling, general and administrative
33

 
27

Research and development
36

 
45

 
 
 
 
($ in millions)
March 31, 2020
 
December 31, 2019
Receivables from AstraZeneca included in Other current assets
$
142

 
$
128

Payables to AstraZeneca included in Accrued and other current liabilities (2)
326

 
577

(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone payments.
Eisai
In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with Keytruda for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in Research and development expenses.
Under the agreement, Merck made an upfront payment to Eisai of $750 million and agreed to make payments of up to $650 million for certain option rights through 2021 (of which $325 million was paid in March 2019, $200 million was paid in March 2020 and $125 million is expected to be paid in March 2021). In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
Prior to 2020, Merck accrued sales-based milestone payments aggregating $950 million related to Lenvima. Of these amounts, $50 million was paid to Eisai in 2019 and an additional $300 million was paid in the first quarter of 2020. Potential future sales-based milestone payments of $3.0 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of $250 million in the aggregate from Merck to Eisai. Potential future regulatory milestone payments of $135 million remain under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $921 million at March 31, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Alliance revenue
$
128

 
$
74

 
 
 
 
Cost of sales (1)
35

 
51

Selling, general and administrative
11

 
19

Research and development
64

 
47

 
 
 
 
($ in millions)
March 31, 2020
 
December 31, 2019
Receivables from Eisai included in Other current assets
$
140

 
$
150

Payables to Eisai included in Accrued and other current liabilities (2)
425

 
700

Payables to Eisai included in Other Noncurrent Liabilities (3)
300

 
525

(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone and future option payments.
(3) Includes accrued milestone payments.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer’s vericiguat, which is in development for the potential treatment of worsening heart failure. Under the agreement, Bayer leads commercialization of Adempas in the Americas, while Merck leads commercialization in the rest of the world. For vericiguat, if approved, Bayer will lead commercialization in the rest of world and Merck will lead in the Americas. Both companies share in development costs and profits on sales and have the right to co-promote in territories where they are not the lead. Merck records sales of Adempas in its marketing territories, as well as alliance revenue, which is Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories. In addition, the agreement provides for additional contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.
Prior to 2020, Merck accrued $725 million of sales-based milestone payments for this collaboration, of which $350 million was paid to Bayer in 2018. There is an additional $400 million potential future sales-based milestone payment that has not yet been accrued as it is not deemed by the Company to be probable at this time.
The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was $844 million at March 31, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Net sales of Adempas recorded by Merck
$
56

 
$
48

Alliance revenue
53

 
42

Total sales
109

 
90

 
 
 
 
Cost of sales (1)
28

 
29

Selling, general and administrative
15

 
8

Research and development
25

 
30

 
 
 
 
($ in millions)
March 31, 2020
 
December 31, 2019
Receivables from Bayer included in Other current assets
$
50

 
$
49

Payables to Bayer included in Other Noncurrent Liabilities (2)
375

 
375

(1) Includes amortization of intangible assets.
(2) Represents accrued milestone payment.
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.20.1
Other (Income) Expense, Net (Tables)
 3 Months Ended
Mar. 31, 2020
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Interest income
$
(25
)
 
$
(89
)
Interest expense
212

 
209

Exchange losses
54

 
101

(Income) loss from investments in equity securities, net (1)
(52
)
 
25

Net periodic defined benefit plan (credit) cost other than service cost
(90
)
 
(141
)
Other, net
(28
)
 
83

 
$
71

 
$
188


(1) 
Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
XML 43 R37.htm IDEA: XBRL DOCUMENT v3.20.1
Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details) - ArQule
$ in Millions
Jan. 16, 2020
USD ($)
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]  
Payment to acquire business $ 2,700
Share-based compensation payments attributable to precombination service 138
Transaction costs $ 95
XML 44 R56.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories - Narrative (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Inventory [Line Items]    
Inventories classified in Other assets $ 1,630 $ 1,480
Inventories Not Expected to be Sold Within One Year    
Inventory [Line Items]    
Inventories classified in Other assets 1,400 1,300
Inventories Produced in Preparation for Product Launches    
Inventory [Line Items]    
Inventories classified in Other assets $ 258 $ 168
XML 45 R52.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Information on Available-for-sale Investments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost $ 64   $ 1,768
Debt securities, unrealized gains 0   17
Debt securities, unrealized losses 0   0
Debt securities, fair value 64   1,785
Publicly traded equity securities, fair value 779   838
Total debt and publicly traded equity securities, fair value 843   2,623
Unrealized net losses (gains) 4 $ (114)  
U.S. government and agency securities      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 62   266
Debt securities, unrealized gains 0   3
Debt securities, unrealized losses 0   0
Debt securities, fair value 62   269
Foreign government bonds      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 2   0
Debt securities, unrealized gains 0   0
Debt securities, unrealized losses 0   0
Debt securities, fair value 2   0
Commercial paper      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 0   668
Debt securities, unrealized gains 0   0
Debt securities, unrealized losses 0   0
Debt securities, fair value 0   668
Corporate notes and bonds      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 0   608
Debt securities, unrealized gains 0   13
Debt securities, unrealized losses 0   0
Debt securities, fair value 0   621
Asset-backed securities      
Debt Securities, Available-for-sale [Line Items]      
Debt securities, amortized cost 0   226
Debt securities, unrealized gains 0   1
Debt securities, unrealized losses 0   0
Debt securities, fair value $ 0   $ 227
ZIP 46 0000310158-20-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000310158-20-000009-xbrl.zip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�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htm IDEA: XBRL DOCUMENT v3.20.1
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Statement of Cash Flows [Abstract]    
Restricted cash $ 35 $ 258

XML 48 R3.htm IDEA: XBRL DOCUMENT v3.20.1
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Statement of Comprehensive Income [Abstract]    
Net Income Attributable to Merck & Co., Inc. $ 3,219 $ 2,915
Other Comprehensive (Loss) Income Net of Taxes:    
Net unrealized gain (loss) on derivatives, net of reclassifications 104 (48)
Net unrealized (loss) gain on investments, net of reclassifications (18) 82
Benefit plan net gain and prior service credit, net of amortization 60 15
Cumulative translation adjustment (344) 150
Other comprehensive income (loss), net of taxes (198) 199
Comprehensive Income Attributable to Merck & Co., Inc. $ 3,021 $ 3,114
XML 49 R66.htm IDEA: XBRL DOCUMENT v3.20.1
Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance $ 26,001 $ 26,882
Other comprehensive income (loss) before reclassification adjustments, pretax (152) 218
Tax (43) 3
Other comprehensive income (loss) before reclassification adjustments, net of taxes (195) 221
Reclassification adjustments, pretax 1 (28)
Tax (4) 6
Reclassification adjustments, net of taxes (3) (22)
Other comprehensive income (loss), net of taxes (198) 199
Equity, ending balance 26,300 27,670
Derivatives    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance 31 166
Other comprehensive income (loss) before reclassification adjustments, pretax 178 (13)
Tax (37) 3
Other comprehensive income (loss) before reclassification adjustments, net of taxes 141 (10)
Reclassification adjustments, pretax (47) (48)
Tax 10 10
Reclassification adjustments, net of taxes (37) (38)
Other comprehensive income (loss), net of taxes 104 (48)
Equity, ending balance 135 118
Investments    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance 18 (78)
Other comprehensive income (loss) before reclassification adjustments, pretax 3 76
Tax 0 0
Other comprehensive income (loss) before reclassification adjustments, net of taxes 3 76
Reclassification adjustments, pretax (21) 6
Tax 0 0
Reclassification adjustments, net of taxes (21) 6
Other comprehensive income (loss), net of taxes (18) 82
Equity, ending balance 0 4
Employee Benefit Plans    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance (4,261) (3,556)
Other comprehensive income (loss) before reclassification adjustments, pretax 0 (1)
Tax 5 6
Other comprehensive income (loss) before reclassification adjustments, net of taxes 5 5
Reclassification adjustments, pretax 69 14
Tax (14) (4)
Reclassification adjustments, net of taxes 55 10
Other comprehensive income (loss), net of taxes 60 15
Equity, ending balance (4,201) (3,541)
Cumulative Translation Adjustment    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance (1,981) (2,077)
Other comprehensive income (loss) before reclassification adjustments, pretax (333) 156
Tax (11) (6)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (344) 150
Reclassification adjustments, pretax 0 0
Tax 0 0
Reclassification adjustments, net of taxes 0 0
Other comprehensive income (loss), net of taxes (344) 150
Equity, ending balance (2,325) (1,927)
Accumulated Other Comprehensive Income (Loss)    
Accumulated Other Comprehensive Income (Loss) [Roll Forward]    
Equity, beginning balance (6,193) (5,545)
Equity, ending balance $ (6,391) $ (5,346)
XML 50 R62.htm IDEA: XBRL DOCUMENT v3.20.1
Other (Income) Expense, Net (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Other Income and Expenses [Abstract]    
Interest income $ (25) $ (89)
Interest expense 212 209
Exchange losses 54 101
(Income) loss from investments in equity securities, net (1) (52) 25
Net periodic defined benefit plan (credit) cost other than service cost (90) (141)
Other, net (28) 83
Other (income) expense, net $ 71 $ 188
XML 51 R49.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gross amounts recognized in the consolidated balance sheet, asset $ 710,000,000 $ 288,000,000
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset (89,000,000) (84,000,000)
Cash collateral received, asset (216,000,000) (34,000,000)
Net amounts, asset 405,000,000 170,000,000
Gross amounts recognized in the consolidated balance sheet, liability 93,000,000 97,000,000
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability (89,000,000) (84,000,000)
Cash collateral received, liability 0 0
Net amounts, liability $ 4,000,000 $ 13,000,000
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.20.1
Restructuring - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]      
Cumulative costs since program inception $ 1,100    
Estimate of cumulative pre tax costs that will result in cash outlays 60.00%    
Estimate of cumulative pre tax costs that will be noncash 40.00%    
Expected restructuring and related cost $ 2,500    
Total pretax restructuring costs $ 168 $ 187  
Forecast      
Restructuring Cost and Reserve [Line Items]      
Expected restructuring and related cost     $ 800
XML 53 R45.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Foreign exchange contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income $ (3) $ (11)
Foreign exchange contracts | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing (8) (8)
Euro-denominated notes    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (51) (30)
Euro-denominated notes | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing $ 0 $ 0
XML 54 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Contingencies Commitments and Contingencies (Policies)
 3 Months Ended
Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]  
Legal Costs, Policy Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
XML 55 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Earnings Per Share
 3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Earnings Per Share
Earnings Per Share
The calculations of earnings per share are as follows:
 
Three Months Ended 
 March 31,
($ and shares in millions except per share amounts)
2020
 
2019
Net income attributable to Merck & Co., Inc.
$
3,219

 
$
2,915

Average common shares outstanding
2,533

 
2,585

Common shares issuable (1)
14

 
18

Average common shares outstanding assuming dilution
2,547

 
2,603

Basic earnings per common share attributable to Merck & Co., Inc. common shareholders
$
1.27

 
$
1.13

Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders
$
1.26

 
$
1.12

(1) 
Issuable primarily under share-based compensation plans.
For both the first quarter of 2020 and 2019, 2 million of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.
XML 56 R28.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments (Tables)
 3 Months Ended
Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
 
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
 
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
 
Three Months Ended March 31,
 
Three Months Ended March 31,
($ in millions)
2020
 
2019
 
2020
 
2019
Net Investment Hedging Relationships
 
 
 
 
 
 
 
Foreign exchange contracts
$
(3
)
 
$
(11
)
 
$
(8
)
 
$
(8
)
Euro-denominated notes
(51
)
 
(30
)
 
—

 
—

(1) No amounts were reclassified from AOCI into income related to the sale of a subsidiary.
Summary of Interest Rate Swaps Held At March 31, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.
 
March 31, 2020
($ in millions)
Par Value of Debt
 
Number of Interest Rate Swaps Held
 
Total Swap Notional Amount
3.875% notes due 2021
$
1,150

 
5

 
$
1,150

2.40% notes due 2022
1,000

 
4

 
1,000

2.35% notes due 2022
1,250

 
5

 
1,250
Amounts Recorded on Balance Sheet Related to Fair Value Hedges
The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
 
Carrying Amount of Hedged Liabilities
 
Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount
($ in millions)
March 31, 2020
 
December 31, 2019
 
March 31, 2020
 
December 31, 2019
Balance Sheet Line Item in which Hedged Item is Included
 
 
 
 
 
 
 
Loans payable and current portion of long-term debt
$
1,160

 
$
1,249

 
$
11

 
$
(1
)
Long-Term Debt
2,315

 
3,409

 
69

 
14
Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
 
 
March 31, 2020
 
December 31, 2019
 
 
Fair Value of Derivative
 
U.S. Dollar
Notional
 
Fair Value of Derivative
 
U.S. Dollar
Notional
($ in millions)
Balance Sheet Caption
Asset
 
Liability
 
Asset
 
Liability
 
Derivatives Designated as Hedging Instruments
 
 
 
 
 
 
 
 
 
 
 
 
Interest rate swap contracts
Other current assets
$
11

 
$
—

 
$
1,150

 
$
—

 
$
—

 
$
—

Interest rate swap contracts
Other Assets
70

 
—

 
2,250

 
15

 
—

 
3,400

Interest rate swap contracts
Accrued and other current liabilities
—

 
—

 
—

 
—

 
1

 
1,250

Foreign exchange contracts
Other current assets
194

 
—

 
6,546

 
152

 
—

 
6,117

Foreign exchange contracts
Other Assets
88

 
—

 
2,064

 
55

 
—

 
2,160

Foreign exchange contracts
Accrued and other current liabilities
—

 
7

 
734

 
—

 
22

 
1,748

Foreign exchange contracts
Other Noncurrent Liabilities
—

 
1

 
5

 
—

 
1

 
53

 
 
$
363


$
8


$
12,749


$
222


$
24


$
14,728

Derivatives Not Designated as Hedging Instruments
 
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts
Other current assets
$
347

 
$
—

 
$
10,039

 
$
66

 
$
—

 
$
7,245

Foreign exchange contracts
Accrued and other current liabilities
—

 
85

 
4,665

 
—

 
73

 
8,693

 
 
$
347

 
$
85

 
$
14,704

 
$
66

 
$
73

 
$
15,938

 
 
$
710


$
93


$
27,453


$
288


$
97


$
30,666
Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 
March 31, 2020
 
December 31, 2019
($ in millions)
Asset
 
Liability
 
Asset
 
Liability
Gross amounts recognized in the condensed consolidated balance sheet
$
710

 
$
93

 
$
288

 
$
97

Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet
(89
)
 
(89
)
 
(84
)
 
(84
)
Cash collateral received
(216
)
 
—

 
(34
)
 
—

Net amounts
$
405

 
$
4

 
$
170

 
$
13
Location and Amount of Pretax (Gains) Losses of Derivatives
The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:
 
Sales
 
Other (income) expense, net (1)
 
Other comprehensive income (loss)
 
Three Months Ended March 31,
 
Three Months Ended March 31,
 
Three Months Ended March 31,
($ in millions)
2020
 
2019
 
2020
 
2019
 
2020
 
2019
Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded
$
12,057

 
$
10,816

 
$
71

 
$
188

 
$
(198
)
 
$
199

(Gain) loss on fair value hedging relationships
 
 
 
 
 
 
 
 
 
 
 
Interest rate swap contracts
 
 
 
 
 
 
 
 
 
 
 
Hedged items
—

 
—

 
67

 
33

 
—

 
—

Derivatives designated as hedging instruments
—

 
—

 
(67
)
 
(23
)
 
—

 
—

Impact of cash flow hedging relationships
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts
 
 
 
 
 
 
 
 
 
 
 
Amount of gain (loss) recognized in OCI on derivatives
—

 
—

 
—

 
—

 
178

 
(13
)
Increase (decrease) in Sales as a result of AOCI reclassifications
46

 
44

 
—

 
—

 
(46
)
 
(44
)
Interest rate contracts
 
 
 
 
 
 
 
 
 
 
 
Amount of gain recognized in Other (income) expense, net on derivatives
—

 
—

 
(1
)
 
(1
)
 
—

 
—

Amount of loss recognized in OCI on derivatives
—

 
—

 
—

 
—

 
(1
)
 
(4
)
(1) Interest expense is a component of Other (income) expense, net.
Income Statement Effects of Derivatives Not Designated as Hedging Instruments
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
 
 
 
Amount of Derivative Pretax (Gain) Loss Recognized in Income
 
 
 
Three Months Ended March 31,
($ in millions)
Income Statement Caption
 
2020
 
2019
Derivatives Not Designated as Hedging Instruments
 
 
 
 
 
Foreign exchange contracts (1)
Other (income) expense, net
 
$
(180
)
 
$
118

Foreign exchange contracts (2)
Sales
 
(7
)
 
10

(1) These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2) These derivative contracts serve as economic hedges of forecasted transactions.
Information on Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 
March 31, 2020
 
December 31, 2019
 
Amortized
Cost
 
Gross Unrealized
 
Fair
Value
 
Amortized
Cost
 
Gross Unrealized
 
Fair
Value
($ in millions)
Gains
 
Losses
 
Gains
 
Losses
 
U.S. government and agency securities
$
62

 
$
—

 
$
—

 
$
62

 
$
266

 
$
3

 
$
—

 
$
269

Foreign government bonds
2

 
—

 
—

 
2

 
—

 
—

 
—

 
—

Commercial paper
—

 
—

 
—

 
—

 
668

 
—

 
—

 
668

Corporate notes and bonds
—

 
—

 
—

 
—

 
608

 
13

 
—

 
621

Asset-backed securities
—

 
—

 
—

 
—

 
226

 
1

 
—

 
227

Total debt securities
$
64


$
—


$
—


$
64


$
1,768


$
17


$
—


$
1,785

Publicly traded equity securities (1)
 
 
 
 
 
 
779

 


 


 


 
838

Total debt and publicly traded equity securities








 
$
843

 








 
$
2,623


(1) Unrealized net losses recognized in Other (income) expense, net on equity securities still held at March 31, 2020 were $4 million in the first quarter of 2020. Unrealized net gains recognized in Other (income) expense, net on equity securities still held at March 31, 2019 were $114 million in the first quarter of 2019.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
 
Fair Value Measurements Using
 
Fair Value Measurements Using
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
($ in millions)
March 31, 2020
 
December 31, 2019
Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investments
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Foreign government bonds
$
—

 
$
2

 
$
—

 
$
2

 
$
—

 
$
—

 
$
—

 
$
—

Commercial paper
—

 
—

 
—

 
—

 
—

 
668

 
—

 
668

Corporate notes and bonds
—

 
—

 
—

 
—

 
—

 
621

 
—

 
621

Asset-backed securities (1)
—

 
—

 
—

 
—

 
—

 
227

 
—

 
227

U.S. government and agency securities
—

 
—

 
—

 
—

 
—

 
209

 
—

 
209

Publicly traded equity securities
560

 
—

 
—

 
560

 
518

 
—

 
—

 
518

 
560


2


—


562


518


1,725


—


2,243

Other assets (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
62

 
—

 
—

 
62

 
60

 
—

 
—

 
60

Publicly traded equity securities
219

 
—

 
—

 
219

 
320

 
—

 
—

 
320

 
281


—


—


281


380


—


—


380

Derivative assets (3)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Forward exchange contracts
—

 
455

 
—

 
455

 
—

 
169

 
—

 
169

Purchased currency options
—

 
174

 
—

 
174

 
—

 
104

 
—

 
104

Interest rate swaps
—

 
81

 
—

 
81

 
—

 
15

 
—

 
15

 
—


710


—


710


—


288


—


288

Total assets
$
841


$
712


$
—


$
1,553


$
898


$
2,013


$
—


$
2,911

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration
$
—

 
$
—

 
$
694

 
$
694

 
$
—

 
$
—

 
$
767

 
$
767

Derivative liabilities (3)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Forward exchange contracts
—

 
90

 
—

 
90

 
—

 
95

 
—

 
95

Written currency options
—

 
3

 
—

 
3

 
—

 
1

 
—

 
1

Interest rate swaps
—

 
—

 
—

 
—

 
—

 
1

 
—

 
1

 
—

 
93

 
—

 
93

 
—

 
97

 
—

 
97

Total liabilities
$
—


$
93


$
694


$
787


$
—


$
97


$
767


$
864

(1) 
Primarily all of the asset-backed securities were highly-rated (Standard & Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less.
(2) 
Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(3) 
The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
Information About the Changes in Liabilities for Contingent Consideration
Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:
 
Three Months Ended March 31,
($ in millions)
2020
 
2019
Fair value January 1
$
767

 
$
788

Changes in estimated fair value (1)
33

 
(36
)
Payments
(106
)
 
(85
)
Fair value March 31 (2)(3)
$
694

 
$
667

(1) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2) Balance at March 31, 2020 includes $119 million recorded as a current liability for amounts expected to be paid within the next 12 months.
(3) At March 31, 2020 and December 31, 2019, $520 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.
XML 58 R39.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborative Arrangements - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended 21 Months Ended 29 Months Ended 37 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Jan. 31, 2020
Mar. 31, 2019
Mar. 31, 2018
Jul. 31, 2017
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2019
Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Research and development             $ 2,209 $ 1,931          
Other liabilities, noncurrent   $ 11,550         11,550   $ 11,970   $ 11,970 $ 11,970  
Lynparza | Other Assets                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Finite-lived intangible assets   928         928            
Lenvima | Other Assets                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Finite-lived intangible assets   921         921            
Adempas | Other intangible assets                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Finite-lived intangible assets   844         844            
AstraZeneca                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront and milestone payments           $ 1,600              
License option payment related to collaborative arrangement           $ 750              
AstraZeneca | Sales-Based Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contingent milestone payments collaborative arrangement             3,100            
AstraZeneca | Sales-Based Milestones | Lynparza                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Probable contingent payments collaborative arrangement                       $ 1,000  
Milestone payments made to collaborative partner     $ 250           200 $ 250      
AstraZeneca | Regulatory Milestones | Lynparza                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payments made to collaborative partner                 60 140      
Contingent milestone payments collaborative arrangement             1,700            
Eisai                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront and milestone payments         $ 750                
License option payment related to collaborative arrangement   $ 200   $ 325                  
Eisai | Forecast                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
License option payment related to collaborative arrangement $ 125                       $ 650
Eisai | Sales-Based Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contingent milestone payments collaborative arrangement             3,000            
Eisai | Sales-Based Milestones | Lenvima                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Probable contingent payments collaborative arrangement                     $ 950    
Milestone payments made to collaborative partner             300   $ 50        
Eisai | Regulatory Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Contingent milestone payments collaborative arrangement             135            
Eisai | Regulatory Milestones | Lenvima                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payments made to collaborative partner                   250      
Bayer AG | Sales-Based Milestones                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Probable contingent payments collaborative arrangement                   725      
Milestone payments made to collaborative partner                   $ 350      
Contingent milestone payments collaborative arrangement             $ 400            
XML 59 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Share-Based Compensation Plans (Tables)
 3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Amounts of Share-Based Compensation Cost Recorded in Consolidated Statement of Income
The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Pretax share-based compensation expense
$
108

 
$
93

Income tax benefit
(15
)
 
(14
)
Total share-based compensation expense, net of taxes
$
93

 
$
79
Assumptions Used to Determine Weighted-Average Fair Value of Options Granted The Company did not grant any stock options during the first three months of 2020 or 2019.
At March 31, 2020, there was $1.1 billion of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of 2.4 years. The Company typically communicates the value of annual share-based compensation awards to employees during the first quarter, but the related share amounts are not established and communicated until early May. Therefore, while the number of RSU, PSU and stock option grants disclosed above do not reflect any amounts relating to the annual grants, share-based compensation costs for the first quarter of 2020 and 2019 and unrecognized compensation expense at March 31, 2020 reflect an impact relating to the awards communicated to employees. For segment reporting, share-based compensation costs are unallocated expenses.
  
XML 61 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Other Comprehensive Income (Loss) (Tables)
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Changes in AOCI by Component
Changes in AOCI by component are as follows:
 
Three Months Ended March 31,
($ in millions)
Derivatives
 
Investments
 
Employee
Benefit
Plans
 
Cumulative
Translation
Adjustment
 
Accumulated Other
Comprehensive
Income (Loss)
Balance January 1, 2019, net of taxes
$
166

 
$
(78
)
 
$
(3,556
)
 
$
(2,077
)
 
$
(5,545
)
Other comprehensive income (loss) before reclassification adjustments, pretax
(13
)
 
76

 
(1
)
 
156

 
218

Tax
3

 
—

 
6

 
(6
)
 
3

Other comprehensive income (loss) before reclassification adjustments, net of taxes
(10
)
 
76

 
5

 
150

 
221

Reclassification adjustments, pretax
(48
)
(1) 
6

(2) 
14

(3) 
—

 
(28
)
Tax
10

 
—

 
(4
)
 
—

 
6

Reclassification adjustments, net of taxes
(38
)

6


10


—

 
(22
)
Other comprehensive income (loss), net of taxes
(48
)
 
82

 
15

 
150

 
199

Balance March 31, 2019, net of taxes
$
118

 
$
4

 
$
(3,541
)
 
$
(1,927
)
 
$
(5,346
)
Balance January 1, 2020, net of taxes
$
31

 
$
18

 
$
(4,261
)
 
$
(1,981
)
 
$
(6,193
)
Other comprehensive income (loss) before reclassification adjustments, pretax
178

 
3

 
—

 
(333
)
 
(152
)
Tax
(37
)
 
—

 
5

 
(11
)
 
(43
)
Other comprehensive income (loss) before reclassification adjustments, net of taxes
141

 
3

 
5

 
(344
)
 
(195
)
Reclassification adjustments, pretax
(47
)
(1) 
(21
)
(2) 
69

(3) 
—

 
1

Tax
10

 
—

 
(14
)
 
—

 
(4
)
Reclassification adjustments, net of taxes
(37
)

(21
)

55


—

 
(3
)
Other comprehensive income (loss), net of taxes
104

 
(18
)
 
60

 
(344
)
 
(198
)
Balance March 31, 2020, net of taxes
$
135


$
—


$
(4,201
)

$
(2,325
)

$
(6,391
)
(1) 
Relates to foreign currency cash flow hedges that were reclassified from AOCI to Sales.
(2) Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from AOCI to Other (income) expense, net.
(3) Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 10).
 
XML 62 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Share-Based Compensation Plans
 3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation Plans
Share-Based Compensation Plans
The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant.
The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:
 
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Pretax share-based compensation expense
$
108

 
$
93

Income tax benefit
(15
)
 
(14
)
Total share-based compensation expense, net of taxes
$
93

 
$
79


During the first three months of 2020, the Company granted 58 thousand RSUs with a weighted-average grant date fair value of $85.66 per RSU and during the first three months of 2019 granted 70 thousand RSUs with a weighted-average grant date fair value of $77.39 per RSU. During the first three months of 2020, the Company granted 770 thousand PSUs with a weighted-average grant date fair value of $75.65 per PSU and during the first three months of 2019 granted 609 thousand PSUs with a weighted-average grant date fair value of $90.50 per PSU. The Company did not grant any stock options during the first three months of 2020 or 2019.
At March 31, 2020, there was $1.1 billion of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of 2.4 years. The Company typically communicates the value of annual share-based compensation awards to employees during the first quarter, but the related share amounts are not established and communicated until early May. Therefore, while the number of RSU, PSU and stock option grants disclosed above do not reflect any amounts relating to the annual grants, share-based compensation costs for the first quarter of 2020 and 2019 and unrecognized compensation expense at March 31, 2020 reflect an impact relating to the awards communicated to employees. For segment reporting, share-based compensation costs are unallocated expenses.
  
XML 63 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments
 3 Months Ended
Mar. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments
Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated other comprehensive income (AOCI) and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI and remain in AOCI until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded component). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
 
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
 
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
 
Three Months Ended March 31,
 
Three Months Ended March 31,
($ in millions)
2020
 
2019
 
2020
 
2019
Net Investment Hedging Relationships
 
 
 
 
 
 
 
Foreign exchange contracts
$
(3
)
 
$
(11
)
 
$
(8
)
 
$
(8
)
Euro-denominated notes
(51
)
 
(30
)
 
—

 
—

(1) No amounts were reclassified from AOCI into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk.
In February 2020, five interest rate swaps with notional amounts of $250 million each matured. These swaps effectively converted the Company’s $1.25 billion, 1.85% fixed-rate notes due 2020 to variable rate debt. At March 31, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.
 
March 31, 2020
($ in millions)
Par Value of Debt
 
Number of Interest Rate Swaps Held
 
Total Swap Notional Amount
3.875% notes due 2021
$
1,150

 
5

 
$
1,150

2.40% notes due 2022
1,000

 
4

 
1,000

2.35% notes due 2022
1,250

 
5

 
1,250

The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
 
Carrying Amount of Hedged Liabilities
 
Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount
($ in millions)
March 31, 2020
 
December 31, 2019
 
March 31, 2020
 
December 31, 2019
Balance Sheet Line Item in which Hedged Item is Included
 
 
 
 
 
 
 
Loans payable and current portion of long-term debt
$
1,160

 
$
1,249

 
$
11

 
$
(1
)
Long-Term Debt
2,315

 
3,409

 
69

 
14

Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
 
 
March 31, 2020
 
December 31, 2019
 
 
Fair Value of Derivative
 
U.S. Dollar
Notional
 
Fair Value of Derivative
 
U.S. Dollar
Notional
($ in millions)
Balance Sheet Caption
Asset
 
Liability
 
Asset
 
Liability
 
Derivatives Designated as Hedging Instruments
 
 
 
 
 
 
 
 
 
 
 
 
Interest rate swap contracts
Other current assets
$
11

 
$
—

 
$
1,150

 
$
—

 
$
—

 
$
—

Interest rate swap contracts
Other Assets
70

 
—

 
2,250

 
15

 
—

 
3,400

Interest rate swap contracts
Accrued and other current liabilities
—

 
—

 
—

 
—

 
1

 
1,250

Foreign exchange contracts
Other current assets
194

 
—

 
6,546

 
152

 
—

 
6,117

Foreign exchange contracts
Other Assets
88

 
—

 
2,064

 
55

 
—

 
2,160

Foreign exchange contracts
Accrued and other current liabilities
—

 
7

 
734

 
—

 
22

 
1,748

Foreign exchange contracts
Other Noncurrent Liabilities
—

 
1

 
5

 
—

 
1

 
53

 
 
$
363


$
8


$
12,749


$
222


$
24


$
14,728

Derivatives Not Designated as Hedging Instruments
 
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts
Other current assets
$
347

 
$
—

 
$
10,039

 
$
66

 
$
—

 
$
7,245

Foreign exchange contracts
Accrued and other current liabilities
—

 
85

 
4,665

 
—

 
73

 
8,693

 
 
$
347

 
$
85

 
$
14,704

 
$
66

 
$
73

 
$
15,938

 
 
$
710


$
93


$
27,453


$
288


$
97


$
30,666


As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 
March 31, 2020
 
December 31, 2019
($ in millions)
Asset
 
Liability
 
Asset
 
Liability
Gross amounts recognized in the condensed consolidated balance sheet
$
710

 
$
93

 
$
288

 
$
97

Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet
(89
)
 
(89
)
 
(84
)
 
(84
)
Cash collateral received
(216
)
 
—

 
(34
)
 
—

Net amounts
$
405

 
$
4

 
$
170

 
$
13


The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:
 
Sales
 
Other (income) expense, net (1)
 
Other comprehensive income (loss)
 
Three Months Ended March 31,
 
Three Months Ended March 31,
 
Three Months Ended March 31,
($ in millions)
2020
 
2019
 
2020
 
2019
 
2020
 
2019
Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded
$
12,057

 
$
10,816

 
$
71

 
$
188

 
$
(198
)
 
$
199

(Gain) loss on fair value hedging relationships
 
 
 
 
 
 
 
 
 
 
 
Interest rate swap contracts
 
 
 
 
 
 
 
 
 
 
 
Hedged items
—

 
—

 
67

 
33

 
—

 
—

Derivatives designated as hedging instruments
—

 
—

 
(67
)
 
(23
)
 
—

 
—

Impact of cash flow hedging relationships
 
 
 
 
 
 
 
 
 
 
 
Foreign exchange contracts
 
 
 
 
 
 
 
 
 
 
 
Amount of gain (loss) recognized in OCI on derivatives
—

 
—

 
—

 
—

 
178

 
(13
)
Increase (decrease) in Sales as a result of AOCI reclassifications
46

 
44

 
—

 
—

 
(46
)
 
(44
)
Interest rate contracts
 
 
 
 
 
 
 
 
 
 
 
Amount of gain recognized in Other (income) expense, net on derivatives
—

 
—

 
(1
)
 
(1
)
 
—

 
—

Amount of loss recognized in OCI on derivatives
—

 
—

 
—

 
—

 
(1
)
 
(4
)
(1) Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
 
 
 
Amount of Derivative Pretax (Gain) Loss Recognized in Income
 
 
 
Three Months Ended March 31,
($ in millions)
Income Statement Caption
 
2020
 
2019
Derivatives Not Designated as Hedging Instruments
 
 
 
 
 
Foreign exchange contracts (1)
Other (income) expense, net
 
$
(180
)
 
$
118

Foreign exchange contracts (2)
Sales
 
(7
)
 
10

(1) These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2) These derivative contracts serve as economic hedges of forecasted transactions.
At March 31, 2020, the Company estimates $136 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCI to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.

Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 
March 31, 2020
 
December 31, 2019
 
Amortized
Cost
 
Gross Unrealized
 
Fair
Value
 
Amortized
Cost
 
Gross Unrealized
 
Fair
Value
($ in millions)
Gains
 
Losses
 
Gains
 
Losses
 
U.S. government and agency securities
$
62

 
$
—

 
$
—

 
$
62

 
$
266

 
$
3

 
$
—

 
$
269

Foreign government bonds
2

 
—

 
—

 
2

 
—

 
—

 
—

 
—

Commercial paper
—

 
—

 
—

 
—

 
668

 
—

 
—

 
668

Corporate notes and bonds
—

 
—

 
—

 
—

 
608

 
13

 
—

 
621

Asset-backed securities
—

 
—

 
—

 
—

 
226

 
1

 
—

 
227

Total debt securities
$
64


$
—


$
—


$
64


$
1,768


$
17


$
—


$
1,785

Publicly traded equity securities (1)
 
 
 
 
 
 
779

 


 


 


 
838

Total debt and publicly traded equity securities








 
$
843

 








 
$
2,623


(1) Unrealized net losses recognized in Other (income) expense, net on equity securities still held at March 31, 2020 were $4 million in the first quarter of 2020. Unrealized net gains recognized in Other (income) expense, net on equity securities still held at March 31, 2019 were $114 million in the first quarter of 2019.
At March 31, 2020 and March 31, 2019, the Company also had $450 million and $542 million, respectively, of equity investments without readily determinable fair values included in Other Assets. During the first three months of 2019, the Company recognized unrealized losses of $9 million in Other (income) expense, net related to certain of these investments held at March 31, 2019 based on unfavorable observable price changes. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values still held at March 31, 2020 were $109 million and $21 million, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities, Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities, Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
 
Fair Value Measurements Using
 
Fair Value Measurements Using
 
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
($ in millions)
March 31, 2020
 
December 31, 2019
Assets
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investments
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Foreign government bonds
$
—

 
$
2

 
$
—

 
$
2

 
$
—

 
$
—

 
$
—

 
$
—

Commercial paper
—

 
—

 
—

 
—

 
—

 
668

 
—

 
668

Corporate notes and bonds
—

 
—

 
—

 
—

 
—

 
621

 
—

 
621

Asset-backed securities (1)
—

 
—

 
—

 
—

 
—

 
227

 
—

 
227

U.S. government and agency securities
—

 
—

 
—

 
—

 
—

 
209

 
—

 
209

Publicly traded equity securities
560

 
—

 
—

 
560

 
518

 
—

 
—

 
518

 
560


2


—


562


518


1,725


—


2,243

Other assets (2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
U.S. government and agency securities
62

 
—

 
—

 
62

 
60

 
—

 
—

 
60

Publicly traded equity securities
219

 
—

 
—

 
219

 
320

 
—

 
—

 
320

 
281


—


—


281


380


—


—


380

Derivative assets (3)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Forward exchange contracts
—

 
455

 
—

 
455

 
—

 
169

 
—

 
169

Purchased currency options
—

 
174

 
—

 
174

 
—

 
104

 
—

 
104

Interest rate swaps
—

 
81

 
—

 
81

 
—

 
15

 
—

 
15

 
—


710


—


710


—


288


—


288

Total assets
$
841


$
712


$
—


$
1,553


$
898


$
2,013


$
—


$
2,911

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contingent consideration
$
—

 
$
—

 
$
694

 
$
694

 
$
—

 
$
—

 
$
767

 
$
767

Derivative liabilities (3)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Forward exchange contracts
—

 
90

 
—

 
90

 
—

 
95

 
—

 
95

Written currency options
—

 
3

 
—

 
3

 
—

 
1

 
—

 
1

Interest rate swaps
—

 
—

 
—

 
—

 
—

 
1

 
—

 
1

 
—

 
93

 
—

 
93

 
—

 
97

 
—

 
97

Total liabilities
$
—


$
93


$
694


$
787


$
—


$
97


$
767


$
864

(1) 
Primarily all of the asset-backed securities were highly-rated (Standard & Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less.
(2) 
Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(3) 
The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of March 31, 2020 and December 31, 2019, Cash and cash equivalents included $6.8 billion and $8.9 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:
 
Three Months Ended March 31,
($ in millions)
2020
 
2019
Fair value January 1
$
767

 
$
788

Changes in estimated fair value (1)
33

 
(36
)
Payments
(106
)
 
(85
)
Fair value March 31 (2)(3)
$
694

 
$
667

(1) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2) Balance at March 31, 2020 includes $119 million recorded as a current liability for amounts expected to be paid within the next 12 months.
(3) At March 31, 2020 and December 31, 2019, $520 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.
The increase in the estimated fair value of liabilities for contingent consideration in the first quarter of 2020 primarily relates to MK-7264 (gefapixant), a program obtained in connection with the acquisition of Afferent Pharmaceuticals, following the conclusion of Phase 3 studies evaluating gefapixant for the treatment of chronic cough. The decline in the estimated fair value of liabilities for contingent consideration in the first quarter of 2019 primarily relates to a decision not to pursue an acute cough indication for gefapixant. The payments of contingent consideration in both periods relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at March 31, 2020, was $30.6 billion compared with a carrying value of $28.0 billion and at December 31, 2019, was $28.8 billion compared with a carrying value of $26.3 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the United States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $1.9 billion and $2.7 billion of accounts receivable in the first quarter of 2020 and the fourth quarter of 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $216 million and $34 million at March 31, 2020 and December 31, 2019, respectively. The
obligation to return such collateral is recorded in Accrued and other current liabilities. No cash collateral was advanced by the Company to counterparties as of March 31, 2020 or December 31, 2019.
XML 64 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Acquisitions, Research Collaborations and License Agreements
 3 Months Ended
Mar. 31, 2020
Business Combinations [Abstract]  
Acquisitions, Divestitures, Research Collaborations and License Agreements
Acquisitions, Research Collaborations and License Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138 million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95 million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in Selling, general and administrative expenses in the first quarter of 2020. ArQule’s lead investigational candidate, MK-1026 (formerly ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.
The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
 
 
($ in millions)
January 16, 2020
Cash and cash equivalents
$
145

IPR&D MK-1026 (formerly ARQ 531) (1)
2,280

IPR&D MK-7075 (formerly ARQ 092) (1)
170

Licensing arrangement for ARQ 087
80

Deferred income tax liabilities
(434
)
Other assets and liabilities, net
35

Total identifiable net assets
2,276

Goodwill (2)
414

Consideration transferred
$
2,690

(1) 
The fair values of the identifiable intangible assets related to in-process research and development (IPR&D) were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed.
(2) 
The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.
 
XML 65 R5.htm IDEA: XBRL DOCUMENT v3.20.1
CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 89 $ 86
Inventories classified in Other assets 1,630 1,480
Accumulated depreciation $ 17,706 $ 17,686
Common stock, par value (in dollars per share) $ 0.50 $ 0.50
Common stock, shares authorized (shares) 6,500,000,000 6,500,000,000
Common stock, shares issued (in shares) 3,577,103,522 3,577,103,522
Treasury stock, shares (shares) 1,053,090,194 1,038,087,496
XML 66 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page - shares
 3 Months Ended
Mar. 31, 2020
Apr. 30, 2020
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2020  
Document Transition Report false  
Entity File Number 1-6571  
Entity Registrant Name Merck & Co., Inc.  
Entity Incorporation, State or Country Code NJ  
Entity Tax Identification Number 22-1918501  
Entity Address, Address Line One 2000 Galloping Hill Road  
Entity Address, City or Town Kenilworth  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07033  
City Area Code (908)  
Local Phone Number 740-4000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   2,524,101,191
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0000310158  
Current Fiscal Year End Date --12-31  
Common Stock    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock ($0.50 par value)  
Trading Symbol MRK  
Security Exchange Name NYSE  
1.125% Notes due 2021    
Entity Information [Line Items]    
Title of 12(b) Security 1.125% Notes due 2021  
Trading Symbol MRK/21  
Security Exchange Name NYSE  
0.500% Notes due 2024    
Entity Information [Line Items]    
Title of 12(b) Security 0.500% Notes due 2024  
Trading Symbol MRK 24  
Security Exchange Name NYSE  
1.875% Notes due 2026    
Entity Information [Line Items]    
Title of 12(b) Security 1.875% Notes due 2026  
Trading Symbol MRK/26  
Security Exchange Name NYSE  
2.500% Notes due 2034    
Entity Information [Line Items]    
Title of 12(b) Security 2.500% Notes due 2034  
Trading Symbol MRK/34  
Security Exchange Name NYSE  
1.375% Notes due 2036    
Entity Information [Line Items]    
Title of 12(b) Security 1.375% Notes due 2036  
Trading Symbol MRK 36A  
Security Exchange Name NYSE  
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)
$ in Millions
 3 Months Ended
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Fair value, beginning balance $ 767 $ 788    
Changes in estimated fair value 33 (36)    
Payments (106) (85)    
Fair value, ending balance 694 667    
Current liability     $ 119  
Contingent consideration 694 $ 667 694 $ 767
Sanofi Pasteur        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Fair value, beginning balance 625      
Fair value, ending balance 520      
Contingent consideration $ 625   $ 520 $ 625
Contingent consideration, measurement input, discount rate (as percent)       0.115
Measurement Input, Discount Rate | Sanofi Pasteur        
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Contingent consideration, measurement input, discount rate (as percent)       0.08
XML 68 R50.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Derivative Instruments, Gain (Loss) [Line Items]    
Sales $ 12,057 $ 10,816
Other (income) expense, net 71 188
Other comprehensive income (loss) (198) 199
Interest rate swap contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain (loss) recognized in OCI on derivatives (1) (4)
Interest rate swap contracts | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Hedged items 67 33
Derivatives designated as hedging instruments (67) (23)
Amount of gain recognized in Other (income) expense, net on derivatives (1) (1)
Foreign exchange contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of gain (loss) recognized in OCI on derivatives 178 (13)
Increase (decrease) in Sales as a result of AOCI reclassifications (46) (44)
Foreign exchange contracts | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest    
Derivative Instruments, Gain (Loss) [Line Items]    
Sales $ 46 $ 44
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.20.1
Equity - Rollforward Reconciliations (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Shares, beginning balance (in shares) 3,577,103,522  
Equity, beginning balance $ 26,001 $ 26,882
Net income attributable to Merck & Co., Inc. 3,219 2,915
Other comprehensive income (loss), net of taxes (198) 199
Cash dividends declared on common stock (1,549) (1,429)
Treasury stock shares purchased (1,281) (1,090)
Share-based compensation plans and other 107 243
Net income (loss) attributable to noncontrolling interests 0 (53)
Noncontrolling interest, changes in ownership interest, other $ 1 3
Shares, ending balance (in shares) 3,577,103,522  
Equity, ending balance $ 26,300 $ 27,670
Cash dividends declared on common stock (in dollars per share) $ 0.61 $ 0.55
Common Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Shares, beginning balance (in shares) 3,577,000,000 3,577,000,000
Equity, beginning balance $ 1,788 $ 1,788
Shares, ending balance (in shares) 3,577,000,000 3,577,000,000
Equity, ending balance $ 1,788 $ 1,788
Other Paid-In Capital    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance 39,660 38,808
Share-based compensation plans and other 37 (40)
Equity, ending balance 39,697 38,768
Retained Earnings    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance 46,602 42,579
Net income attributable to Merck & Co., Inc. 3,219 2,915
Cash dividends declared on common stock (1,549) (1,429)
Equity, ending balance 48,272 44,065
Accumulated Other Comprehensive Loss    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance (6,193) (5,545)
Other comprehensive income (loss), net of taxes (198) 199
Equity, ending balance $ (6,391) $ (5,346)
Treasury Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Shares, beginning balance (in shares) 1,038,000,000 985,000,000
Equity, beginning balance $ (55,950) $ (50,929)
Treasury stock shares purchased (in shares) 16,000,000 14,000,000
Treasury stock shares purchased $ (1,281) $ (1,090)
Share-based compensation plans and other (in shares) (1,000,000) (5,000,000)
Share-based compensation plans and other $ 70 $ 283
Shares, ending balance (in shares) 1,053,000,000 994,000,000
Equity, ending balance $ (57,161) $ (51,736)
Non- controlling Interests    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Equity, beginning balance 94 181
Net income (loss) attributable to noncontrolling interests   (53)
Noncontrolling interest, changes in ownership interest, other 1 3
Equity, ending balance $ 95 $ 131
XML 70 mrk0331202010q_htm.xml IDEA: XBRL DOCUMENT 0000310158 2020-01-01 2020-03-31 0000310158 2020-04-30 0000310158 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000310158 mrk:A1.875Notesdue2026Member 2020-01-01 2020-03-31 0000310158 mrk:A1.375Notesdue2036Member 2020-01-01 2020-03-31 0000310158 mrk:A0.500Notesdue2024Member 2020-01-01 2020-03-31 0000310158 mrk:A2.500Notesdue2034Member 2020-01-01 2020-03-31 0000310158 mrk:A1.125Notesdue2021Member 2020-01-01 2020-03-31 0000310158 2019-01-01 2019-03-31 0000310158 2020-03-31 0000310158 2019-12-31 0000310158 2019-03-31 0000310158 2018-12-31 0000310158 mrk:ArQuleMember 2020-01-16 0000310158 mrk:ArQuleMember mrk:IPRDMK1026Member 2020-01-16 0000310158 mrk:ArQuleMember mrk:IPRDMK7075Member 2020-01-16 0000310158 mrk:ArQuleMember 2020-01-16 2020-01-16 0000310158 mrk:ArQuleMember us-gaap:MeasurementInputDiscountRateMember 2020-01-16 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:BayerAGMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember 2020-03-01 2020-03-31 0000310158 mrk:EisaiMember 2019-03-01 2019-03-31 0000310158 mrk:LenvimaMember us-gaap:OtherNoncurrentAssetsMember 2020-03-31 0000310158 mrk:EisaiMember 2018-03-01 2018-03-31 0000310158 mrk:EisaiMember srt:ScenarioForecastMember 2021-03-01 2021-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:AstraZenecaMember 2017-07-01 2017-07-31 0000310158 mrk:BayerAGMember mrk:SalesBasedMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:LynparzaMember us-gaap:OtherNoncurrentAssetsMember 2020-03-31 0000310158 mrk:AdempasMember us-gaap:OtherIntangibleAssetsMember 2020-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember srt:ScenarioForecastMember 2018-03-01 2021-03-31 0000310158 mrk:AstraZenecaMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:RegulatoryMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2017-08-01 2019-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-01-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2018-04-01 2019-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2019-01-01 2019-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-12-31 0000310158 mrk:EisaiMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember mrk:RegulatoryMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:BayerAGMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-12-31 0000310158 mrk:EisaiMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:EisaiMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-03-31 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-03-31 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-03-31 0000310158 us-gaap:OtherRestructuringMember 2019-01-01 2019-03-31 0000310158 mrk:AcceleratedDepreciationMember 2019-01-01 2019-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-03-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-03-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-03-31 0000310158 us-gaap:RestructuringChargesMember 2019-01-01 2019-03-31 0000310158 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-03-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-03-31 0000310158 us-gaap:RestructuringChargesMember 2020-01-01 2020-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0000310158 mrk:AcceleratedDepreciationMember 2020-01-01 2020-03-31 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-03-31 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-03-31 0000310158 us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-03-31 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-03-31 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-03-31 0000310158 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2019-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2020-03-31 0000310158 us-gaap:OtherRestructuringMember 2020-03-31 0000310158 us-gaap:OtherRestructuringMember 2019-12-31 0000310158 mrk:AcceleratedDepreciationMember 2020-03-31 0000310158 mrk:AcceleratedDepreciationMember 2019-12-31 0000310158 srt:ScenarioForecastMember 2020-12-31 0000310158 us-gaap:InterestRateSwapMember 2020-02-29 0000310158 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000310158 us-gaap:InterestRateSwapMember 2020-03-31 0000310158 srt:MaximumMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-03-31 0000310158 mrk:A1.85NotesDue2020Member 2020-02-29 0000310158 us-gaap:FairValueInputsLevel2Member 2020-03-31 0000310158 mrk:SanofiPasteurMember 2019-12-31 0000310158 mrk:SanofiPasteurMember 2020-03-31 0000310158 srt:MaximumMember us-gaap:NondesignatedMember 2020-01-01 2020-03-31 0000310158 2019-10-01 2019-12-31 0000310158 mrk:SanofiPasteurMember us-gaap:MeasurementInputDiscountRateMember 2019-12-31 0000310158 us-gaap:AssetBackedSecuritiesMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000310158 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-03-31 0000310158 us-gaap:NondesignatedMember 2020-03-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:NondesignatedMember 2019-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-03-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-31 0000310158 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember 2019-01-01 2019-03-31 0000310158 mrk:EurodominatedNotesMember 2019-01-01 2019-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-31 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-03-31 0000310158 mrk:EurodominatedNotesMember 2020-01-01 2020-03-31 0000310158 us-gaap:InterestRateSwapMember mrk:A2.40NotesDue2022Member 2020-03-31 0000310158 us-gaap:InterestRateSwapMember mrk:A3.875NotesDue2021Member 2020-03-31 0000310158 us-gaap:InterestRateSwapMember mrk:A2.35NotesDue2022Member 2020-03-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:AssetBackedSecuritiesMember 2020-03-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-03-31 0000310158 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:CommercialPaperMember 2020-03-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2019-01-01 2019-03-31 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2020-01-01 2020-03-31 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-31 0000310158 us-gaap:InterestRateSwapMember 2019-01-01 2019-03-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-03-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-03-31 0000310158 us-gaap:InterestRateSwapMember 2020-01-01 2020-03-31 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2019-12-31 0000310158 mrk:LongTermDebtExcludingCurrentMaturitiesMember 2020-03-31 0000310158 mrk:LongTermDebtExcludingCurrentMaturitiesMember 2019-12-31 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2020-03-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2019-12-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2020-03-31 0000310158 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2020-03-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2019-12-31 0000310158 mrk:NewJerseyStateCourtMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-03-31 0000310158 mrk:FosamaxMember 2020-03-31 0000310158 mrk:OtherStateCourtMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-03-31 0000310158 mrk:FederalMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2014-03-01 2014-03-31 0000310158 mrk:LegalDefenseCostsMember 2019-12-31 0000310158 mrk:JanuviaMember mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember 2020-03-31 0000310158 mrk:CaliforniaStateCourtMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-03-31 0000310158 mrk:FederalMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-03-31 0000310158 mrk:LegalDefenseCostsMember 2020-03-31 0000310158 mrk:OtherStateCourtMember mrk:JanuviaMember 2020-03-31 0000310158 mrk:JanuviaMember 2020-03-31 0000310158 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000310158 us-gaap:TreasuryStockMember 2018-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000310158 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000310158 us-gaap:RetainedEarningsMember 2019-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000310158 us-gaap:CommonStockMember 2019-12-31 0000310158 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2019-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2020-03-31 0000310158 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000310158 us-gaap:CommonStockMember 2018-12-31 0000310158 us-gaap:TreasuryStockMember 2019-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000310158 us-gaap:RetainedEarningsMember 2020-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000310158 us-gaap:TreasuryStockMember 2020-03-31 0000310158 us-gaap:TreasuryStockMember 2019-03-31 0000310158 us-gaap:CommonStockMember 2020-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2019-03-31 0000310158 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000310158 us-gaap:RetainedEarningsMember 2018-12-31 0000310158 us-gaap:CommonStockMember 2019-03-31 0000310158 us-gaap:RetainedEarningsMember 2019-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2018-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000310158 us-gaap:PerformanceSharesMember 2020-01-01 2020-03-31 0000310158 us-gaap:PerformanceSharesMember 2019-01-01 2019-03-31 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-03-31 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-03-31 0000310158 mrk:HealthcareServicesSegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-03-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000310158 srt:AsiaPacificMember 2020-01-01 2020-03-31 0000310158 country:US 2019-01-01 2019-03-31 0000310158 us-gaap:EMEAMember 2019-01-01 2019-03-31 0000310158 country:JP 2020-01-01 2020-03-31 0000310158 country:JP 2019-01-01 2019-03-31 0000310158 srt:LatinAmericaMember 2020-01-01 2020-03-31 0000310158 country:CN 2020-01-01 2020-03-31 0000310158 mrk:OtherCountriesMember 2020-01-01 2020-03-31 0000310158 mrk:OtherCountriesMember 2019-01-01 2019-03-31 0000310158 srt:AsiaPacificMember 2019-01-01 2019-03-31 0000310158 srt:LatinAmericaMember 2019-01-01 2019-03-31 0000310158 us-gaap:EMEAMember 2020-01-01 2020-03-31 0000310158 country:US 2020-01-01 2020-03-31 0000310158 country:CN 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-03-31 0000310158 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0000310158 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:CorporateNonSegmentMember country:US 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 mrk:InternationalMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 mrk:InternationalMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2020-01-01 2020-03-31 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-03-31 iso4217:USD pure iso4217:USD shares shares mrk:interest_rate_swap mrk:segment mrk:Claim mrk:Case false --12-31 Q1 2020 0000310158 17686000000 17706000000 86000000 89000000 2000000 0.55 0.61 0.50 0.50 6500000000 6500000000 3577103522 3577103522 0.02350 0.0240 0.03875 0 258000000 35000000 1038087496 1053090194 10-Q true 2020-03-31 false 1-6571 Merck & Co., Inc. NJ 22-1918501 2000 Galloping Hill Road Kenilworth NJ 07033 (908) 740-4000 Yes Yes Large Accelerated Filer false false false Common Stock ($0.50 par value) MRK NYSE 1.125% Notes due 2021 MRK/21 NYSE 0.500% Notes due 2024 MRK 24 NYSE 1.875% Notes due 2026 MRK/26 NYSE 2.500% Notes due 2034 MRK/34 NYSE 1.375% Notes due 2036 MRK 36A NYSE 2524101191 12057000000 10816000000 3312000000 3052000000 2555000000 2425000000 2209000000 1931000000 72000000 153000000 -71000000 -188000000 8219000000 7749000000 3838000000 3067000000 619000000 205000000 3219000000 2862000000 0 -53000000 3219000000 2915000000 1.27 1.13 1.26 1.12 3219000000 2915000000 104000000 -48000000 -18000000 82000000 -60000000 -15000000 -344000000 150000000 -198000000 199000000 3021000000 3114000000 7425000000 9676000000 7000000 774000000 8182000000 6778000000 5846000000 5978000000 4714000000 4277000000 26174000000 27483000000 555000000 1469000000 15269000000 15053000000 19767000000 19425000000 16096000000 14196000000 7052000000 6771000000 84913000000 84397000000 6361000000 3610000000 3572000000 3738000000 10932000000 12549000000 1033000000 736000000 1585000000 1587000000 23483000000 22220000000 21637000000 22736000000 1943000000 1470000000 11550000000 11970000000 1788000000 1788000000 39697000000 39660000000 48272000000 46602000000 -6391000000 -6193000000 83366000000 81857000000 57161000000 55950000000 26205000000 25907000000 95000000 94000000 26300000000 26001000000 84913000000 84397000000 3219000000 2862000000 821000000 898000000 0 104000000 82000000 194000000 108000000 93000000 -143000000 -120000000 3666000000 2935000000 707000000 1336000000 986000000 595000000 49000000 974000000 1816000000 1899000000 2545000000 0 -136000000 -38000000 -1628000000 368000000 3583000000 -4135000000 1951000000 0 0 4958000000 1281000000 1090000000 1551000000 1428000000 26000000 173000000 -316000000 -92000000 -1490000000 -1614000000 -63000000 20000000 -2474000000 110000000 9934000000 7967000000 7460000000 8077000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements of Merck &amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. </span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements of Merck &amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Planned Spin-Off of Women’s Health, Legacy Brands and Biosimilars into New Company </span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2020, Merck announced its intention to spin-off products from its women’s health, trusted legacy brands and biosimilars businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The legacy brands included in the transaction consist of dermatology, non-opioid pain, respiratory, and select cardiovascular products including </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zetia</span><span style="font-family:inherit;font-size:10pt;"> (ezetimibe) and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Vytorin </span><span style="font-family:inherit;font-size:10pt;">(ezetimibe and simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the first half of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women’s health, legacy brands and biosimilars businesses will be reflected as discontinued operations in the Company’s consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div> <div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Acquisitions, Research Collaborations and License Agreements</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 billion</span></span><span style="font-family:inherit;font-size:10pt;"> included </span><span style="font-family:inherit;font-size:10pt;"><span>$138 million</span></span><span style="font-family:inherit;font-size:10pt;"> of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred </span><span style="font-family:inherit;font-size:10pt;"><span>$95 million</span></span><span style="font-family:inherit;font-size:10pt;"> of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative</span><span style="font-family:inherit;font-size:10pt;"> expenses in the first quarter of 2020. ArQule’s lead investigational candidate, MK-1026 (formerly ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 16, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D MK-1026 (formerly ARQ 531) </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D MK-7075 (formerly ARQ 092) </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangement for ARQ 087</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets and liabilities, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total identifiable net assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>414</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consideration transferred</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:1px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">The fair values of the identifiable intangible assets related to in-process research and development (IPR&amp;D) were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>12.5%</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. Actual cash flows are likely to be different than those assumed. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:1px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div></td></tr></table><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:0.78125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2700000000 138000000 95000000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:85%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">January 16, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D MK-1026 (formerly ARQ 531) </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D MK-7075 (formerly ARQ 092) </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangement for ARQ 087</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(434</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets and liabilities, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total identifiable net assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>414</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consideration transferred</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,690</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:13px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:1px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">The fair values of the identifiable intangible assets related to in-process research and development (IPR&amp;D) were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>12.5%</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. Actual cash flows are likely to be different than those assumed. </span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:1px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup> </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div> 145000000 2280000000 170000000 80000000 434000000 35000000 2276000000 414000000 2690000000 0.125 Collaborative Arrangements<div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AstraZeneca</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor currently approved for certain types of advanced ovarian, breast and pancreatic cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> (pembrolizumab) and Imfinzi. The companies will also jointly develop and commercialize AstraZeneca’s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications. In April 2020, Koselugo</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">was approved for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> in combination with Lynparza or </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development</span><span style="font-family:inherit;font-size:10pt;"> costs.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the agreement, Merck made an upfront payment to AstraZeneca of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in 2017 and made payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$750 million</span></span><span style="font-family:inherit;font-size:10pt;"> over a multi-year period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to 2020, Merck accrued sales-based milestone payments aggregating </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> related to Lynparza, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$200 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid to AstraZeneca in 2019 and 2018, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid in the first quarter of 2020. Potential future sales-based milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$60 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$140 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 billion</span></span><span style="font-family:inherit;font-size:10pt;"> remain under the agreement.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was </span><span style="font-family:inherit;font-size:10pt;"><span>$928 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and is included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Intangibles, Net</span><span style="font-family:inherit;font-size:10pt;"> on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information related to this collaboration is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables from AstraZeneca included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to AstraZeneca included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued and other current liabilities</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>577</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents amortization of capitalized milestone payments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes accrued milestone payments.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Eisai</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;"> for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Keytruda</span><span style="font-family:inherit;font-size:10pt;">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Research and development </span><span style="font-family:inherit;font-size:10pt;">expenses. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the agreement, Merck made an upfront payment to Eisai of </span><span style="font-family:inherit;font-size:10pt;"><span>$750 million</span></span><span style="font-family:inherit;font-size:10pt;"> and agreed to make payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$650 million</span></span><span style="font-family:inherit;font-size:10pt;"> for certain option rights through 2021 (of which </span><span style="font-family:inherit;font-size:10pt;"><span>$325 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid in March 2019, </span><span style="font-family:inherit;font-size:10pt;"><span>$200 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid in March 2020 and </span><span style="font-family:inherit;font-size:10pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:10pt;"> is expected to be paid in March 2021). In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to 2020, Merck accrued sales-based milestone payments aggregating </span><span style="font-family:inherit;font-size:10pt;"><span>$950 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to Lenvima. Of these amounts, </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid to Eisai in 2019 and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$300 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid in the first quarter of 2020. Potential future sales-based milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate from Merck to Eisai. Potential future regulatory milestone payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$135 million</span></span><span style="font-family:inherit;font-size:10pt;"> remain under the agreement.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was </span><span style="font-family:inherit;font-size:10pt;"><span>$921 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and is included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Intangibles, Net</span><span style="font-family:inherit;font-size:10pt;"> on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information related to this collaboration is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables from Eisai included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to Eisai included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued and other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to Eisai included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Noncurrent Liabilities</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents amortization of capitalized milestone payments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes accrued milestone and future option payments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes accrued milestone payments.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Bayer AG</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer’s vericiguat, which is in development for the potential treatment of worsening heart failure. Under the agreement, Bayer leads commercialization of Adempas in the Americas, while Merck leads commercialization in the rest of the world. For vericiguat, if approved, Bayer will lead commercialization in the rest of world and Merck will lead in the Americas. Both companies share in development costs and profits on sales and have the right to co-promote in territories where they are not the lead. Merck records sales of Adempas in its marketing territories, as well as alliance revenue, which is Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories. In addition, the agreement provides for additional contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to 2020, Merck accrued </span><span style="font-family:inherit;font-size:10pt;"><span>$725 million</span></span><span style="font-family:inherit;font-size:10pt;"> of sales-based milestone payments for this collaboration, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$350 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid to Bayer in 2018. There is an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$400 million</span></span><span style="font-family:inherit;font-size:10pt;"> potential future sales-based milestone payment that has not yet been accrued as it is not deemed by the Company to be probable at this time.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was </span><span style="font-family:inherit;font-size:10pt;"><span>$844 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and is included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Intangibles, Net </span><span style="font-family:inherit;font-size:10pt;">on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information related to this collaboration is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales of Adempas recorded by Merck</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total sales</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables from Bayer included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to Bayer included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Noncurrent Liabilities</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes amortization of intangible assets.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents accrued milestone payment.</span></div> 1600000000 750000000 1000000000.0 200000000 250000000 250000000 3100000000 60000000 140000000 1700000000 928000000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information related to this collaboration is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables from AstraZeneca included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to AstraZeneca included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued and other current liabilities</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>577</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents amortization of capitalized milestone payments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes accrued milestone payments.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information related to this collaboration is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables from Eisai included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to Eisai included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued and other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to Eisai included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Noncurrent Liabilities</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents amortization of capitalized milestone payments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes accrued milestone and future option payments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes accrued milestone payments.</span></div><div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized financial information related to this collaboration is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales of Adempas recorded by Merck</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Alliance revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total sales</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables from Bayer included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payables to Bayer included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Noncurrent Liabilities</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes amortization of intangible assets.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents accrued milestone payment.</span></div> 145000000 79000000 28000000 19000000 33000000 27000000 36000000 45000000 142000000 128000000 326000000 577000000 750000000 650000000 325000000 200000000 125000000 950000000 50000000 300000000 3000000000.0 250000000 135000000 921000000 128000000 74000000 35000000 51000000 11000000 19000000 64000000 47000000 140000000 150000000 425000000 700000000 300000000 525000000 725000000 350000000 400000000 844000000 56000000 48000000 53000000 42000000 109000000 90000000 28000000 29000000 15000000 8000000 25000000 30000000 50000000 49000000 375000000 375000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In early 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 billion</span></span><span style="font-family:inherit;font-size:10pt;">. The Company estimates that approximately </span><span style="font-family:inherit;font-size:10pt;"><span>60%</span></span><span style="font-family:inherit;font-size:10pt;"> of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span>40%</span></span><span style="font-family:inherit;font-size:10pt;"> of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$800 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded total pretax costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$168 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$187 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, related to restructuring program activities. Since inception of the Restructuring Program through </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, Merck has recorded total pretax accumulated costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 billion</span></span><span style="font-family:inherit;font-size:10pt;">. For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Separation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Separation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other activity in </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 10) and share-based compensation.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the charges and spending relating to restructuring program activities for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Separation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring reserves January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>690</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>759</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Payments) receipts, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-cash activity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring reserves March 31, 2020 </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>569</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>626</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div>The remaining cash outlays are expected to be substantially completed by the end of 2023. 2500000000 0.60 0.40 800000000 168000000 187000000 1100000000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Separation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:60%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Separation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>187</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 25000000 43000000 68000000 0 11000000 0 11000000 0 17000000 0 17000000 47000000 0 25000000 72000000 47000000 53000000 68000000 168000000 0 34000000 0 34000000 128000000 0 25000000 153000000 128000000 34000000 25000000 187000000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the charges and spending relating to restructuring program activities for the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Separation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring reserves January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>690</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>759</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Payments) receipts, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(290</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-cash activity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restructuring reserves March 31, 2020 </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>569</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>626</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div>The remaining cash outlays are expected to be substantially completed by the end of 2023. 690000000 0 69000000 759000000 47000000 53000000 68000000 168000000 168000000 0 122000000 290000000 0 53000000 -42000000 11000000 569000000 0 57000000 626000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Instruments</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Risk Management</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>two years</span></span><span style="font-family:inherit;font-size:10pt;"> into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;">), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;">) and reclassified into </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales</span><span style="font-family:inherit;font-size:10pt;"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales</span><span style="font-family:inherit;font-size:10pt;"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:10pt;">. The forward contracts are not designated as hedges and are marked to market through </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:10pt;">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;"> and remain in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded component). Changes in fair value of the excluded components are recognized in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;">. The Company recognizes in earnings the initial value of the excluded component on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effects of the Company’s net investment hedges on </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;"> and the Consolidated Statement of Income are shown below:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amount of Pretax (Gain) Loss Recognized in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Net Investment Hedging Relationships</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Euro-denominated notes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> No amounts were reclassified from AOCI into income related to the sale of a subsidiary.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Rate Risk Management</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2020, </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> interest rate swaps with notional amounts of </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;"> each matured. These swaps effectively converted the Company’s </span><span style="font-family:inherit;font-size:10pt;"><span>$1.25 billion</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>1.85%</span></span><span style="font-family:inherit;font-size:10pt;"> fixed-rate notes due 2020 to variable rate debt. At </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company was a party to </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>14</span></span><span style="font-family:inherit;font-size:10pt;"> pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Par Value of Debt</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Number of Interest Rate Swaps Held</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total Swap Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3.875% notes due 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2.40% notes due 2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2.35% notes due 2022</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Carrying Amount of Hedged Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Balance Sheet Line Item in which Hedged Item is Included</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loans payable and current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Long-Term Debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,315</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:22%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value of Derivative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. Dollar</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Notional</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value of Derivative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. Dollar</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Notional</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance Sheet Caption</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivatives Designated as Hedging Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,150</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accrued and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,546</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accrued and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Noncurrent Liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>363</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>12,749</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivatives Not Designated as Hedging Instruments</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accrued and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8,693</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15,938</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>27,453</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>30,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</span><span style="font-family:inherit;font-size:10pt;"> below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross amounts recognized in the condensed consolidated balance sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(89</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(89</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash collateral received</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net amounts</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>405</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other (income) expense, net </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive income (loss)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>12,057</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>10,816</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>188</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(Gain) loss on fair value hedging relationships</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Interest rate swap contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hedged items</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Impact of cash flow hedging relationships</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Foreign exchange contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amount of gain (loss) recognized in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:7.5pt;"> on derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Increase (decrease) in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Sales</span><span style="font-family:inherit;font-size:7.5pt;"> as a result of </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:7.5pt;"> reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Interest rate contracts</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amount of gain recognized in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:7.5pt;"> on derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amount of loss recognized in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:7.5pt;"> on derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Interest expense is a component of </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income Statement Caption</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivatives Not Designated as Hedging Instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sales</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company estimates </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$136 million</span></span><span style="font-family:inherit;font-size:10pt;"> of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales</span><span style="font-family:inherit;font-size:10pt;">. The amount ultimately reclassified to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales</span><span style="font-family:inherit;font-size:10pt;"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Investments in Debt and Equity Securities</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information on investments in debt and equity securities is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Value</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. government and agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign government bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate notes and bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>608</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>621</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,785</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Publicly traded equity securities </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>779</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total debt and publicly traded equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>843</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,623</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Unrealized net losses recognized in </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> on equity securities still held at </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> were </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$4 million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> in the </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">first</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> quarter of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. Unrealized net gains recognized in </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> on equity securities still held at </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March 31, 2019</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> were </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$114 million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> in the </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">first</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> quarter of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">2019</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company also had </span><span style="font-family:inherit;font-size:10pt;"><span>$450 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$542 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of equity investments without readily determinable fair values included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Assets</span><span style="font-family:inherit;font-size:10pt;">. During the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized unrealized losses of </span><span style="font-family:inherit;font-size:10pt;"><span>$9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:10pt;"> related to certain of these investments held at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> based on unfavorable observable price changes. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values still held at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$109 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$21 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1</span><span style="font-family:inherit;font-size:10pt;"> - Quoted prices (unadjusted) in active markets for identical assets or liabilities, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2</span><span style="font-family:inherit;font-size:10pt;"> - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3</span><span style="font-family:inherit;font-size:10pt;"> - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value Measurements Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">($ in millions)</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Investments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign government bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate notes and bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset-backed securities</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. government and agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Publicly traded equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>562</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other assets </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. government and agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Publicly traded equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivative assets </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Forward exchange contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Purchased currency options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>841</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>712</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,553</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>898</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivative liabilities </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Forward exchange contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Written currency options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>767</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>864</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Primarily all of the asset-backed securities were highly-rated (Standard &amp; Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>5</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> years or less. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span><span style="font-family:inherit;font-size:10pt;"> included </span><span style="font-family:inherit;font-size:10pt;"><span>$6.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.9 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contingent Consideration</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in estimated fair value</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value March 31 </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(3)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>667</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Recorded in </span><span style="font-family:inherit;font-size:8pt;">Cost of sales, Research and development</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> expenses, and </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. Includes cumulative translation adjustments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Balance at </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> includes </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$119 million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> At </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">December 31, 2019</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$520 million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$625 million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>11.5%</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>8%</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> to present value the cash flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The increase in the estimated fair value of liabilities for contingent consideration in the first quarter of 2020 primarily relates to MK-7264 (gefapixant), a program obtained in connection with the acquisition of Afferent Pharmaceuticals, following the conclusion of Phase 3 studies evaluating gefapixant for the treatment of chronic cough. The decline in the estimated fair value of liabilities for contingent consideration in the first quarter of 2019 primarily relates to a decision not to pursue an acute cough indication for gefapixant. The payments of contingent consideration in both periods relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Fair Value Measurements</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of loans payable and long-term debt (including current portion) at </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$30.6 billion</span></span><span style="font-family:inherit;font-size:10pt;"> compared with a carrying value of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$28.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and at </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$28.8 billion</span></span><span style="font-family:inherit;font-size:10pt;"> compared with a carrying value of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$26.3 billion</span></span><span style="font-family:inherit;font-size:10pt;">. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company’s accounts receivable arise from product sales in the United States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.7 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of accounts receivable in the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and the fourth quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">de minimis</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was </span><span style="font-family:inherit;font-size:10pt;"><span>$216 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$34 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. The </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obligation to return such collateral is recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued and other current liabilities</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> cash collateral was advanced by the Company to counterparties as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div> P2Y P1Y <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effects of the Company’s net investment hedges on </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;"> and the Consolidated Statement of Income are shown below:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amount of Pretax (Gain) Loss Recognized in </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Net Investment Hedging Relationships</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Euro-denominated notes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> No amounts were reclassified from AOCI into income related to the sale of a subsidiary.</span></div> 3000000 11000000 8000000 8000000 51000000 30000000 0 0 5 250000000 1250000000 0.0185 At <span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company was a party to </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>14</span></span><span style="font-family:inherit;font-size:10pt;"> pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.</span><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Par Value of Debt</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Number of Interest Rate Swaps Held</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total Swap Notional Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">3.875% notes due 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2.40% notes due 2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2.35% notes due 2022</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 14 1150000000 5 1150000000 1000000000 4 1000000000 1250000000 5 1250000000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:49%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Carrying Amount of Hedged Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Balance Sheet Line Item in which Hedged Item is Included</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loans payable and current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Long-Term Debt</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,315</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 1160000000 1249000000 11000000 -1000000 2315000000 3409000000 69000000 14000000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:22%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value of Derivative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. Dollar</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Notional</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair Value of Derivative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. Dollar</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Notional</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance Sheet Caption</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivatives Designated as Hedging Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,150</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,250</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,400</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swap contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accrued and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,546</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>6,117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accrued and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>734</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other Noncurrent Liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>363</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>12,749</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivatives Not Designated as Hedging Instruments</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10,039</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>7,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accrued and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4,665</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>8,693</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14,704</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>73</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15,938</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>27,453</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>30,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 11000000 1150000000 0 0 70000000 2250000000 15000000 3400000000 0 0 1000000 1250000000 194000000 6546000000 152000000 6117000000 88000000 2064000000 55000000 2160000000 7000000 734000000 22000000 1748000000 1000000 5000000 1000000 53000000 363000000 8000000 12749000000 222000000 24000000 14728000000 347000000 10039000000 66000000 7245000000 85000000 4665000000 73000000 8693000000 347000000 85000000 14704000000 66000000 73000000 15938000000 710000000 93000000 27453000000 288000000 97000000 30666000000 The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Liability</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross amounts recognized in the condensed consolidated balance sheet</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(89</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(89</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash collateral received</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net amounts</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>405</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 710000000 93000000 288000000 97000000 89000000 89000000 84000000 84000000 216000000 0 34000000 0 405000000 4000000 170000000 13000000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other (income) expense, net </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive income (loss)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>12,057</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>10,816</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>188</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">(Gain) loss on fair value hedging relationships</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Interest rate swap contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Hedged items</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Impact of cash flow hedging relationships</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Foreign exchange contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amount of gain (loss) recognized in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:7.5pt;"> on derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Increase (decrease) in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Sales</span><span style="font-family:inherit;font-size:7.5pt;"> as a result of </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:7.5pt;"> reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Interest rate contracts</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amount of gain recognized in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:7.5pt;"> on derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:24px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Amount of loss recognized in </span><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:7.5pt;"> on derivatives</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Interest expense is a component of </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net.</span></div> 12057000000 10816000000 -71000000 -188000000 -198000000 199000000 -67000000 -33000000 67000000 23000000 178000000 -13000000 46000000 44000000 -46000000 -44000000 -1000000 -1000000 -1000000 -4000000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:58%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income Statement Caption</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivatives Not Designated as Hedging Instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts</span><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign exchange contracts </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sales</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div> 180000000 -118000000 7000000 -10000000 136000000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information on investments in debt and equity securities is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Value</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortized</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. government and agency securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign government bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate notes and bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>608</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>621</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset-backed securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,785</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Publicly traded equity securities </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>779</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total debt and publicly traded equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>843</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,623</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Unrealized net losses recognized in </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> on equity securities still held at </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> were </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$4 million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> in the </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">first</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> quarter of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. Unrealized net gains recognized in </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> on equity securities still held at </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March 31, 2019</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> were </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$114 million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> in the </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">first</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> quarter of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">2019</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div> 62000000 0 0 62000000 266000000 3000000 0 269000000 2000000 0 0 2000000 0 0 0 0 0 0 0 0 668000000 0 0 668000000 0 0 0 0 608000000 13000000 0 621000000 0 0 0 0 226000000 1000000 0 227000000 64000000 0 0 64000000 1768000000 17000000 0 1785000000 779000000 838000000 843000000 2623000000 -4000000 114000000 450000000 542000000 9000000 109000000 21000000 <div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value Measurements Using</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Fair Value Measurements Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Level 3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;font-style:italic;">($ in millions)</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:inherit;font-size:7.5pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Investments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Foreign government bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Corporate notes and bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Asset-backed securities</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. government and agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Publicly traded equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>560</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>562</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other assets </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S. government and agency securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Publicly traded equity securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivative assets </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Forward exchange contracts</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Purchased currency options</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>841</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>712</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,553</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>898</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,911</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Other liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>767</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Derivative liabilities </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Forward exchange contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Written currency options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest rate swaps</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>787</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>767</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>864</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Primarily all of the asset-backed securities were highly-rated (Standard &amp; Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>5</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> years or less. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup> </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div> 0 2000000 0 2000000 0 0 0 0 0 0 0 0 0 668000000 0 668000000 0 0 0 0 0 621000000 0 621000000 0 0 0 0 0 227000000 0 227000000 0 0 0 0 0 209000000 0 209000000 560000000 0 0 560000000 518000000 0 0 518000000 560000000 2000000 0 562000000 518000000 1725000000 0 2243000000 62000000 0 0 62000000 60000000 0 0 60000000 219000000 0 0 219000000 320000000 0 0 320000000 281000000 0 0 281000000 380000000 0 0 380000000 0 455000000 0 455000000 0 169000000 0 169000000 0 174000000 0 174000000 0 104000000 0 104000000 0 81000000 0 81000000 0 15000000 0 15000000 0 710000000 0 710000000 0 288000000 0 288000000 841000000 712000000 0 1553000000 898000000 2013000000 0 2911000000 0 0 694000000 694000000 0 0 767000000 767000000 0 90000000 0 90000000 0 95000000 0 95000000 0 3000000 0 3000000 0 1000000 0 1000000 0 0 0 0 0 1000000 0 1000000 0 93000000 0 93000000 0 97000000 0 97000000 0 93000000 694000000 787000000 0 97000000 767000000 864000000 P5Y 6800000000 8900000000 <div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value January 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in estimated fair value</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value March 31 </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)(3)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>694</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>667</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Recorded in </span><span style="font-family:inherit;font-size:8pt;">Cost of sales, Research and development</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> expenses, and </span><span style="font-family:inherit;font-size:8pt;">Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. Includes cumulative translation adjustments.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> Balance at </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> includes </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$119 million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> At </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">December 31, 2019</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">, </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$520 million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> and </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>$625 million</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>11.5%</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><span>8%</span></span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> to present value the cash flows.</span></div> 767000000 788000000 33000000 -36000000 106000000 85000000 694000000 667000000 119000000 520000000 625000000 0.115 0.08 30600000000 28000000000.0 28800000000 26300000000 1900000000 2700000000 216000000 34000000 0 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</span></div><div style="line-height:120%;padding-top:6px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consisted of:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,772</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,629</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total (approximates current cost)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,614</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,629</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decrease to LIFO cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(138</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(171</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,476</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,458</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognized as:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts recognized as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Assets</span><span style="font-family:inherit;font-size:10pt;"> are comprised almost entirely of raw materials and work in process inventories. At </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, these amounts included </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 billion</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of inventories not expected to be sold within one year. In addition, these amounts included </span><span style="font-family:inherit;font-size:10pt;"><span>$258 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$168 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, of inventories produced in preparation for product launches.</span></div> <div style="line-height:120%;padding-top:6px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories consisted of:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,772</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials and work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,629</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>207</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total (approximates current cost)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,614</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,629</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Decrease to LIFO cost</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(138</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(171</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,476</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,458</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Recognized as:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,846</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,978</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,630</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,480</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1753000000 1772000000 5629000000 5650000000 232000000 207000000 7614000000 7629000000 138000000 171000000 7476000000 7458000000 5846000000 5978000000 1630000000 1480000000 1400000000 1300000000 258000000 168000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Liability Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fosamax</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fosamax</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fosamax</span><span style="font-family:inherit;font-size:10pt;"> Litigation). As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>3,590</span></span><span style="font-family:inherit;font-size:10pt;"> cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fosamax</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Glynn v. Merck</span><span style="font-family:inherit;font-size:10pt;">, the jury returned a verdict in Merck’s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck’s </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">motion for judgment as a matter of law in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Glynn</span><span style="font-family:inherit;font-size:10pt;"> case and held that the plaintiff’s failure to warn claim was preempted by federal law.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court’s preemption decision in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Glynn</span><span style="font-family:inherit;font-size:10pt;"> case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately </span><span style="font-family:inherit;font-size:10pt;"><span>650</span></span><span style="font-family:inherit;font-size:10pt;"> cases on preemption grounds. Plaintiffs in approximately </span><span style="font-family:inherit;font-size:10pt;"><span>515</span></span><span style="font-family:inherit;font-size:10pt;"> of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Merck filed its initial brief on February 21, 2020, as required by the District Court.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accordingly, as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>970</span></span><span style="font-family:inherit;font-size:10pt;"> cases were actively pending in the Femur Fracture MDL.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>2,345</span></span><span style="font-family:inherit;font-size:10pt;"> cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>275</span></span><span style="font-family:inherit;font-size:10pt;"> cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, there are </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>four</span></span><span style="font-family:inherit;font-size:10pt;"> Femur Fracture cases pending in other state courts.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits. </span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia/Janumet</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia</span><span style="font-family:inherit;font-size:10pt;"> and/or </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, Merck is aware of approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>1,410</span></span><span style="font-family:inherit;font-size:10pt;"> product users alleging that </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia</span><span style="font-family:inherit;font-size:10pt;"> and/or </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;"> caused the development of pancreatic cancer and other injuries. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2015, the MDL and California State Court–in separate opinions–granted summary judgment to defendants on grounds of federal preemption.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceeding agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Daubert </span><span style="font-family:inherit;font-size:10pt;">motions. Under the stipulated case management schedule, the hearings for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Daubert</span><span style="font-family:inherit;font-size:10pt;"> and summary judgment motions are expected to take place in the second half of 2020.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>six</span></span><span style="font-family:inherit;font-size:10pt;"> product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck’s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Merck Sharp &amp; Dohme Corp. v. Albrecht </span><span style="font-family:inherit;font-size:10pt;">(relating to the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Fosamax</span><span style="font-family:inherit;font-size:10pt;"> matter discussed above). Merck filed the opinion in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Albrecht</span><span style="font-family:inherit;font-size:10pt;"> with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Albrecht</span><span style="font-family:inherit;font-size:10pt;">, that preemption presents a legal question to be resolved by the court.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>50</span></span><span style="font-family:inherit;font-size:10pt;"> additional claims. The Company intends to continue defending against these lawsuits.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Vioxx</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, Merck is a defendant in a lawsuit brought by the Attorney General of Utah alleging that Merck misrepresented the safety of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Vioxx</span><span style="font-family:inherit;font-size:10pt;">. The lawsuit is pending in Utah state court. Utah seeks damages and penalties under the Utah False Claims Act. A bench trial in this matter has been rescheduled for April 6, 2021.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Governmental Proceedings</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, in April 2019, Merck received a set of investigative interrogatories from the California Attorney General’s Office pursuant to its investigation of conduct and agreements that allegedly affected or delayed competition to Lantus in the insulin market. The interrogatories seek information concerning Merck’s development of an insulin glargine product, and its subsequent termination, as well as Merck’s patent litigation against Sanofi S.A. concerning Lantus and the resolution of that litigation. In February 2020, Merck received a subpoena for documents. Merck is cooperating with the California Attorney General’s investigation.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, the Company’s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Commercial and Other Litigation</span></div><div style="line-height:174%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zetia</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Antitrust Litigation</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zetia</span><span style="font-family:inherit;font-size:10pt;"> alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants’ motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants’ motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants’ motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. The Merck Defendants moved to dismiss the new allegations in both complaints. In October 2019, the magistrate judge issued a report and recommendation recommending that the district judge grant the motions in their entirety. In December 2019, the district court adopted this report and recommendation in part. The district court granted the Merck Defendants’ motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. Trial in this matter has been rescheduled to begin on February 23, 2021.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bravecto Litigation</span></div><div style="line-height:120%;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, the Company was served with a complaint in the United States District Court for the District of New Jersey, seeking to certify a nationwide class action of purchasers or users of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bravecto</span><span style="font-family:inherit;font-size:10pt;"> (fluralaner) products in the United States or its territories between May 1, 2014 and December 27, 2019. The complaint contends </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bravecto</span><span style="font-family:inherit;font-size:10pt;"> causes neurological events and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. A similar case was filed in Quebec, Canada in May 2019.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Patent Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the U.S. Food and Drug Administration (FDA) seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bridion </span><span style="font-family:inherit;font-size:10pt;">—</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Between January and March 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bridion</span><span style="font-family:inherit;font-size:10pt;"> (sugammadex) Injection. In March and April 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier. No schedule for the cases has been set by the courts.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia, Janumet, Janumet XR</span><span style="font-family:inherit;font-size:10pt;"> — In February 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of a patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Januvia</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet XR</span><span style="font-family:inherit;font-size:10pt;"> following expiration of key patent protection in 2022, but prior to the expiration of the later-granted patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026, and a later granted patent owned by the Company covering the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;"> formulation which expires in 2028. Par Pharmaceutical dismissed its case in the U.S. District Court for the District of New Jersey against the Company and will litigate the action in the U.S. District Court for the District of Delaware. The Company filed a patent infringement lawsuit against Mylan Pharmaceuticals Inc. and Mylan Inc. (Mylan) in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. In February 2020, the Company amended its complaint against one defendant, Teva Pharmaceuticals USA, Inc., to add patent infringement claims related to a patent that expires in 2025 and covers certain processes for manufacturing sitagliptin. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single 3-day trial on invalidity issues in October 2021. The Court will schedule separate 1-day trials on infringement issues if necessary. In the Company’s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has settled with three generic companies such that these generic companies can bring their products to the market in November 2026 or earlier under certain circumstances.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2019, Mylan filed a petition for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Inter Partes</span><span style="font-family:inherit;font-size:10pt;"> Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of the 2026 patent. The Company filed a Patent Owner Preliminary Response in the IPR proceeding in February 2020. The Company expects the USPTO to determine whether it will institute the IPR proceeding in May 2020.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In Germany, a generic company has sought the revocation of the Supplementary Protection Certificate (SPC) for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;">. If the generic company is successful, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet</span><span style="font-family:inherit;font-size:10pt;"> could lose market exclusivity in Germany as early as July 2022. It is possible that challenges to the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Janumet </span><span style="font-family:inherit;font-size:10pt;">SPC could occur in other European countries.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Litigation</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Defense Reserves</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> of approximately </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$255 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$240 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div> Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. 3590 650 515 970 2345 275 4 1410 6 50 255000000 240000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:31%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="vertical-align:middle;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;vertical-align:middle;">  </span></div><div style="text-align:center;vertical-align:middle;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;vertical-align:middle;">Common Stock</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Paid-In</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Capital</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Earnings</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loss</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">controlling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interests</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ and shares in millions except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Shares</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Par Value</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Shares</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,577</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>38,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>42,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5,545</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>985</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(50,929</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income attributable to Merck &amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other comprehensive income, net of taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash dividends declared on common stock ($0.55 per share)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,429</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,429</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treasury stock shares purchased</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,090</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,090</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Share-based compensation plans and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>283</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other changes in noncontrolling ownership interests</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,577</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,788</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>38,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>44,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>994</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(51,736</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>27,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,577</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,788</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>39,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>46,602</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6,193</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,038</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(55,950</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26,001</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income attributable to Merck &amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other comprehensive loss, net of taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(198</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(198</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash dividends declared on common stock ($0.61 per share)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treasury stock shares purchased</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,281</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,281</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Share-based compensation plans and other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other changes in noncontrolling ownership interests</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,577</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,788</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>39,697</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>48,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,053</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(57,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.6640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"/></tr><tr><td style="width:31%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="vertical-align:middle;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;vertical-align:middle;">  </span></div><div style="text-align:center;vertical-align:middle;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;vertical-align:middle;">Common Stock</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Paid-In</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Capital</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Retained</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Earnings</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loss</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">controlling</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interests</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ and shares in millions except per share amounts)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Shares</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Par Value</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Shares</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cost</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,577</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>38,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>42,579</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5,545</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>985</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(50,929</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26,882</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income attributable to Merck &amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>2,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other comprehensive income, net of taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash dividends declared on common stock ($0.55 per share)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,429</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,429</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treasury stock shares purchased</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,090</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,090</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Share-based compensation plans and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>283</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other changes in noncontrolling ownership interests</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at March 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,577</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,788</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>38,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>44,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(5,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>994</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(51,736</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>27,670</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at January 1, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,577</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,788</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>39,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>46,602</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6,193</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,038</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(55,950</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26,001</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net income attributable to Merck &amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other comprehensive loss, net of taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(198</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(198</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash dividends declared on common stock ($0.61 per share)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Treasury stock shares purchased</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,281</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1,281</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Share-based compensation plans and other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other changes in noncontrolling ownership interests</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Balance at March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>3,577</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,788</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>39,697</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>48,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(6,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>1,053</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(57,161</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>26,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:30.6640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3577000000 1788000000 38808000000 42579000000 -5545000000 985000000 -50929000000 181000000 26882000000 2915000000 2915000000 199000000 199000000 1429000000 1429000000 14000000 1090000000 1090000000 40000000 5000000 -283000000 -243000000 -53000000 -53000000 3000000 3000000 3577000000 1788000000 38768000000 44065000000 -5346000000 994000000 -51736000000 131000000 27670000000 3577000000 1788000000 39660000000 46602000000 -6193000000 1038000000 -55950000000 94000000 26001000000 3219000000 3219000000 -198000000 -198000000 1549000000 1549000000 16000000 1281000000 1281000000 -37000000 1000000 -70000000 -107000000 1000000 1000000 3577000000 1788000000 39697000000 48272000000 -6391000000 1053000000 -57161000000 95000000 26300000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Share-Based Compensation Plans</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant.</span></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pretax share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total share-based compensation expense, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, the Company granted </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>58 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> RSUs with a weighted-average grant date fair value of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$85.66</span></span><span style="font-family:inherit;font-size:10pt;"> per RSU and during the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> granted </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>70 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> RSUs with a weighted-average grant date fair value of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$77.39</span></span><span style="font-family:inherit;font-size:10pt;"> per RSU. During the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>770 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> PSUs with a weighted-average grant date fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$75.65</span></span><span style="font-family:inherit;font-size:10pt;"> per PSU and during the first </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> granted </span><span style="font-family:inherit;font-size:10pt;"><span>609 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> PSUs with a weighted-average grant date fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$90.50</span></span><span style="font-family:inherit;font-size:10pt;"> per PSU. The Company did not grant any stock options during the first three months of 2020 or 2019. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.4 years</span></span><span style="font-family:inherit;font-size:10pt;">. The Company typically communicates the value of annual share-based compensation awards to employees during the first quarter, but the related share amounts are not established and communicated until early May. Therefore, while the number of RSU, PSU and stock option grants disclosed above do not reflect any amounts relating to the annual grants, share-based compensation costs for the first quarter of 2020 and 2019 and unrecognized compensation expense at March 31, 2020 reflect an impact relating to the awards communicated to employees. For segment reporting, share-based compensation costs are unallocated expenses.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.84375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">  </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pretax share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax benefit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total share-based compensation expense, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 108000000 93000000 15000000 14000000 93000000 79000000 58000 85.66 70000 77.39 770000 75.65 609000 90.50 The Company did not grant any stock options during the first three months of 2020 or 2019. <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.4 years</span></span><span style="font-family:inherit;font-size:10pt;">. The Company typically communicates the value of annual share-based compensation awards to employees during the first quarter, but the related share amounts are not established and communicated until early May. Therefore, while the number of RSU, PSU and stock option grants disclosed above do not reflect any amounts relating to the annual grants, share-based compensation costs for the first quarter of 2020 and 2019 and unrecognized compensation expense at March 31, 2020 reflect an impact relating to the awards communicated to employees. For segment reporting, share-based compensation costs are unallocated expenses.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.84375%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">  </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1100000000 P2Y4M24D <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pension and Other Postretirement Benefit Plans</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">  </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">International</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(103</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(206</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Curtailments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">  </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring actions, curtailments were recorded on pension plans as reflected in the tables above.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other (income) expense, net</span><span style="font-family:inherit;font-size:10pt;"> (see Note 11), with the exception of certain amounts for termination benefits and curtailments, which are recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restructuring costs</span><span style="font-family:inherit;font-size:10pt;"> if the event giving rise to the termination benefits or curtailment is related to restructuring actions as noted above.</span></div> <div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">  </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">International</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(194</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(103</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(206</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(108</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Termination benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Curtailments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 86000000 74000000 71000000 60000000 109000000 34000000 114000000 45000000 194000000 103000000 206000000 108000000 -12000000 -3000000 -12000000 -3000000 -75000000 -31000000 -35000000 -16000000 3000000 1000000 2000000 0 -2000000 1000000 0 0 69000000 33000000 4000000 10000000 <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:83%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">  </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected return on plan assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 13000000 12000000 14000000 17000000 19000000 18000000 -22000000 -21000000 -14000000 -10000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other (Income) Expense, Net</span></div><div style="line-height:120%;padding-top:6px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net, consisted of:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exchange losses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss from investments in equity securities, net </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic defined benefit plan (credit) cost other than service cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>188</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. </span></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The higher exchange losses in the first quarter of 2019 reflect losses on forward exchange contracts related to the acquisition of Antelliq Corporation.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net (as reflected in the table above) in the first quarter of 2019 includes </span><span style="font-family:inherit;font-size:10pt;"><span>$84 million</span></span><span style="font-family:inherit;font-size:10pt;"> of goodwill impairment charges related to certain businesses in the Healthcare Services segment. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest paid for the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>$195 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> <div style="line-height:120%;padding-top:6px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) expense, net, consisted of:</span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(89</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exchange losses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss from investments in equity securities, net </span><span style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net periodic defined benefit plan (credit) cost other than service cost</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>188</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. </span></div> 25000000 89000000 212000000 209000000 -54000000 -101000000 52000000 -25000000 -90000000 -141000000 28000000 -83000000 -71000000 -188000000 84000000 250000000 195000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Taxes on Income</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The effective income tax rates of </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"><span>16.1%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>6.7%</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. In addition, the effective income tax rate for the first quarter of 2019 reflects the favorable impact of a </span><span style="font-family:inherit;font-size:10pt;"><span>$360 million</span></span><span style="font-family:inherit;font-size:10pt;"> net tax benefit related to the settlement of certain federal income tax matters. </span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$107 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$360 million</span></span><span style="font-family:inherit;font-size:10pt;"> net tax benefit in the first quarter of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.</span></div> 0.161 0.067 360000000 107000000 360000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Earnings Per Share</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The calculations of earnings per share are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ and shares in millions except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Merck &amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,915</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,533</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,585</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common shares issuable </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average common shares outstanding assuming dilution </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,547</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.26</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Issuable primarily under share-based compensation plans.</span></div></td></tr></table><span style="font-family:inherit;font-size:10pt;">For both the </span><span style="font-family:inherit;font-size:10pt;">first</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>2 million</span></span> of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive. <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The calculations of earnings per share are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ and shares in millions except per share amounts)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to Merck &amp; Co., Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,219</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,915</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average common shares outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,533</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,585</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common shares issuable </span><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Average common shares outstanding assuming dilution </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,547</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.26</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Issuable primarily under share-based compensation plans.</span></div> 3219000000 2915000000 2533000000 2585000000 14000000 18000000 2547000000 2603000000 1.27 1.13 1.26 1.12 2000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Comprehensive Income (Loss)</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> by component are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivatives</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Investments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Employee</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Benefit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Plans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cumulative</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Translation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Adjustment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accumulated Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income (Loss)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance January 1, 2019, net of taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2,077</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5,545</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss), net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance March 31, 2019, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3,541</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,927</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance January 1, 2020, net of taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4,261</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,981</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(6,193</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(344</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss), net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(344</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(198</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance March 31, 2020, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>135</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(6,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Relates to foreign currency cash flow hedges that were reclassified from </span><span style="font-family:inherit;font-size:8pt;">AOCI</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> to </span><span style="font-family:inherit;font-size:8pt;">Sales</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from </span><span style="font-family:inherit;font-size:8pt;">AOCI </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">to</span><span style="font-family:inherit;font-size:8pt;"> Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. </span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 10).</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:39.453125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> by component are as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Derivatives</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Investments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Employee</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Benefit</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Plans</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cumulative</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Translation</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Adjustment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accumulated Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Comprehensive</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income (Loss)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance January 1, 2019, net of taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3,556</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2,077</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5,545</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>218</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss), net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(48</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance March 31, 2019, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3,541</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,927</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(5,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance January 1, 2020, net of taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4,261</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,981</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(6,193</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>178</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(344</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(195</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, pretax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Tax</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Reclassification adjustments, net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss), net of taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(18</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(344</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(198</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance March 31, 2020, net of taxes</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>135</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(2,325</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(6,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">Relates to foreign currency cash flow hedges that were reclassified from </span><span style="font-family:inherit;font-size:8pt;">AOCI</span><span style="font-family:inherit;font-size:8pt;font-style:italic;"> to </span><span style="font-family:inherit;font-size:8pt;">Sales</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from </span><span style="font-family:inherit;font-size:8pt;">AOCI </span><span style="font-family:inherit;font-size:8pt;font-style:italic;">to</span><span style="font-family:inherit;font-size:8pt;"> Other (income) expense, net</span><span style="font-family:inherit;font-size:8pt;font-style:italic;">. </span></div><div style="line-height:120%;padding-top:4px;text-align:justify;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3) </sup></span><span style="font-family:inherit;font-size:8pt;font-style:italic;">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 10).</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:39.453125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"/></tr><tr><td style="width:100%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 166000000 -78000000 -3556000000 -2077000000 -5545000000 -13000000 76000000 -1000000 156000000 218000000 -3000000 0 -6000000 6000000 -3000000 -10000000 76000000 5000000 150000000 221000000 48000000 -6000000 -14000000 0 28000000 10000000 0 -4000000 0 6000000 38000000 -6000000 -10000000 0 22000000 -48000000 82000000 15000000 150000000 199000000 118000000 4000000 -3541000000 -1927000000 -5346000000 31000000 18000000 -4261000000 -1981000000 -6193000000 178000000 3000000 0 -333000000 -152000000 37000000 0 -5000000 11000000 43000000 141000000 3000000 5000000 -344000000 -195000000 47000000 21000000 -69000000 0 -1000000 10000000 0 -14000000 0 -4000000 37000000 21000000 -55000000 0 3000000 104000000 -18000000 60000000 -344000000 -198000000 135000000 0 -4201000000 -2325000000 -6391000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Segment Reporting</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s operations are principally managed on a products basis and include </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> operating segments, which are the Pharmaceutical, Animal Health and Healthcare Services segments. The Pharmaceutical and Animal Health segments are the only reportable segments. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Healthcare Services segment provided services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company has been in the process of divesting the businesses in the Healthcare Services segment. The remaining businesses were divested during the first quarter of 2020.</span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of the Company’s products were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"> ($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">U.S.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Int’l</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">U.S.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Int’l</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Pharmaceutical:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Oncology</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Keytruda</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3,284</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,284</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>985</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2,269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Alliance revenue - Lynparza</span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Alliance revenue - Lenvima</span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Emend</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Vaccines</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Gardasil/Gardasil </span><span style="font-family:inherit;font-size:7pt;">9</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>461</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>636</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>362</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>838</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">ProQuad/M-M-R </span><span style="font-family:inherit;font-size:7pt;">II</span><span style="font-family:inherit;font-size:7pt;font-style:italic;">/Varivax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>435</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Pneumovax </span><span style="font-family:inherit;font-size:7pt;">23</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">RotaTeq</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Vaqta</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Hospital Acute Care</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Bridion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Noxafil</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Invanz</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Prevymis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Cancidas</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Primaxin</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Cubicin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Zerbaxa</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Immunology</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Simponi</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Remicade</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Neuroscience</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Belsomra</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Virology</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Isentress/Isentress</span><span style="font-family:inherit;font-size:7pt;"> </span><span style="font-family:inherit;font-size:7pt;font-style:italic;">HD</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Zepatier</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Cardiovascular</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Zetia</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Vytorin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Atozet</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Adempas</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Alliance revenue - Adempas </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Diabetes</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Januvia</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>384</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>824</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Janumet</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>364</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Women’s Health</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Implanon/Nexplanon</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">NuvaRing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>185</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Diversified Brands</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Singulair</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Cozaar/Hyzaar</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Nasonex</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Arcoxia</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Follistim AQ</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other pharmaceutical </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>409</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>780</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>328</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>754</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total Pharmaceutical segment sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>4,714</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>10,655</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>4,215</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5,448</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>9,663</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Animal Health:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Livestock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>577</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>739</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Companion Animals</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>253</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>414</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total Animal Health segment sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>384</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>294</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>731</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other segment sales </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total segment sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6,771</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>11,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>4,548</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>10,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>12,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>4,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6,261</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>10,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">U.S. plus international may not equal total due to rounding.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. Other in the first quarter of 2020 and 2019 also includes approximately </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><span>$75 million</span></span><span style="font-family:inherit;font-size:7pt;font-style:italic;"> and </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><span>$15 million</span></span><span style="font-family:inherit;font-size:7pt;font-style:italic;">, respectively, related to the sale of the marketing rights for certain products.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 billion</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consolidated sales by geographic area where derived are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,555</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe, Middle East and Africa</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,534</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>864</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia Pacific (other than China and Japan)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>728</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Latin America</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>556</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of segment profits to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income before taxes</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment profits:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical segment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Animal Health segment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other segment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment profits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,956</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other profits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unallocated:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(381</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(359</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,843</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of purchase accounting adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(295</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(397</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other unallocated, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.</span></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div> 3 <div style="line-height:120%;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of the Company’s products were as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"> ($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">U.S.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Int’l</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">U.S.</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Int’l</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Pharmaceutical:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Oncology</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Keytruda</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3,284</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,284</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>985</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2,269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Alliance revenue - Lynparza</span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>85</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Alliance revenue - Lenvima</span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> (1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Emend</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Vaccines</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Gardasil/Gardasil </span><span style="font-family:inherit;font-size:7pt;">9</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>461</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>636</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>362</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>476</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>838</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">ProQuad/M-M-R </span><span style="font-family:inherit;font-size:7pt;">II</span><span style="font-family:inherit;font-size:7pt;font-style:italic;">/Varivax</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>333</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>435</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Pneumovax </span><span style="font-family:inherit;font-size:7pt;">23</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">RotaTeq</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Vaqta</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Hospital Acute Care</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Bridion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Noxafil</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Invanz</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Prevymis</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Cancidas</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Primaxin</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Cubicin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Zerbaxa</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Immunology</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Simponi</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Remicade</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Neuroscience</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Belsomra</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Virology</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Isentress/Isentress</span><span style="font-family:inherit;font-size:7pt;"> </span><span style="font-family:inherit;font-size:7pt;font-style:italic;">HD</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>108</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>255</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Zepatier</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Cardiovascular</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Zetia</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Vytorin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Atozet</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>122</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Adempas</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Alliance revenue - Adempas </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Diabetes</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Januvia</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>774</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>384</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>824</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Janumet</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>364</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Women’s Health</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Implanon/Nexplanon</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">NuvaRing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>185</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>219</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Diversified Brands</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Singulair</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>151</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>191</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Cozaar/Hyzaar</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>99</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Nasonex</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Arcoxia</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Follistim AQ</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other pharmaceutical </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>409</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>780</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>328</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>754</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total Pharmaceutical segment sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>4,714</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>10,655</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>4,215</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5,448</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>9,663</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Animal Health:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Livestock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>577</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>739</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>117</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>611</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Companion Animals</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>253</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>414</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total Animal Health segment sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>384</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>294</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>731</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other segment sales </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Total segment sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6,771</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>11,892</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>4,548</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6,179</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>10,727</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other </span><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>5,137</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>12,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>4,555</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>6,261</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>10,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">U.S. plus international may not equal total due to rounding.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-style:italic;">Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020. </span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:inherit;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup> </span></div>Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. 1906000000 1378000000 3284000000 1284000000 985000000 2269000000 85000000 60000000 145000000 50000000 29000000 79000000 90000000 38000000 128000000 50000000 24000000 74000000 5000000 38000000 43000000 63000000 53000000 117000000 461000000 636000000 1097000000 362000000 476000000 838000000 333000000 102000000 435000000 343000000 153000000 496000000 182000000 75000000 256000000 125000000 59000000 185000000 140000000 82000000 222000000 154000000 57000000 211000000 30000000 30000000 60000000 29000000 18000000 47000000 143000000 157000000 299000000 119000000 136000000 255000000 8000000 87000000 94000000 91000000 99000000 190000000 6000000 59000000 64000000 14000000 58000000 72000000 26000000 33000000 60000000 18000000 14000000 32000000 3000000 52000000 55000000 1000000 60000000 61000000 0 51000000 51000000 0 59000000 59000000 15000000 31000000 46000000 42000000 46000000 88000000 20000000 16000000 37000000 12000000 14000000 26000000 0 215000000 215000000 0 208000000 208000000 0 88000000 88000000 0 123000000 123000000 27000000 53000000 79000000 24000000 44000000 67000000 75000000 170000000 245000000 108000000 147000000 255000000 18000000 37000000 55000000 33000000 81000000 114000000 -2000000 147000000 145000000 0 140000000 140000000 3000000 50000000 53000000 3000000 94000000 97000000 0 122000000 122000000 0 94000000 94000000 0 56000000 56000000 0 48000000 48000000 49000000 5000000 53000000 40000000 2000000 42000000 355000000 419000000 774000000 384000000 440000000 824000000 113000000 390000000 503000000 167000000 364000000 530000000 149000000 45000000 195000000 149000000 50000000 199000000 26000000 37000000 63000000 185000000 34000000 219000000 5000000 151000000 155000000 5000000 186000000 191000000 7000000 95000000 102000000 4000000 99000000 103000000 6000000 65000000 71000000 -1000000 97000000 96000000 0 70000000 70000000 0 75000000 75000000 21000000 21000000 41000000 29000000 28000000 57000000 409000000 780000000 1194000000 328000000 754000000 1082000000 4714000000 5941000000 10655000000 4215000000 5448000000 9663000000 162000000 577000000 739000000 117000000 494000000 611000000 222000000 253000000 475000000 177000000 237000000 414000000 384000000 830000000 1214000000 294000000 731000000 1025000000 23000000 0 23000000 39000000 0 39000000 5121000000 6771000000 11892000000 4548000000 6179000000 10727000000 16000000 149000000 165000000 7000000 82000000 89000000 5137000000 6920000000 12057000000 4555000000 6261000000 10816000000 75000000 15000000 3200000000 2600000000 <div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consolidated sales by geographic area where derived are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,555</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe, Middle East and Africa</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,534</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>864</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>811</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia Pacific (other than China and Japan)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>728</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Latin America</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>556</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>427</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,816</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5137000000 4555000000 3534000000 3103000000 864000000 746000000 811000000 799000000 728000000 745000000 556000000 561000000 427000000 307000000 12057000000 10816000000 <div style="line-height:120%;padding-top:8px;text-indent:60px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of segment profits to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income before taxes</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:81%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Three Months Ended <br/> March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-style:italic;">($ in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment profits:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical segment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,574</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Animal Health segment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other segment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment profits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,956</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,991</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other profits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unallocated:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(381</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(359</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,097</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,843</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of purchase accounting adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(295</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(397</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(72</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other unallocated, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,067</span></span></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 7477000000 6574000000 478000000 415000000 1000000 2000000 7956000000 6991000000 139000000 30000000 25000000 89000000 212000000 209000000 381000000 359000000 2097000000 1843000000 295000000 397000000 72000000 153000000 1225000000 1082000000 3838000000 3067000000 XML 71 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Equity (Tables)
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Equity
 
Three Months Ended March 31,
 
  
Common Stock
Other
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests
Total
($ and shares in millions except per share amounts)
Shares
Par Value
Shares
Cost
Balance at January 1, 2019
3,577

$
1,788

$
38,808

$
42,579

$
(5,545
)
985

$
(50,929
)
$
181

$
26,882

Net income attributable to Merck & Co., Inc.
—

—

—

2,915

—

—

—

—

2,915

Other comprehensive income, net of taxes
—

—

—

—

199

—

—

—

199

Cash dividends declared on common stock ($0.55 per share)
—

—

—

(1,429
)
—

—

—

—

(1,429
)
Treasury stock shares purchased
—

—

—

—

—

14

(1,090
)
—

(1,090
)
Share-based compensation plans and other
—

—

(40
)
—

—

(5
)
283

—

243

Net loss attributable to noncontrolling interests
—

—

—

—

—

—

—

(53
)
(53
)
Other changes in noncontrolling ownership interests
—

—

—

—

—

—

—

3

3

Balance at March 31, 2019
3,577

$
1,788

$
38,768

$
44,065

$
(5,346
)
994

$
(51,736
)
$
131

$
27,670

Balance at January 1, 2020
3,577

$
1,788

$
39,660

$
46,602

$
(6,193
)
1,038

$
(55,950
)
$
94

$
26,001

Net income attributable to Merck & Co., Inc.
—

—

—

3,219

—

—

—

—

3,219

Other comprehensive loss, net of taxes
—

—

—

—

(198
)
—

—

—

(198
)
Cash dividends declared on common stock ($0.61 per share)
—

—

—

(1,549
)
—

—

—

—

(1,549
)
Treasury stock shares purchased
—

—

—

—

—

16

(1,281
)
—

(1,281
)
Share-based compensation plans and other
—

—

37

—

—

(1
)
70

—

107

Other changes in noncontrolling ownership interests
—

—

—

—

—

—

—

1

1

Balance at March 31, 2020
3,577

$
1,788

$
39,697

$
48,272

$
(6,391
)
1,053

$
(57,161
)
$
95

$
26,300

 
XML 72 R34.htm IDEA: XBRL DOCUMENT v3.20.1
Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2020
Earnings Per Share [Abstract]  
Calculations of Earnings Per Share
The calculations of earnings per share are as follows:
 
Three Months Ended 
 March 31,
($ and shares in millions except per share amounts)
2020
 
2019
Net income attributable to Merck & Co., Inc.
$
3,219

 
$
2,915

Average common shares outstanding
2,533

 
2,585

Common shares issuable (1)
14

 
18

Average common shares outstanding assuming dilution
2,547

 
2,603

Basic earnings per common share attributable to Merck & Co., Inc. common shareholders
$
1.27

 
$
1.13

Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders
$
1.26

 
$
1.12

(1) 
Issuable primarily under share-based compensation plans.
XML 73 R38.htm IDEA: XBRL DOCUMENT v3.20.1
Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)
$ in Millions
Mar. 31, 2020
USD ($)
Jan. 16, 2020
USD ($)
Dec. 31, 2019
USD ($)
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]      
Goodwill $ 19,767   $ 19,425
ArQule      
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]      
Cash and cash equivalents   $ 145  
Licensing arrangement   80  
Deferred income tax liabilities   (434)  
Other assets and liabilities, net   35  
Total identifiable net assets   2,276  
Goodwill   414  
Consideration transferred   $ 2,690  
Measurement Input, Discount Rate | ArQule      
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]      
Present value discount rate   0.125  
IPR&D MK-1026 | ArQule      
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]      
IPR&D   $ 2,280  
IPR&D MK-7075 | ArQule      
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]      
IPR&D   $ 170  
XML 74 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Pension and Other Postretirement Benefit Plans
 3 Months Ended
Mar. 31, 2020
Retirement Benefits [Abstract]  
Pension and Other Postretirement Benefit Plans
Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components: 
  
Three Months Ended 
 March 31,
 
2020
 
2019
($ in millions)
U.S.
 
International
 
U.S.
 
International
Service cost
$
86

 
$
74

 
$
71

 
$
60

Interest cost
109

 
34

 
114

 
45

Expected return on plan assets
(194
)
 
(103
)
 
(206
)
 
(108
)
Amortization of unrecognized prior service credit
(12
)
 
(3
)
 
(12
)
 
(3
)
Net loss amortization
75

 
31

 
35

 
16

Termination benefits
3

 
1

 
2

 
—

Curtailments
2

 
(1
)
 
—

 
—

 
$
69


$
33


$
4


$
10

The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  
Three Months Ended 
 March 31,
($ in millions)
2020
 
2019
Service cost
$
13

 
$
12

Interest cost
14

 
17

Expected return on plan assets
(19
)
 
(18
)
Amortization of unrecognized prior service credit
(22
)
 
(21
)
 
$
(14
)
 
$
(10
)

In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring actions, curtailments were recorded on pension plans as reflected in the tables above.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 11), with the exception of certain amounts for termination benefits and curtailments, which are recorded in Restructuring costs if the event giving rise to the termination benefits or curtailment is related to restructuring actions as noted above.
XML 75 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories
 3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Inventories
Inventories
Inventories consisted of:
($ in millions)
March 31, 2020
 
December 31, 2019
Finished goods
$
1,753

 
$
1,772

Raw materials and work in process
5,629

 
5,650

Supplies
232

 
207

Total (approximates current cost)
7,614

 
7,629

Decrease to LIFO cost
(138
)
 
(171
)
 
$
7,476

 
$
7,458

Recognized as:
 
 
 
Inventories
$
5,846

 
$
5,978

Other assets
1,630

 
1,480


Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At March 31, 2020 and December 31, 2019, these amounts included $1.4 billion and $1.3 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $258 million and $168 million at March 31, 2020 and December 31, 2019, respectively, of inventories produced in preparation for product launches.
JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mrk0331202010q.htm": { "axisCustom": 0, "axisStandard": 34, "contextCount": 643, "dts": { "calculationLink": { "local": [ "mrk-20200331_cal.xml" ] }, "definitionLink": { "local": [ "mrk-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "mrk0331202010q.htm" ] }, "labelLink": { "local": [ "mrk-20200331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "mrk-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "mrk-20200331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 582, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 21, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 26 }, "keyCustom": 24, "keyStandard": 333, "memberCustom": 77, "memberStandard": 66, "nsprefix": "mrk", "nsuri": "http://www.merck.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.merck.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Collaborative Arrangements", "role": "http://www.merck.com/role/CollaborativeArrangements", "shortName": "Collaborative Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Restructuring", "role": "http://www.merck.com/role/Restructuring", "shortName": "Restructuring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Financial Instruments", "role": "http://www.merck.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Inventories", "role": "http://www.merck.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Contingencies", "role": "http://www.merck.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Equity", "role": "http://www.merck.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Share-Based Compensation Plans", "role": "http://www.merck.com/role/ShareBasedCompensationPlans", "shortName": "Share-Based Compensation Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Pension and Other Postretirement Benefit Plans", "role": "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlans", "shortName": "Pension and Other Postretirement Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Other (Income) Expense, Net", "role": "http://www.merck.com/role/OtherIncomeExpenseNet", "shortName": "Other (Income) Expense, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Taxes on Income", "role": "http://www.merck.com/role/TaxesOnIncome", "shortName": "Taxes on Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME", "role": "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "mrk:CostsExpensesAndOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Earnings Per Share", "role": "http://www.merck.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Other Comprehensive Income (Loss)", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss", "shortName": "Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Segment Reporting", "role": "http://www.merck.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Basis of Presentation (Policies)", "role": "http://www.merck.com/role/BasisOfPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalCostsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2207201 - Disclosure - Contingencies Commitments and Contingencies (Policies)", "role": "http://www.merck.com/role/ContingenciesCommitmentsAndContingenciesPolicies", "shortName": "Contingencies Commitments and Contingencies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalCostsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables)", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsTables", "shortName": "Acquisitions, Research Collaborations and License Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Collaborative Arrangements (Tables)", "role": "http://www.merck.com/role/CollaborativeArrangementsTables", "shortName": "Collaborative Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Restructuring (Tables)", "role": "http://www.merck.com/role/RestructuringTables", "shortName": "Restructuring (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Financial Instruments (Tables)", "role": "http://www.merck.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Inventories (Tables)", "role": "http://www.merck.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "role": "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Equity (Tables)", "role": "http://www.merck.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Share-Based Compensation Plans (Tables)", "role": "http://www.merck.com/role/ShareBasedCompensationPlansTables", "shortName": "Share-Based Compensation Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)", "role": "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansTables", "shortName": "Pension and Other Postretirement Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Other (Income) Expense, Net (Tables)", "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables", "shortName": "Other (Income) Expense, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.merck.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Other Comprehensive Income (Loss) (Tables)", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables", "shortName": "Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Segment Reporting (Tables)", "role": "http://www.merck.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "D2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsAcquisitionsDetails", "shortName": "Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "D2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails", "shortName": "Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "I2020Q1Jan16_us-gaap_BusinessAcquisitionAxis_mrk_ArQuleMember", "decimals": "-6", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Collaborative Arrangements - Narrative (Details)", "role": "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "shortName": "Collaborative Arrangements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "D2017Q3July_srt_CounterpartyNameAxis_mrk_AstraZenecaMember", "decimals": "-8", "lang": null, "name": "mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET", "role": "http://www.merck.com/role/CondensedConsolidatedBalanceSheet", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Collaborative Arrangements - Schedule of Transactions (Details)", "role": "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "shortName": "Collaborative Arrangements - Schedule of Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1_srt_CounterpartyNameAxis_mrk_AstraZenecaMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember", "decimals": "-6", "lang": null, "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Restructuring - Narrative (Details)", "role": "http://www.merck.com/role/RestructuringNarrativeDetails", "shortName": "Restructuring - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)", "role": "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails", "shortName": "Restructuring - Charges Activities by Type of Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember", "decimals": "-6", "lang": null, "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404404 - Disclosure - Restructuring - Activities by Program (Details)", "role": "http://www.merck.com/role/RestructuringActivitiesByProgramDetails", "shortName": "Restructuring - Activities by Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Financial Instruments - Narrative (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "shortName": "Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails", "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails", "shortName": "Financial Instruments - Summary of Interest Rate Swaps Held (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_LongtermDebtTypeAxis_mrk_A3.875NotesDue2021Member", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:HedgedLiabilityFairValueHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405405 - Disclosure - Financial Instruments - Fair Value Hedges (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails", "shortName": "Financial Instruments - Fair Value Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1_us-gaap_BalanceSheetLocationAxis_mrk_LongTermDebtCurrentMaturitiesMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:HedgedLiabilityFairValueHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405406 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "shortName": "Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember", "decimals": "-6", "lang": null, "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405407 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails", "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "lang": null, "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InventoryNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "role": "http://www.merck.com/role/CondensedConsolidatedBalanceSheetParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405408 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails", "shortName": "Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405409 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails", "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CurrencySwapMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405410 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails", "shortName": "Financial Instruments - Information on Available-for-sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405411 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD_us-gaap_FinancialInstrumentAxis_us-gaap_AssetBackedSecuritiesMember", "decimals": null, "lang": "en-US", "name": "mrk:InvestmentsPrimaryWeightedAverageLifeofCollateral", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405412 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails", "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Inventories - Inventories (Details)", "role": "http://www.merck.com/role/InventoriesInventoriesDetails", "shortName": "Inventories - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InventoryNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Inventories - Narrative (Details)", "role": "http://www.merck.com/role/InventoriesNarrativeDetails", "shortName": "Inventories - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1_us-gaap_PublicUtilitiesInventoryAxis_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember", "decimals": "-8", "lang": null, "name": "us-gaap:InventoryNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_mrk_LegalDefenseCostsMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Contingencies - Narrative (Details)", "role": "http://www.merck.com/role/ContingenciesNarrativeDetails", "shortName": "Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1_us-gaap_ValuationAllowancesAndReservesTypeAxis_mrk_LegalDefenseCostsMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Equity - Rollforward Reconciliations (Details)", "role": "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "shortName": "Equity - Rollforward Reconciliations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Share-Based Compensation Plans - Expense Allocations (Details)", "role": "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails", "shortName": "Share-Based Compensation Plans - Expense Allocations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "role": "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Share-Based Compensation Plans - Narrative (Details)", "role": "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "shortName": "Share-Based Compensation Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2020Q1", "decimals": "-8", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Pension and Other Postretirement Benefit Plans (Details)", "role": "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails", "shortName": "Pension and Other Postretirement Benefit Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InvestmentIncomeInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Other (Income) Expense, Net (Details)", "role": "http://www.merck.com/role/OtherIncomeExpenseNetDetails", "shortName": "Other (Income) Expense, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details)", "role": "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails", "shortName": "Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412401 - Disclosure - Taxes on Income (Details)", "role": "http://www.merck.com/role/TaxesOnIncomeDetails", "shortName": "Taxes on Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Earnings Per Share (Details)", "role": "http://www.merck.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FI2019Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Other Comprehensive Income (Loss) (Details)", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails", "shortName": "Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Segment Reporting - Narrative (Details)", "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails", "shortName": "Segment Reporting - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - Segment Reporting - Sales of Company's Products (Details)", "role": "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails", "shortName": "Segment Reporting - Sales of Company's Products (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "lang": null, "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415404 - Disclosure - Segment Reporting - Revenues by Geographic Area (Details)", "role": "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails", "shortName": "Segment Reporting - Revenues by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1QTD_srt_StatementGeographicalAxis_us-gaap_EMEAMember", "decimals": "-6", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004001 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)", "role": "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlowsParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - Segment Reporting - Profits to Income Before Taxes (Details)", "role": "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "shortName": "Segment Reporting - Profits to Income Before Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1QTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember", "decimals": "-6", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Basis of Presentation", "role": "http://www.merck.com/role/BasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "mrk:AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Acquisitions, Research Collaborations and License Agreements", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreements", "shortName": "Acquisitions, Research Collaborations and License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk0331202010q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "mrk:AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 145, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "U.S.", "verboseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r453" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r455" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r450" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r451" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "mrk_A0.500Notesdue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "0.500% Notes due 2024 [Member]", "label": "0.500% Notes due 2024 [Member]", "terseLabel": "0.500% Notes due 2024" } } }, "localname": "A0.500Notesdue2024Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A1.125Notesdue2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.125% Notes due 2021 [Member]", "label": "1.125% Notes due 2021 [Member]", "terseLabel": "1.125% Notes due 2021" } } }, "localname": "A1.125Notesdue2021Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A1.375Notesdue2036Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.375% Notes due 2036 [Member]", "label": "1.375% Notes due 2036 [Member]", "terseLabel": "1.375% Notes due 2036" } } }, "localname": "A1.375Notesdue2036Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A1.85NotesDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.85% Notes Due 2020 [Member]", "label": "1.85% Notes Due 2020 [Member]", "terseLabel": "1.85% Notes Due 2020" } } }, "localname": "A1.85NotesDue2020Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A1.875Notesdue2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.875% Notes due 2026 [Member]", "label": "1.875% Notes due 2026 [Member]", "terseLabel": "1.875% Notes due 2026" } } }, "localname": "A1.875Notesdue2026Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A2.35NotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.35% Notes Due 2022 [Member]", "label": "2.35% Notes Due 2022 [Member]", "terseLabel": "2.35% notes due 2022" } } }, "localname": "A2.35NotesDue2022Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.40NotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.40% Notes Due 2022 [Member]", "label": "2.40% Notes Due 2022 [Member]", "terseLabel": "2.40% notes due 2022" } } }, "localname": "A2.40NotesDue2022Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.500Notesdue2034Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.500% Notes due 2034 [Member]", "label": "2.500% Notes due 2034 [Member]", "terseLabel": "2.500% Notes due 2034" } } }, "localname": "A2.500Notesdue2034Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A3.875NotesDue2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.875% Notes Due 2021", "label": "3.875% Notes Due 2021 [Member]", "terseLabel": "3.875% notes due 2021" } } }, "localname": "A3.875NotesDue2021Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "mrk_AcceleratedDepreciationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accelerated Depreciation [Member]", "label": "Accelerated Depreciation [Member]", "terseLabel": "Accelerated Depreciation" } } }, "localname": "AcceleratedDepreciationMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails" ], "xbrltype": "domainItemType" }, "mrk_AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information related to acquisitions, divestitures, research collaborations and license agreements.", "label": "Acquisitions Divestitures Research Collaborations And License Agreements [Text Block]", "terseLabel": "Acquisitions, Divestitures, Research Collaborations and License Agreements" } } }, "localname": "AcquisitionsDivestituresResearchCollaborationsAndLicenseAgreementsTextBlock", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "mrk_AdempasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adempas", "label": "Adempas [Member]", "terseLabel": "Adempas" } } }, "localname": "AdempasMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AllianceRevenueAdempasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alliance Revenue - Adempas [Member]", "label": "Alliance Revenue - Adempas [Member]", "terseLabel": "Alliance revenue - Adempas (2)" } } }, "localname": "AllianceRevenueAdempasMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AlliancerevenueLynparzaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alliance revenue - Lynparza [Member]", "label": "Alliance revenue - Lynparza [Member]", "terseLabel": "Alliance revenue - Lynparza (1)" } } }, "localname": "AlliancerevenueLynparzaMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AmortizationOfPurchaseAccountingAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of purchase accounting adjustments.", "label": "Amortization Of Purchase Accounting Adjustments", "negatedLabel": "Amortization of purchase accounting adjustments" } } }, "localname": "AmortizationOfPurchaseAccountingAdjustments", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_AnimalHealthsegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Animal Health segment [Member]", "label": "Animal Health segment [Member]", "terseLabel": "Total Animal Health segment sales", "verboseLabel": "Animal Health segment" } } }, "localname": "AnimalHealthsegmentMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ArQuleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ArQule [Member]", "label": "ArQule [Member]", "terseLabel": "ArQule" } } }, "localname": "ArQuleMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "mrk_ArcoxiaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arcoxia [Member].", "label": "Arcoxia [Member]", "terseLabel": "Arcoxia" } } }, "localname": "ArcoxiaMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AstraZenecaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "AstraZeneca [Member]", "label": "AstraZeneca [Member]", "terseLabel": "AstraZeneca" } } }, "localname": "AstraZenecaMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "domainItemType" }, "mrk_AtozetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Atozet [Member]", "label": "Atozet [Member]", "terseLabel": "Atozet" } } }, "localname": "AtozetMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BayerAGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bayer AG [Member]", "label": "Bayer AG [Member]", "terseLabel": "Bayer AG" } } }, "localname": "BayerAGMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "domainItemType" }, "mrk_BelsomraMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Belsomra [Member]", "label": "Belsomra [Member]", "terseLabel": "Belsomra" } } }, "localname": "BelsomraMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BridionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bridion [Member].", "label": "Bridion [Member]", "terseLabel": "Bridion" } } }, "localname": "BridionMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net", "terseLabel": "Other assets and liabilities, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CaliforniaStateCourtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "California state court.", "label": "California State Court [Member]", "terseLabel": "California state court" } } }, "localname": "CaliforniaStateCourtMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_CancidasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cancidas [Member].", "label": "Cancidas [Member]", "terseLabel": "Cancidas" } } }, "localname": "CancidasMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cases Company Agreed To Toll Statute Of Limitations[Member]", "label": "Cases Company Agreed ToToll Statute Of Limitations [Member]", "terseLabel": "Cases Company Agreed To Toll Statute Of Limitations" } } }, "localname": "CasesCompanyAgreedToTollStatuteOfLimitationsMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_CollaborativeArrangementProfitSharing": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Profit Sharing", "label": "Collaborative Arrangement, Profit Sharing", "terseLabel": "Alliance revenue" } } }, "localname": "CollaborativeArrangementProfitSharing", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementSalesNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Sales, Net", "label": "Collaborative Arrangement, Sales, Net", "terseLabel": "Net sales of Adempas recorded by Merck" } } }, "localname": "CollaborativeArrangementSalesNet", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangements [Abstract]", "label": "Collaborative Arrangements [Abstract]" } } }, "localname": "CollaborativeArrangementsAbstract", "nsuri": "http://www.merck.com/20200331", "xbrltype": "stringItemType" }, "mrk_CompanionAnimalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Companion Animals [Member]", "label": "Companion Animals [Member]", "terseLabel": "Companion Animals" } } }, "localname": "CompanionAnimalsMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Component of Other Income / Expense of Nonoperating [Table]", "label": "Component of Other Income / Expense of Nonoperating [Line Items]", "terseLabel": "Component of Other Income / Expense of Nonoperating [Line Items]" } } }, "localname": "ComponentofOtherIncomeExpenseofNonoperatingLineItems", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "mrk_ComponentofOtherIncomeExpenseofNonoperatingTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component of Other Income / Expense of Nonoperating [Table]", "label": "Component of Other Income / Expense of Nonoperating [Table]", "terseLabel": "Component of Other Income / Expense of Nonoperating [Table]" } } }, "localname": "ComponentofOtherIncomeExpenseofNonoperatingTable", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "mrk_ContingentPaymentsCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.", "label": "Contingent Payments Collaborative Arrangement", "terseLabel": "Contingent milestone payments collaborative arrangement" } } }, "localname": "ContingentPaymentsCollaborativeArrangement", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CostsExpensesAndOther": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense.", "label": "Costs Expenses And Other", "totalLabel": "Total Costs, Expenses and Other" } } }, "localname": "CostsExpensesAndOther", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "mrk_CozaarHyzaarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cozaar/Hyzaar [Member].", "label": "Cozaar Hyzaar [Member]", "terseLabel": "Nasonex" } } }, "localname": "CozaarHyzaarMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_CubicinMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cubicin [Member]", "label": "Cubicin [Member]", "terseLabel": "Cubicin" } } }, "localname": "CubicinMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_DebtSecuritiesandEquitySecuritiesFVNI": { "auth_ref": [], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities and Equity Securities, FV-NI", "label": "Debt Securities and Equity Securities, FV-NI", "totalLabel": "Total debt and publicly traded equity securities, fair value" } } }, "localname": "DebtSecuritiesandEquitySecuritiesFVNI", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_EisaiMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eisai [Member]", "label": "Eisai [Member]", "terseLabel": "Eisai" } } }, "localname": "EisaiMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "domainItemType" }, "mrk_EmendMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Emend [Member].", "label": "Emend [Member]", "terseLabel": "Emend" } } }, "localname": "EmendMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Estimate of cumulative pre tax costs that will be noncash.", "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash", "terseLabel": "Estimate of cumulative pre tax costs that will be noncash" } } }, "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).", "label": "Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays", "terseLabel": "Estimate of cumulative pre tax costs that will result in cash outlays" } } }, "localname": "EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_EurodominatedNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Euro-dominated Notes [Member]", "label": "Euro-dominated Notes [Member]", "terseLabel": "Euro-denominated notes" } } }, "localname": "EurodominatedNotesMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails" ], "xbrltype": "domainItemType" }, "mrk_FederalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Federal.", "label": "Federal [Member]", "terseLabel": "Federal" } } }, "localname": "FederalMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_FemurFractureLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Femur Fracture litigation.", "label": "Femur Fracture Litigation [Member]", "terseLabel": "Femur Fracture Litigation" } } }, "localname": "FemurFractureLitigationMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_FollistimAqMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Follistim AQ [Member].", "label": "Follistim Aq [Member]", "terseLabel": "Follistim AQ" } } }, "localname": "FollistimAqMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_FosamaxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fosamax [Member].", "label": "Fosamax [Member]", "terseLabel": "Fosamax" } } }, "localname": "FosamaxMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_GardasilGardasil9Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gardasil/Gardasil 9 [Member].", "label": "Gardasil/Gardasil 9 [Member]", "terseLabel": "Gardasil/Gardasil 9" } } }, "localname": "GardasilGardasil9Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_HealthcareServicesSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Healthcare Services segment [Member]", "label": "Healthcare Services Segment [Member]", "terseLabel": "Healthcare Services Segment" } } }, "localname": "HealthcareServicesSegmentMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_IPRDMK1026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "IPR&D MK-1026 [Member]", "label": "IPR&D MK-1026 [Member]", "terseLabel": "IPR&D MK-1026" } } }, "localname": "IPRDMK1026Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "mrk_IPRDMK7075Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "IPR&D MK-7075 [Member]", "label": "IPR&D MK-7075 [Member]", "terseLabel": "IPR&D MK-7075" } } }, "localname": "IPRDMK7075Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "mrk_ImplanonNexplanonMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Implanon/Nexplanon [Member].", "label": "Implanon/Nexplanon [Member]", "terseLabel": "Implanon/Nexplanon" } } }, "localname": "ImplanonNexplanonMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_IntangibleAssetMeasurementInput": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible Asset, Measurement Input", "label": "Intangible Asset, Measurement Input", "terseLabel": "Present value discount rate" } } }, "localname": "IntangibleAssetMeasurementInput", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "decimalItemType" }, "mrk_InternationalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "International [Member]", "label": "International [Member]", "terseLabel": "International" } } }, "localname": "InternationalMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_InvanzMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Invanz [Member].", "label": "Invanz [Member]", "terseLabel": "Invanz" } } }, "localname": "InvanzMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoriesProducedinPreparationforProductLaunchesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inventories Produced in Preparation for Product Launches [Member]", "label": "Inventories Produced in Preparation for Product Launches [Member]", "terseLabel": "Inventories Produced in Preparation for Product Launches" } } }, "localname": "InventoriesProducedinPreparationforProductLaunchesMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoryNetAndInventoryNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/InventoriesInventoriesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total of current and noncurrent inventories.", "label": "Inventory Net And Inventory Noncurrent", "totalLabel": "Total current and noncurrent inventories" } } }, "localname": "InventoryNetAndInventoryNoncurrent", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inventory Not Expected to be Sold Within One Year [Member]", "label": "Inventory Not Expected to be Sold Within One Year [Member]", "terseLabel": "Inventories Not Expected to be Sold Within One Year" } } }, "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoryTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inventory [Table]", "label": "Inventory [Table]", "terseLabel": "Inventory [Table]" } } }, "localname": "InventoryTable", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investments, Primary Weighted Average Life of Collateral", "label": "Investments, Primary Weighted Average Life of Collateral", "terseLabel": "Primary weighted average life of collateral" } } }, "localname": "InvestmentsPrimaryWeightedAverageLifeofCollateral", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "durationItemType" }, "mrk_IsentressIsentressHDMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Isentress/Isentress HD [Member].", "label": "Isentress/Isentress HD [Member]", "terseLabel": "Isentress/Isentress HD" } } }, "localname": "IsentressIsentressHDMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_JanumetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Janumet [Member].", "label": "Janumet [Member]", "terseLabel": "Janumet" } } }, "localname": "JanumetMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_JanuviaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Januvia [Member] .", "label": "Januvia [Member]", "terseLabel": "Januvia" } } }, "localname": "JanuviaMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_KeytrudaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Keytruda [Member]", "label": "Keytruda [Member]", "terseLabel": "Keytruda" } } }, "localname": "KeytrudaMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LegalDefenseCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Legal Defense Costs [Member]", "label": "Legal Defense Costs [Member]", "terseLabel": "Legal Defense Costs" } } }, "localname": "LegalDefenseCostsMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_LenvimaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lenvima [Member]", "label": "Lenvima [Member]", "terseLabel": "Alliance revenue - Lenvima (1)", "verboseLabel": "Lenvima" } } }, "localname": "LenvimaMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_Licenseoptionpaymentrelatedtocollaborativearrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "License option payment related to collaborative arrangement", "label": "License option payment related to collaborative arrangement", "terseLabel": "License option payment related to collaborative arrangement" } } }, "localname": "Licenseoptionpaymentrelatedtocollaborativearrangement", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_LivestockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Livestock [Member]", "label": "Livestock [Member]", "terseLabel": "Livestock" } } }, "localname": "LivestockMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LongTermDebtCurrentMaturitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long Term Debt, Current Maturities [Member]", "label": "Long Term Debt, Current Maturities [Member]", "terseLabel": "Loans payable and current portion of long-term debt" } } }, "localname": "LongTermDebtCurrentMaturitiesMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "domainItemType" }, "mrk_LongTermDebtExcludingCurrentMaturitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long Term Debt Excluding Current Maturities [Member]", "label": "Long Term Debt Excluding Current Maturities [Member]", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtExcludingCurrentMaturitiesMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "domainItemType" }, "mrk_LossContingencyClaimsonAppealNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Claims on Appeal, Number", "label": "Loss Contingency, Claims on Appeal, Number", "terseLabel": "Loss contingency, claims on appeal, number (in legal matters)" } } }, "localname": "LossContingencyClaimsonAppealNumber", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mrk_LynparzaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lynparza [Member]", "label": "Lynparza [Member]", "terseLabel": "Lynparza" } } }, "localname": "LynparzaMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_MilestonePaymentsMadetoCollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Milestone Payments Made to Collaborative Partner", "label": "Milestone Payments Made to Collaborative Partner", "terseLabel": "Milestone payments made to collaborative partner" } } }, "localname": "MilestonePaymentsMadetoCollaborativePartner", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_NasonexMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nasonex [Member].", "label": "Nasonex [Member]", "terseLabel": "Cozaar/Hyzaar" } } }, "localname": "NasonexMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_NewJerseyStateCourtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "New Jersey state court member.", "label": "New Jersey State Court [Member]", "terseLabel": "New Jersey state court" } } }, "localname": "NewJerseyStateCourtMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_Noncontrollinginterestchangesinownershipinterestother": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncontrolling interest, changes in ownership interest, other", "label": "Noncontrolling interest, changes in ownership interest, other", "terseLabel": "Noncontrolling interest, changes in ownership interest, other" } } }, "localname": "Noncontrollinginterestchangesinownershipinterestother", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_NoxafilMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Noxafil [Member].", "label": "Noxafil [Member]", "terseLabel": "Noxafil" } } }, "localname": "NoxafilMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_NuvaringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NuvaRing [Member].", "label": "Nuvaring [Member]", "terseLabel": "NuvaRing" } } }, "localname": "NuvaringMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.", "label": "Offsetting Assets And Liabilities [Table Text Block]", "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis" } } }, "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "mrk_OtherCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Countries [Member]", "label": "Other Countries [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountriesMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherNonoperatingIncomeExpenseOther": { "auth_ref": [], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 6.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other nonoperating income and expense items not separately disclosed.", "label": "Other Nonoperating Income Expense, Other", "negatedLabel": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpenseOther", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "mrk_OtherPharmaceuticalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other pharmaceutical.", "label": "Other Pharmaceutical [Member]", "terseLabel": "Other pharmaceutical (3)" } } }, "localname": "OtherPharmaceuticalMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherStateCourtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other state court.", "label": "Other State Court [Member]", "terseLabel": "Other state courts" } } }, "localname": "OtherStateCourtMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_PharmaceuticalsegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharmaceutical segment.", "label": "Pharmaceutical segment [Member]", "terseLabel": "Total Pharmaceutical segment sales", "verboseLabel": "Pharmaceutical segment" } } }, "localname": "PharmaceuticalsegmentMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_Pneumovax23Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pneumovax 23[Member].", "label": "Pneumovax 23 [Member]", "terseLabel": "Pneumovax 23" } } }, "localname": "Pneumovax23Member", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PrevymisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prevymis [Member]", "label": "Prevymis [Member]", "terseLabel": "Prevymis" } } }, "localname": "PrevymisMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PrimaxinMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primaxin [Member].", "label": "Primaxin [Member]", "terseLabel": "Primaxin" } } }, "localname": "PrimaxinMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ProQuadMMRIIVarivaxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ProQuad/M-M-R II/Varivax [Member].", "label": "ProQuad MMR II Varivax [Member]", "terseLabel": "ProQuad/M-M-R II/Varivax" } } }, "localname": "ProQuadMMRIIVarivaxMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ProbableContingentPaymentsCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Probable Contingent Payments Collaborative Arrangement", "label": "Probable Contingent Payments Collaborative Arrangement", "terseLabel": "Probable contingent payments collaborative arrangement" } } }, "localname": "ProbableContingentPaymentsCollaborativeArrangement", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_RecognizedAsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recognized as.", "label": "Recognized As [Abstract]", "terseLabel": "Recognized as:" } } }, "localname": "RecognizedAsAbstract", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "stringItemType" }, "mrk_RegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regulatory Milestones [Member]", "label": "Regulatory Milestones [Member]", "terseLabel": "Regulatory Milestones" } } }, "localname": "RegulatoryMilestonesMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_RemicadeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remicade [Member].", "label": "Remicade [Member]", "terseLabel": "Remicade" } } }, "localname": "RemicadeMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_RestructuringReserveNoncashActivity": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation.", "label": "Restructuring Reserve Noncash Activity", "negatedTerseLabel": "Non-cash activity" } } }, "localname": "RestructuringReserveNoncashActivity", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails" ], "xbrltype": "monetaryItemType" }, "mrk_RotateqMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RotaTeq [Member]", "label": "Rotateq [Member]", "terseLabel": "RotaTeq" } } }, "localname": "RotateqMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_SalesBasedMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales-Based Milestones [Member]", "label": "Sales-Based Milestones [Member]", "terseLabel": "Sales-Based Milestones" } } }, "localname": "SalesBasedMilestonesMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_SalesDiscounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sales Discounts", "label": "Sales Discounts", "terseLabel": "Sales discounts" } } }, "localname": "SalesDiscounts", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_SanofiPasteurMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sanofi Pasteur [Member]", "label": "Sanofi Pasteur [Member]", "terseLabel": "Sanofi Pasteur" } } }, "localname": "SanofiPasteurMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "mrk_SegmentReportingUnallocatedOtherExpensesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other net expenses not allocated to segments.", "label": "Segment Reporting Unallocated Other Expenses Net", "negatedLabel": "Other unallocated, net" } } }, "localname": "SegmentReportingUnallocatedOtherExpensesNet", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_SimponiMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Simponi [Member].", "label": "Simponi [Member]", "terseLabel": "Simponi" } } }, "localname": "SimponiMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_SingulairMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Singulair [Member].", "label": "Singulair [Member]", "terseLabel": "Singulair" } } }, "localname": "SingulairMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_StockholdersEquityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Stockholders Equity [Table]", "label": "Stockholders Equity [Line Items]", "terseLabel": "Stockholders Equity [Line Items]" } } }, "localname": "StockholdersEquityLineItems", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "stringItemType" }, "mrk_StockholdersEquityTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stockholders Equity [Table]", "label": "Stockholders Equity [Table]", "terseLabel": "Stockholders Equity [Table]" } } }, "localname": "StockholdersEquityTable", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "stringItemType" }, "mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Upfront and milestone payments made to partner as part of collaborative arrangement.", "label": "Upfront And Milestone Payments Made To Collaborative Partner", "terseLabel": "Upfront and milestone payments" } } }, "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_VaqtaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vaqta [Member]", "label": "Vaqta [Member]", "terseLabel": "Vaqta" } } }, "localname": "VaqtaMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_VytorinMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vytorin [Member] .", "label": "Vytorin [Member]", "terseLabel": "Vytorin" } } }, "localname": "VytorinMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ZepatierMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zepatier [Member]", "label": "Zepatier [Member]", "terseLabel": "Zepatier" } } }, "localname": "ZepatierMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ZerbaxaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zerbaxa [Member]", "label": "Zerbaxa [Member]", "terseLabel": "Zerbaxa" } } }, "localname": "ZerbaxaMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ZetiaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zetia [Member] .", "label": "Zetia [Member]", "terseLabel": "Zetia" } } }, "localname": "ZetiaMember", "nsuri": "http://www.merck.com/20200331", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific (other than China and Japan)" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r155", "r166" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r67", "r128" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_LatinAmericaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Latin America [Member]", "terseLabel": "Latin America" } } }, "localname": "LatinAmericaMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r169", "r256", "r258", "r441", "r442" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/ContingenciesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/ContingenciesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r171", "r256", "r259", "r443", "r447", "r448" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r238", "r407" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.", "label": "Legal Entity of Counterparty, Type [Axis]", "terseLabel": "Legal Entity of Counterparty, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r26", "r173", "r174", "r257" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $89 in 2020 and $86 in 2019)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableSale": { "auth_ref": [ "r190" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease from sale of accounts receivable.", "label": "Accounts Receivable, Sale", "terseLabel": "Accounts Receivable, Sale" } } }, "localname": "AccountsReceivableSale", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r20", "r417", "r431" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r73", "r79", "r82", "r275", "r345" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r39", "r215" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r79", "r344" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r79", "r89", "r344" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Derivatives" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r70", "r71", "r72", "r79", "r82" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Investments" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r76", "r78", "r79" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r75", "r79", "r82", "r345" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "verboseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r68", "r79", "r82", "r345" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Cumulative Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r27" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Other paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Other Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r147", "r148", "r149", "r150", "r151", "r152" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "Other segment sales (4)", "verboseLabel": "Other segment" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, after Tax", "totalLabel": "Total share-based compensation expense, net of taxes" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r32", "r175", "r189" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r183", "r266" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r160", "r415", "r430" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r60" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r386" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r181" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Debt securities, unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r182" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Debt securities, unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r179", "r196" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Debt securities, amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r177", "r180", "r196" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_TradingSecurities", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt securities, fair value", "verboseLabel": "Investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r293", "r300" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r356", "r361" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r321", "r322" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Transaction costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Acquisitions Research Collaborations And License Agreements Transactions [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r119", "r332" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Changes in estimated fair value" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r326", "r327", "r330" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Fair value, ending balance", "periodStartLabel": "Fair value, beginning balance", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r326", "r328" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Current liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, measurement input, discount rate (as percent)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r324" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r306", "r324" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred income tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r324" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "IPR&D" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r324" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Licensing arrangement" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r323", "r324" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r324" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Consideration transferred" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of any issuance related costs which have not been expensed.", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed", "terseLabel": "Share-based compensation payments attributable to precombination service" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r37", "r122" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r116", "r122", "r124" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $35 million at March 31, 2020 included in Other Assets)", "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 million at January 1, 2020 included in Other Assets)" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r116", "r402" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r383" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "negatedTerseLabel": "Derivatives designated as hedging instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r383" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "negatedTerseLabel": "Hedged items" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r333", "r334", "r336" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r236", "r246" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared on common stock (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Shares, ending balance (in shares)", "periodStartLabel": "Shares, beginning balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheetParenthetical", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r85", "r87", "r88" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income Attributable to Merck & Co., Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r266", "r288", "r444" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes and bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r168" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Other", "verboseLabel": "Other profits" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r97" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales", "verboseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs, Expenses and Other" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Foreign currency" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Loans payable and current portion of long-term debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r18", "r20", "r21", "r416", "r418", "r428" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r404", "r406" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt", "verboseLabel": "Par Value of Debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of loans payable and long-term debt, including current portion" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r46" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Stated interest rate (as percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt, Long-term and Short-term, Combined Amount", "terseLabel": "Debt, carrying amount" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r120", "r127", "r314", "r316" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r307", "r313" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred Income Taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "terseLabel": "Other Assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r272", "r285", "r288" ], "calculation": { "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Net loss amortization" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r273", "r286", "r288" ], "calculation": { "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of unrecognized prior service credit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": { "auth_ref": [ "r276" ], "calculation": { "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.", "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits", "terseLabel": "Termination benefits" } } }, "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r271", "r284", "r288" ], "calculation": { "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r265", "r270", "r283", "r288" ], "calculation": { "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r268", "r281", "r288" ], "calculation": { "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "auth_ref": [ "r274", "r287" ], "calculation": { "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails": { "order": 7.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "negatedLabel": "Curtailments" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r264", "r269", "r282", "r288" ], "calculation": { "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r120", "r158" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "negatedLabel": "Depreciation and amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows", "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r64", "r66" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Net amounts, asset" } } }, "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r62", "r66" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.", "label": "Derivative Asset, Not Offset, Policy Election Deduction", "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset" } } }, "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r61", "r65", "r398" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "netLabel": "Gross amounts recognized in the consolidated balance sheet, asset", "terseLabel": "Derivative assets", "verboseLabel": "Fair Value of Derivative, Asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAverageRemainingMaturity1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Average Remaining Maturity", "terseLabel": "Maximum average period of maturities of contracts in years (less than)" } } }, "localname": "DerivativeAverageRemainingMaturity1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "auth_ref": [ "r63", "r66", "r379" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative, Collateral, Obligation to Return Cash", "negatedLabel": "Cash collateral received, asset", "terseLabel": "Cash collateral received from counterparties" } } }, "localname": "DerivativeCollateralObligationToReturnCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "auth_ref": [ "r63", "r66", "r379" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.", "label": "Derivative, Collateral, Right to Reclaim Cash", "negatedLabel": "Cash collateral received, liability", "terseLabel": "Cash collateral advanced to counterparties" } } }, "localname": "DerivativeCollateralRightToReclaimCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r358" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r357", "r360", "r366", "r374" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r354", "r357", "r366", "r374", "r375", "r381", "r384" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r385" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "terseLabel": "Pretax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r365", "r367" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r61", "r65", "r398" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "netLabel": "Gross amounts recognized in the consolidated balance sheet, liability", "terseLabel": "Derivative liabilities", "verboseLabel": "Fair Value of Derivative, Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r64", "r66" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Net amounts, liability" } } }, "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r62", "r66" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.", "label": "Derivative Liability, Not Offset, Policy Election Deduction", "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability" } } }, "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnDerivativePositionsSubjectToMasterNettingArrangementsAsIfTheyWerePresentedOnNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r351", "r353" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Total swap notional amount", "verboseLabel": "U.S Dollar Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r130", "r350", "r352", "r353", "r354", "r355", "r362", "r366", "r378", "r380", "r384" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r354" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Designated as Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r303" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r252" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends declared on common stock" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r9", "r44" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "Europe, Middle East and Africa" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r95", "r134", "r138", "r139", "r140", "r141", "r144", "r426", "r439" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per common share attributable to Merck & Co., Inc. common shareholders", "verboseLabel": "Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome", "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r95", "r134", "r138", "r139", "r140", "r141", "r144", "r426", "r439" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders", "verboseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome", "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r402" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r129", "r308", "r309" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate (as percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r299" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r298" ], "calculation": { "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "negatedLabel": "Income tax benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r397" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_TradingSecurities", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails": { "order": 2.0, "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Publicly traded equity securities, fair value", "verboseLabel": "Publicly traded equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r188" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedLabel": "(Income) loss from investments in equity securities, net (1)" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r188" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "Unrealized net losses (gains)" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r15", "r19", "r184", "r422", "r429", "r446" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Publicly traded equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investments without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount", "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount", "terseLabel": "Cumulative unrealized losses on investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r187" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "terseLabel": "Cumulative unrealized gains on investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r386", "r387", "r388", "r395" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r266", "r267", "r288", "r387", "r408" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r386", "r387", "r390", "r391", "r396" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r266", "r267", "r288", "r387", "r409" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r266", "r267", "r288", "r387", "r410" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r266", "r267", "r288", "r387", "r411" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r392", "r395" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Information About the Changes in Liabilities for Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r393" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Payments", "terseLabel": "Payments of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r394", "r396" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r356", "r362", "r381" ], "lang": { "en-US": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r200" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Finite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r399", "r400", "r401" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Exchange losses" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r266", "r372" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign exchange contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeFutureMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A standardized contract, traded on a futures exchange, to buy or sell a certain currency, at a specified future date, at a fixed exercise rate (expressed as an exchange).", "label": "Foreign Exchange Future [Member]", "terseLabel": "Forecasted transactions" } } }, "localname": "ForeignExchangeFutureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).", "label": "Foreign Exchange Option [Member]", "terseLabel": "Currency options" } } }, "localname": "ForeignExchangeOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r266", "r444" ], "lang": { "en-US": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Foreign government bonds" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "International" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r204", "r206" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Intangible asset impairment charges" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r120", "r205", "r207", "r209" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedge": { "auth_ref": [ "r376" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability hedged in fair value hedging relationship.", "label": "Hedged Liability, Fair Value Hedge", "terseLabel": "Carrying Amount of Hedged Liabilities" } } }, "localname": "HedgedLiabilityFairValueHedge", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "auth_ref": [ "r377" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "verboseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount" } } }, "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r354", "r375" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r354" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r93", "r134", "r413", "r424", "r440" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Profits", "totalLabel": "Income Before Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome", "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r310" ], "lang": { "en-US": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Taxes on Income" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]", "terseLabel": "Income Tax Examination [Line Items]" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r311", "r315" ], "lang": { "en-US": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]", "terseLabel": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r127", "r159", "r318" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Taxes on Income" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r117", "r123" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "auth_ref": [ "r119" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.", "label": "Increase (Decrease) in Operating Capital", "negatedLabel": "Net changes in assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r211", "r214" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r211", "r214" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r210", "r212" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other Intangibles, Net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r91", "r157", "r403", "r405", "r427" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r266", "r371" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r371" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swap contracts", "verboseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Service (IRS)" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r54" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r57" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 1.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total (approximates current cost)" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r58" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 2.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedLabel": "Decrease to LIFO cost" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r2", "r57", "r202" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.merck.com/role/InventoriesInventoriesDetailsCalc2": { "order": 1.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "verboseLabel": "Inventories (excludes inventories of $1,630 in 2020 and $1,480 in 2019 classified in Other assets - see Note 6)" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet", "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r59" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetailsCalc2": { "order": 2.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "Inventories classified in Other assets", "verboseLabel": "Other assets" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheetParenthetical", "http://www.merck.com/role/InventoriesInventoriesDetails", "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessAndRawMaterials": { "auth_ref": [ "r55" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.", "label": "Inventory, Work in Process and Raw Materials", "terseLabel": "Raw materials and work in process" } } }, "localname": "InventoryWorkInProcessAndRawMaterials", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r99", "r156" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest income", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r125", "r126", "r245" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Legal Costs, Policy" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesCommitmentsAndContingenciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nature of the other party participating in a financial transaction.", "label": "Legal Entity Type of Counterparty [Domain]", "terseLabel": "Legal Entity Type of Counterparty [Domain]" } } }, "localname": "LegalEntityTypeOfCounterpartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r420", "r435" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "verboseLabel": "Payables, current" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r386" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r11", "r12", "r13", "r21", "r22" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "terseLabel": "Payables, Noncurrent" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r49", "r237" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Legal defense costs reserve" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r47", "r250" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r247", "r248" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r247", "r248" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyClaimsDismissedNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of claims dismissed.", "label": "Loss Contingency, Claims Dismissed, Number", "terseLabel": "Loss contingency, claims dismissed, number (in legal matters)" } } }, "localname": "LossContingencyClaimsDismissedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r247", "r248" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Loss contingency, pending claims, number (in legal matters)" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r4", "r43" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Short-term investments" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [ "r38" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r163", "r164" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Unallocated" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r389" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r389" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r53", "r419", "r434" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling Interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r116" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Used in Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r116" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash (Used in) Provided by Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r116", "r118", "r121" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r83", "r86", "r94", "r121", "r143", "r425", "r438" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income Attributable to Merck & Co., Inc.", "totalLabel": "Net Income Attributable to Merck & Co., Inc.", "verboseLabel": "Net income attributable to Merck & Co., Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome", "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome", "http://www.merck.com/role/EarningsPerShareDetails", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r83", "r86", "r342", "r347" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: Net Loss Attributable to Noncontrolling Interests", "verboseLabel": "Net income (loss) attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": { "auth_ref": [ "r263" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.", "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component", "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost" } } }, "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted and Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/BasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non- controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r354" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "verboseLabel": "Derivatives Not Designated as Hedging Instruments" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r351", "r353" ], "lang": { "en-US": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number of Interest Rate Derivatives Held", "terseLabel": "Number of Interest Rate Swaps Held (in interest rate swaps)", "verboseLabel": "Number of interest rate swaps held (in interest rate swaps)" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryOfInterestRateSwapsHeldDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "auth_ref": [ "r79" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax" } } }, "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r79", "r89" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OneTimeTerminationBenefitsMember": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.", "label": "One-time Termination Benefits [Member]", "terseLabel": "Separation Costs" } } }, "localname": "OneTimeTerminationBenefitsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r155", "r166" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments", "verboseLabel": "Total segment profits" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r133", "r135", "r146", "r349" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r356", "r381" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r339", "r340", "r344" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "verboseLabel": "Net unrealized (loss) gain on investments, net of reclassifications" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r74", "r76", "r339", "r344" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Benefit plan net gain and prior service credit, net of amortization" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r339", "r340", "r344" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Cumulative translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "auth_ref": [ "r77", "r317" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "negatedTerseLabel": "Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r76" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "verboseLabel": "Net unrealized gain (loss) on derivatives, net of reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r69", "r76", "r359", "r364", "r382" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Amount of gain (loss) recognized in OCI on derivatives" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r76", "r80" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Increase (decrease) in Sales as a result of AOCI reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r368" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r369" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r84", "r87", "r89", "r251" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other Comprehensive (Loss) Income Net of Taxes:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r84", "r87", "r339", "r340", "r344" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfComprehensiveIncome", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r356", "r381" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r260", "r304" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other (Income) Expense, Net" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other intangible assets" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInventorySupplies": { "auth_ref": [ "r56" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.", "label": "Other Inventory, Supplies, Gross", "terseLabel": "Supplies" } } }, "localname": "OtherInventorySupplies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r44" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other Noncurrent Liabilities", "verboseLabel": "Other liabilities, noncurrent" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r121" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueOfDerivativesSegregatedBetweenThoseDerivativesThatAreDesignatedAsHedgingInstrumentsAndThoseThatAreNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r100" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": 5.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": -1.0 }, "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectOfNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r262", "r277", "r278", "r289" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefit Plans" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r104", "r107", "r131" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r111" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r114", "r222" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "(Payments) receipts, net" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r111" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid to stockholders" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r105", "r329" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payment to acquire business" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r105" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of ArQule, Inc., net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r178" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of securities and other investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r106" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Pension and Other Postretirement Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r261", "r277", "r278", "r289" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Share Units (PSUs)" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r109" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r110", "r113", "r131" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [ "r131" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Net change in short-term borrowings" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r104" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from sales of securities and other investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "auth_ref": [ "r103" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Proceeds from Sale of Intangible Assets", "terseLabel": "Proceeds from Sale of Intangible Assets" } } }, "localname": "ProceedsFromSaleOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r108", "r301" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r83", "r86", "r115", "r160", "r167", "r339", "r341", "r343", "r347", "r348" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net Income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows", "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r216", "r437" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,706 in 2020 and $17,686 in 2019" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r26", "r33", "r436", "r445" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "verboseLabel": "Receivables" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r79" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "negatedLabel": "Reclassification adjustments, pretax" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r79", "r89" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTotalLabel": "Reclassification adjustments, net of taxes" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r77", "r81", "r317" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Reclassification from AOCI, Current Period, Tax", "terseLabel": "Tax" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r162", "r164" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of segment profits to income before taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r112" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Payments on debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r305", "r449" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": 3.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "negatedLabel": "Research and development", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome", "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r14", "r122", "r124", "r414", "r432" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/Restructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r221", "r224", "r230", "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Cumulative costs since program inception" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r221", "r224", "r230", "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Expected restructuring and related cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r221", "r224", "r230", "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Total pretax restructuring costs", "verboseLabel": "Expense" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r120", "r220", "r227", "r232" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": 4.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedLabel": "Restructuring costs", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome", "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r223", "r227", "r233" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r222", "r228" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Restructuring reserve, ending balance", "periodStartLabel": "Restructuring reserve, beginning balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r28", "r252", "r433" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r278", "r280" ], "lang": { "en-US": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r278", "r280" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r261", "r262", "r277", "r278", "r289" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r261", "r262", "r277", "r278", "r289" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r92", "r154", "r155", "r165" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails", "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales", "verboseLabel": "Revenue" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsOnDerivativesNotDesignatedAsHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r79" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Changes in AOCI by Component" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Information on Investments in Debt and Equity Securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r331" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesInLiabilitiesForContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r321", "r322" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Collaboration Arrangements" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r277", "r278", "r279", "r280", "r288" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r357", "r366", "r375" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Location and Amount of Pretax (Gains) Losses of Derivatives" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r362" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Calculations of Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r292", "r297", "r302" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Amounts of Share-Based Compensation Cost Recorded in Consolidated Statement of Income" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Sales of Company's products" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r386", "r387" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Amounts Recorded on Balance Sheet Related to Fair Value Hedges" } } }, "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "auth_ref": [ "r366" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "terseLabel": "Summary of Interest Rate Swaps Held" } } }, "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r34", "r35", "r36" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r268" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Components of net cost of defined benefit plans" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/PensionAndOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r370" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income" } } }, "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r365", "r367" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Other (Income) Expense, Net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Fair Value of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsAndLicenseAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r225", "r226", "r229" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r225", "r226", "r229" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r222", "r231" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r96", "r170" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Consolidated revenues by geographic area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r90", "r92", "r171" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r153", "r160", "r161", "r163", "r208" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r293", "r300" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions Used to Determine Weighted-Average Fair Value of Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r251" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails", "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r98", "r201" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome": { "order": 2.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/CondensedConsolidatedStatementOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r101" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r119" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Pretax share-based compensation expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedStatementOfCashFlows", "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r295" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value per share granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r291", "r294" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r160", "r208", "r218", "r224", "r234", "r441" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails", "http://www.merck.com/role/SegmentReportingProfitsToIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesOfCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r251" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r51", "r251" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationAndAmountOfPretaxGainsLossesOfDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r29", "r30", "r176" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Merck & Co., Inc. stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Merck & Co., Inc. Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityBeforeTreasuryStock": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.", "label": "Stockholders' Equity before Treasury Stock", "totalLabel": "Stockholders' equity before deduction for treasury stock" } } }, "localname": "StockholdersEquityBeforeTreasuryStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r337", "r338", "r346" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Equity, ending balance", "periodStartLabel": "Equity, beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Share-based compensation plans and other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "negatedLabel": "Share-based compensation plans and other (in shares)" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r423" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "totalLabel": "Investments" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r412" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r50", "r253" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r50", "r253" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares (shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r25", "r251", "r252" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury stock shares purchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r50", "r253", "r254" ], "calculation": { "http://www.merck.com/role/CondensedConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "terseLabel": "Less treasury stock, at cost: 1,053,090,194 shares in 2020 and 1,038,087,496 shares in 2019" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CondensedConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r251", "r252", "r253" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Treasury stock shares purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleOfTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesByProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesByTypeOfCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r266", "r421" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government and agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationOnAvailableForSaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r312" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "terseLabel": "Tax benefit recognized related to settlement" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/TaxesOnIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r132" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r141" ], "calculation": { "http://www.merck.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Common shares issuable (1)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r137", "r141" ], "calculation": { "http://www.merck.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Average common shares outstanding assuming dilution" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r136", "r141" ], "calculation": { "http://www.merck.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8615-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8654-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8660-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8663-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8672-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751" }, "r246": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r303": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r336": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r349": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109999712-113959" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109999712-113959" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80845-113994" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r451": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r452": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r453": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r454": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r455": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3),(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(d))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(i)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-03(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" } }, "version": "2.1" } XML 77 R4.htm IDEA: XBRL DOCUMENT v3.20.1
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Current Assets    
Cash and cash equivalents $ 7,425 $ 9,676
Short-term investments 7 774
Accounts receivable (net of allowance for doubtful accounts of $89 in 2020 and $86 in 2019) 8,182 6,778
Inventories (excludes inventories of $1,630 in 2020 and $1,480 in 2019 classified in Other assets - see Note 6) 5,846 5,978
Other current assets 4,714 4,277
Total current assets 26,174 27,483
Investments 555 1,469
Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,706 in 2020 and $17,686 in 2019 15,269 15,053
Goodwill 19,767 19,425
Other Intangibles, Net 16,096 14,196
Other Assets 7,052 6,771
Total Assets 84,913 84,397
Current Liabilities    
Loans payable and current portion of long-term debt 6,361 3,610
Trade accounts payable 3,572 3,738
Accrued and other current liabilities 10,932 12,549
Income taxes payable 1,033 736
Dividends payable 1,585 1,587
Total current liabilities 23,483 22,220
Long-Term Debt 21,637 22,736
Deferred Income Taxes 1,943 1,470
Other Noncurrent Liabilities 11,550 11,970
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019 1,788 1,788
Other paid-in capital 39,697 39,660
Retained earnings 48,272 46,602
Accumulated other comprehensive loss (6,391) (6,193)
Stockholders' equity before deduction for treasury stock 83,366 81,857
Less treasury stock, at cost: 1,053,090,194 shares in 2020 and 1,038,087,496 shares in 2019 57,161 55,950
Total Merck & Co., Inc. stockholders’ equity 26,205 25,907
Noncontrolling Interests 95 94
Total equity 26,300 26,001
Liabilities and Equity $ 84,913 $ 84,397
XML 78 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Basis of Presentation
 3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2020.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Planned Spin-Off of Women’s Health, Legacy Brands and Biosimilars into New Company
In February 2020, Merck announced its intention to spin-off products from its women’s health, trusted legacy brands and biosimilars businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The legacy brands included in the transaction consist of dermatology, non-opioid pain, respiratory, and select cardiovascular products including Zetia (ezetimibe) and Vytorin (ezetimibe and simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the first half of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women’s health, legacy brands and biosimilars businesses will be reflected as discontinued operations in the Company’s consolidated financial statements.
Recently Adopted Accounting Standards
In June 2016, the FASB issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.
Recently Issued Accounting Standards Not Yet Adopted
In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
XML 79 R59.htm IDEA: XBRL DOCUMENT v3.20.1
Share-Based Compensation Plans - Expense Allocations (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Share-based Payment Arrangement [Abstract]    
Pretax share-based compensation expense $ 108 $ 93
Income tax benefit (15) (14)
Total share-based compensation expense, net of taxes $ 93 $ 79
XML 80 R55.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories - Inventories (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Finished goods $ 1,753 $ 1,772
Raw materials and work in process 5,629 5,650
Supplies 232 207
Total (approximates current cost) 7,614 7,629
Decrease to LIFO cost (138) (171)
Total current and noncurrent inventories 7,476 7,458
Recognized as:    
Inventories 5,846 5,978
Other assets $ 1,630 $ 1,480
XML 81 R51.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Foreign currency | Other (income) expense, net    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ (180) $ 118
Forecasted transactions | Sales    
Derivative Instruments, Gain (Loss) [Line Items]    
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ (7) $ 10
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.20.1
Segment Reporting - Narrative (Details)
$ in Billions
 3 Months Ended
Mar. 31, 2020
USD ($)
segment
Mar. 31, 2019
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 3  
Sales discounts | $ $ 3.2 $ 2.6
XML 83 R63.htm IDEA: XBRL DOCUMENT v3.20.1
Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Component of Other Income / Expense of Nonoperating [Line Items]    
Interest paid $ 250 $ 195
Healthcare Services Segment    
Component of Other Income / Expense of Nonoperating [Line Items]    
Goodwill, Impairment Loss   $ 84
XML 84 R40.htm IDEA: XBRL DOCUMENT v3.20.1
Collaborative Arrangements - Schedule of Transactions (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales $ 12,057 $ 10,816  
Cost of sales 3,312 3,052  
Selling, general and administrative 2,555 2,425  
Research and development 2,209 1,931  
Payables, current 23,483   $ 22,220
Other current assets | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables 142   128
Other current assets | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables 140   150
Other current assets | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Receivables 50   49
Accounts payable and accrued liabilities | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables, current 326   577
Accounts payable and accrued liabilities | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables, current 425   700
Other Noncurrent Liabilities | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables, Noncurrent 300   525
Other Noncurrent Liabilities | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Payables, Noncurrent 375   $ 375
Revenue | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 145 79  
Revenue | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Sales 128 74  
Revenue | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Net sales of Adempas recorded by Merck 56 48  
Alliance revenue 53 42  
Sales 109 90  
Cost of sales | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 28 19  
Cost of sales | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 35 51  
Cost of sales | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Cost of sales 28 29  
Selling, general and administrative | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 33 27  
Selling, general and administrative | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 11 19  
Selling, general and administrative | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Selling, general and administrative 15 8  
Research and development | AstraZeneca | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 36 45  
Research and development | Eisai | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development 64 47  
Research and development | Bayer AG | Collaborative Arrangement      
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]      
Research and development $ 25 $ 30  
XML 85 R44.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Narrative (Details)
 3 Months Ended
Mar. 31, 2020
USD ($)
interest_rate_swap
Dec. 31, 2019
USD ($)
Mar. 31, 2019
USD ($)
Feb. 29, 2020
USD ($)
Derivative [Line Items]        
Pretax net unrealized gain on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales $ 136,000,000      
Equity investments without readily determinable fair values 450,000,000   $ 542,000,000  
Unrealized losses recognized on investments in equity securities without readily determinable fair values     9,000,000  
Cumulative unrealized gains on investments 109,000,000      
Cumulative unrealized losses on investments 21,000,000      
Payments of contingent consideration 106,000,000   $ 85,000,000  
Fair value of loans payable and long-term debt, including current portion 30,600,000,000 $ 28,800,000,000    
Debt, carrying amount 28,000,000,000.0 26,300,000,000    
Accounts Receivable, Sale 1,900,000,000 2,700,000,000    
Cash collateral received from counterparties 216,000,000 34,000,000    
Cash collateral advanced to counterparties 0 0    
Total swap notional amount 27,453,000,000 30,666,000,000    
Level 2        
Derivative [Line Items]        
Cash equivalents 6,800,000,000 8,900,000,000    
Derivatives Designated as Hedging Instruments        
Derivative [Line Items]        
Total swap notional amount $ 12,749,000,000 14,728,000,000    
Derivatives Designated as Hedging Instruments | Maximum        
Derivative [Line Items]        
Maximum average period of maturities of contracts in years (less than) 2 years      
Derivatives Not Designated as Hedging Instruments        
Derivative [Line Items]        
Total swap notional amount $ 14,704,000,000 $ 15,938,000,000    
Derivatives Not Designated as Hedging Instruments | Maximum        
Derivative [Line Items]        
Maximum average period of maturities of contracts in years (less than) 1 year      
1.85% Notes Due 2020        
Derivative [Line Items]        
Face amount of debt       $ 1,250,000,000
Stated interest rate (as percent)       1.85%
Interest rate swap contracts        
Derivative [Line Items]        
Number of interest rate swaps held (in interest rate swaps) 14     5
Total swap notional amount       $ 250,000,000
XML 86 R48.htm IDEA: XBRL DOCUMENT v3.20.1
Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
Mar. 31, 2020
Dec. 31, 2019
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 710 $ 288
Fair Value of Derivative, Liability 93 97
U.S Dollar Notional Amount 27,453 30,666
Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 363 222
Fair Value of Derivative, Liability 8 24
U.S Dollar Notional Amount 12,749 14,728
Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 347 66
Fair Value of Derivative, Liability 85 73
U.S Dollar Notional Amount 14,704 15,938
Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 11 0
U.S Dollar Notional Amount 1,150 0
Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 70 15
U.S Dollar Notional Amount 2,250 3,400
Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability 0 1
U.S Dollar Notional Amount 0 1,250
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 194 152
U.S Dollar Notional Amount 6,546 6,117
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 88 55
U.S Dollar Notional Amount 2,064 2,160
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability 7 22
U.S Dollar Notional Amount 734 1,748
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability 1 1
U.S Dollar Notional Amount 5 53
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 347 66
U.S Dollar Notional Amount 10,039 7,245
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability 85 73
U.S Dollar Notional Amount $ 4,665 $ 8,693
XML 87 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Inventories (Tables)
 3 Months Ended
Mar. 31, 2020
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories consisted of:
($ in millions)
March 31, 2020
 
December 31, 2019
Finished goods
$
1,753

 
$
1,772

Raw materials and work in process
5,629

 
5,650

Supplies
232

 
207

Total (approximates current cost)
7,614

 
7,629

Decrease to LIFO cost
(138
)
 
(171
)
 
$
7,476

 
$
7,458

Recognized as:
 
 
 
Inventories
$
5,846

 
$
5,978

Other assets
1,630

 
1,480
XML 88 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Acquisitions, Research Collaborations and License Agreements (Tables)
 3 Months Ended
Mar. 31, 2020
Business Combinations [Abstract]  
Fair Value of Assets Acquired and Liabilities Assumed
The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
 
 
($ in millions)
January 16, 2020
Cash and cash equivalents
$
145

IPR&D MK-1026 (formerly ARQ 531) (1)
2,280

IPR&D MK-7075 (formerly ARQ 092) (1)
170

Licensing arrangement for ARQ 087
80

Deferred income tax liabilities
(434
)
Other assets and liabilities, net
35

Total identifiable net assets
2,276

Goodwill (2)
414

Consideration transferred
$
2,690

(1) 
The fair values of the identifiable intangible assets related to in-process research and development (IPR&D) were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed.
(2) 
The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.
XML 89 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Other Comprehensive Income (Loss)
 3 Months Ended
Mar. 31, 2020
Equity [Abstract]  
Other Comprehensive Income (Loss)
Other Comprehensive Income (Loss)
Changes in AOCI by component are as follows:
 
Three Months Ended March 31,
($ in millions)
Derivatives
 
Investments
 
Employee
Benefit
Plans
 
Cumulative
Translation
Adjustment
 
Accumulated Other
Comprehensive
Income (Loss)
Balance January 1, 2019, net of taxes
$
166

 
$
(78
)
 
$
(3,556
)
 
$
(2,077
)
 
$
(5,545
)
Other comprehensive income (loss) before reclassification adjustments, pretax
(13
)
 
76

 
(1
)
 
156

 
218

Tax
3

 
—

 
6

 
(6
)
 
3

Other comprehensive income (loss) before reclassification adjustments, net of taxes
(10
)
 
76

 
5

 
150

 
221

Reclassification adjustments, pretax
(48
)
(1) 
6

(2) 
14

(3) 
—

 
(28
)
Tax
10

 
—

 
(4
)
 
—

 
6

Reclassification adjustments, net of taxes
(38
)

6


10


—

 
(22
)
Other comprehensive income (loss), net of taxes
(48
)
 
82

 
15

 
150

 
199

Balance March 31, 2019, net of taxes
$
118

 
$
4

 
$
(3,541
)
 
$
(1,927
)
 
$
(5,346
)
Balance January 1, 2020, net of taxes
$
31

 
$
18

 
$
(4,261
)
 
$
(1,981
)
 
$
(6,193
)
Other comprehensive income (loss) before reclassification adjustments, pretax
178

 
3

 
—

 
(333
)
 
(152
)
Tax
(37
)
 
—

 
5

 
(11
)
 
(43
)
Other comprehensive income (loss) before reclassification adjustments, net of taxes
141

 
3

 
5

 
(344
)
 
(195
)
Reclassification adjustments, pretax
(47
)
(1) 
(21
)
(2) 
69

(3) 
—

 
1

Tax
10

 
—

 
(14
)
 
—

 
(4
)
Reclassification adjustments, net of taxes
(37
)

(21
)

55


—

 
(3
)
Other comprehensive income (loss), net of taxes
104

 
(18
)
 
60

 
(344
)
 
(198
)
Balance March 31, 2020, net of taxes
$
135


$
—


$
(4,201
)

$
(2,325
)

$
(6,391
)
(1) 
Relates to foreign currency cash flow hedges that were reclassified from AOCI to Sales.
(2) Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from AOCI to Other (income) expense, net.
(3) Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 10).